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Abstract 
Enhancers are regions of non-coding DNA bound by transcription factors that 
influence gene expression, and are essential for the precise regulation of embryonic 
development. Many enhancers have been identified through reporter assays and 
bioinformatic techniques, but these are unable to show the functional contribution 
of the enhancer to endogenous expression. The SOXB1 proteins, expressed within 
the neural progenitor and spermatogonial stem cell populations are important TFs, 
the absence of which leads to developmental defects in both humans and mice.  
NES is an intermediate filament protein, and is thought to be regulated via a 
SOXB1 bound enhancer, commonly used in transgenic mice models to direct 
expression to NPCs. Through CRISPR mediated deletion of the Nes enhancer we 
show it is active from 9.5dpc in the CNS, and is responsible for up to 70% of 
endogenous Nes expression. Further, we identify possible trans activity of the 
enhancer, a new field of mammalian enhancer research. SOX3 ChIP-Seq identified a 
region upstream of the Wnt-receptor gene, Fzd3 that appeared to be an enhancer. 
Subsequent deletion via CRISPR confirmed enhancer activity in the CNS. Combined 
with LacZ reporter mouse models we show the enhancer directs expression 
specifically to the floor plate, an important region for axon guidance for which FZD3 
is required. SOX3s role within the postnatal testes is largely unknown. Through 
ChIP-Seq we identified putative enhancers bound by SOX3, and present evidence 
that it is important in the regulation of the complex chromatin reorganisation that 
occurs during spermatogenesis. Together, this data presents new insights into the 
role of SOXB1s in development as well as highlighting the importance of functional 
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In order to tightly control gene expression throughout development, regulatory 
elements are essential. Previously only thought of as ‘junk DNA, the non-coding 
genome was thought to be unimportant when compared to the 2% of DNA that 
encoded proteins (Ohno 1972). Within the last few decades it has become apparent 
that the non-coding genome is home to many regulatory elements, such as 
silencers, non-coding RNA, and enhancers (ENCODE Project Consortium 2012). 
Enhancers are cis-regulatory elements comprised of regions of DNA, usually 50-
1500 base pairs (bp) in length, to which specific transcription factors (TF) bind, 
allowing interaction with the target gene promoter, influencing transcription to 






1.1 Transcription Factor Binding 
Enhancers are comprised of varying numbers of transcription factor binding sites 
(TFBS), which are recognised by an individual TF or TF family. Highly specific TF 
binding allows enhancers to precisely control gene expression; for example a gene 
only required in the developing brain will not be activated by a brain specific TF in a 
developing limb (Shlyueva et al. 2014). Figure 1, (Krijger & de Laat 2016) 
demonstrates the various ways in which each enhancer can control target genes. 
There can either be many enhancers for a single tissue, which would allow for it to 
be activated (or repressed) at different timepoints, or various enhancers which will 
be activated by tissue-specific TFs for expression within multiple body regions. 
 
The exact mechanism of how TFs are able to interact with DNA to regulate 
expression is a complex process which is still not completely understood.  Firstly, for 
a TF to recognise and bind a DNA motif, it must contain a DNA binding domain. 
There are many different protein binding DNA domains found across the 
transcription factor families; these include homeodomains (HD), helix-turn-helix 
(HTH) domains and high mobility group box (HMG) domains. The focus of this 
thesis, the SOX family of TFs contain the HMG binding domain, and this will be 






Figure 1 (Krijger & de Laat 2016) 
Various types of enhancers exist within the genome. A. A single gene may contain a 
single or many distinct enhancers to control expression within one tissue type or 
expression region. Or, as shown in (B) a gene may have multiple enhancers which 
are individually able to direct expression to target tissue, for example one enhancer 





The DNA binding domain of each TF will recognise a specific DNA motif, usually a 
8-20 bp region to which the TF directly binds (Halford & Marko 2004). Whilst these 
motifs can be found repeated throughout the genome, it has been estimated by the 
ENCODE consortium that the vast majority of DNA that matches these specific 
motifs will never be bound by a TF (Yesudhas et al. 2017). The environment in which 
these DNA motifs are within is crucial, as will be discussed in section 1.7 where the 
epigenetic modifications and chromatin accessibility is vitally important. 
 
There are three main mechanisms proposed for how a TF finds its correct motif; 
sliding, hopping, and intersegmental transfer. The model lac repressor TF is an 
example of a sliding mechanism. Molecular dynamics simulations have shown the 
TF ‘sliding’ along the DNA searching for the specific binding sites within the major 
grooves of DNA (Hammar et al. 2012).   
 
The hopping mechanism is where the protein ‘hops’ between DNA motifs, 
governed by electrostatic interactions. It is thought that while this is slower that 
siding, the binding affinity between the protein and DNA is stronger (Yesudhas et 
al. 2017). In the intersegmental transfer mechanism model, the TF is bound at one 
DNA motif, and to move to the next the intervening DNA will loop to the second 






Figure 2 (Yesudhas et al. 2017) 
The three protein:DNA recognition mechanisms. The pink ring symbolises the 
transcription factor on the DNA, in the first diagram (sliding), the TF ‘slides’ along 
the DNA and moves between the bases without dissociating until it reaches a TFBS 
to which it binds. The second (hopping) shows the TF continually disassociates and 
reassociates with the DNA until bound. The third (intersegmental transfer) is where 











1.2  Models of Enhancer Activity 
Like TF DNA binding, there are multiple mechanisms/models for enhancer activity. 
There are three proposed models, two of which are well characterised, and a third 
that has been recently proposed. The enhanceosome model, billboard model and 





1.2.1 The Enhanceosome Model 
The enhanceosome model is defined by a requirement for co-operative binding by 
all TFs to the enhancer for activity to occur. Co-operative TF binding relies on the 
architectural remodelling of the chromatin environment. The archetypal 
enhanceosome is that of the interferon-b gene, activated upon viral infection in 
mammalian cells, which establishes the antiviral state (Falvo et al. 2000). A 55 bp 
enhancer upstream of the promoter contains DNA binding motifs for many 
individual TFs, all of which need to bind co-operatively (Merika & Thanos 2001; 
Panne et al. 2007). Once all TFs have bound, the nucleosomes flanking the 
enhancers are acetylated, initiating chromatin remodelling. This allows access for 
the TATA-binding protein to the TATA box, a DNA binding motif, and RNA 
polymerase to the promoter, initiating transcription (Agalioti et al. 2000). If any of 
the individual TFs are unable to bind, or are not present, the interferon-b  anti-viral 
pathway will not be activated. These types of enhancers are more susceptible to 
single base pair changes or small deletions; indeed, in the IF-b enhancer almost 






1.2.2 The Billboard/Information Display Model 
Whilst the enhanceosome model appears to work well for ‘all-or-nothing’ responses, 
such as those involved in immunity,the billboard/information display model is much 
more forgiving to modifications, and is more often found at developmental genes, 
such as those within this thesis (Kulkarni & Arnosti 2003; Struhl 2001). While these 
enhancers are also comprised of different TFBS, expression is not reliant upon co-
operative binding, but rather each TF can control expression in isolation. This allows 
for a much greater flexibility of expression, and is also thought to have an inbuilt 
redundancy, as individual TFs can each control expression of the target without 
having to rely on the entire suite of TFs to be bound at each motif. Unsurprisingly, 
billboard enhancers are more forgiving to sequence changes. An example of a 
partially redundant developmental enhancer was described by Gao and Finkelstein 
(1998) who studied the otd expression within Drosophila. Two separate enhancer 
regions were identified that controlled otd expression. Each was able to produce 
the correct patterning on its own, however not at the same intensities of wildtype. 
When both regions are present, wildtype levels of expression are seen- indicating 






1.2.3 The TF Collective Model 
The third and most recently proposed model of enhancer activity is the TF collective 
model. Like the billboard model, it has a greater amount of flexibility in regards to 
sequence changes, and activity is not abolished by loss of co-operative binding 
(Spitz & Furlong 2012). The differences between the two models lies in the 
combination of both protein:DNA, and protein:protein interactions occurring at the 
enhancer, and not all TFs need to be present or bound for full activity to occur 
(Junion et al. 2012; Khoueiry et al. 2017). For example, if a particular TFs binding 
site is lost, the protein may still be able to be recruited to the active enhancer if the 
other members of the collective are present, through protein:protein interactions 
(Uhl et al. 2016). Because of this lack on constraint of TFBS conservation and 
specificity, these enhancers are not always highly conserved and have increased the 
difficulty in predicting enhancer function and importance through DNA sequence 
alone. 
 
An example of a TF collective enhancer is found within the Drosophila distal-less 
regulatory element, which controls two developmental processes; abdominal 
repression and thoracic activation of gene expression in leg precursor cells. Uhl et al 
and colleagues (2016) generated several mutations which altered the TFBS of the 
enhancer and showed that abdominal repression was extremely robust in regards to 
sequence changes, although abdominal activation was less so. To demonstrate the 
TF collective ability for protein:protein interactions, a HOX factor (one of the TFs) 
containing a DNA-binding domain mutation was still able to induce the thoracic 
repression without binding directly to the DNA, consistent with the transcription 





1.3 Enhancer-Promoter Interactions 
For an enhancer to impact target gene expression, it is assumed that it must first 
come into contact with its cognate promoter. When the enhancer is located closely, 
and proximal to its target gene it can be simple to see how this can occur. However, 
many enhancers are not located close to their target promoter, and are often found 
intronically, intergenically, within other genes, and have even been discovered up to 
1 Mb away from their target promoter (Mora et al. 2016; Pennacchio et al. 2013; 
Lettice et al. 2003). TF binding to the enhancer region results in the recruitment of 
various co-factors and other proteins, enabling the enhancer to regulate the 
expression of the gene of interest. However, once the TF has bound to the 
enhancer, it is not clear how it interacts with the promoter. Whilst there are various 
hypotheses for how this interaction may occur, including DNA looping, tracking, 
and chromatin decompaction, or a combination these, there may still be ways in 
which they are interacting that are yet to be identified. The current hypotheses for 







The most widespread hypothesis for how these interactions are made is through 
looping of the intervening regions of DNA. This allows the enhancer and promoter 
to meet, aided by various other scaffolding proteins. One of the first lines of 
evidence supporting the looping hypothesis came from studies of the b-globin 
gene, and its regulation via the locus control region (LCR) enhancer (Tolhuis et al. 
2002). This study used 3C technology (Dekker et al. 2002), which utilises 
formaldehyde to cross-link proteins to nearby DNA. The frequency of interactions 
between the DNA regions can then be analysed. This method was able to show the 
interaction of enhancer DNA with the transcribed globin genes in erythroid cells, 
where the enhancer was active, but not with the repressed globin genes (Tolhuis et 
al. 2002).  
 
Aside from the physical interaction between the enhancer and promoter, other 
factors also appear to be essential to drive enhancer-activated gene expression. 
One of these, RNA polymerase, must be present for transcription to occur as 
evidenced by Vernimmen et al (2007). However, the point has been raised as to 
whether the physical co-localisation of enhancers and promoters is the underlying 
mechanism of enhancer activated expression, or if it is simply the consequence of 





1.3.2 Tracking Theory 
For close range or proximal enhancers, the tracking theory of enhancer action is 
more prominent. In this model, once the DNA is bound by the TF, the intervening 
chromatin is modified in a way to bring the enhancer and promoter into close 
physical contact without looping out the DNA (Benabdallah & Bickmore 2015; Engel 
et al. 2008; Hatzis & Talianidis 2002). 
 
This model of enhancer activity has not been shown to be active in any distal or 
long-range enhancers however, so whilst it may be occurring in these closely linked 
enhancer promoter interactions, it is most likely not the only way of regulating 






1.3.3 Chromatin Decompaction Theory 
The third model of enhancer activity, chromatin decompaction theory, occurs when 
the chromatin between the enhancer and promoter undergoes decompaction, 
rather than bringing the two elements into closer physical contact. Benabdallah et 
al. (2017) studied the murine sonic hedgehog (Shh) gene and its distant neural 
enhancers approximately 100 and 780 kb away. By using 3D-FISH probes at the 
enhancer and promoter, they analysed the distances between the fluorescent 
signals, theorising that if looping were to occur, the two signals would become 
closer together upon activation. However, at two of the four brain enhancers, SBE4 
and SBE6, these distances actually increased, while the others remained the same. 
The enhancers that increased in distance were also those that showed chromatin 
methylation consistent with active enhancers - suggesting that the decompaction of 
the chromatin was involved in the enhancer promoter interaction. It is not yet known 
if this form of enhancer action is occurring at other loci, but it will be interesting to 
see if the chromatin decompaction is a widespread way in which distal enhancers 







1.4 Super enhancers 
Enhancers can be as small as a few TF binding motifs over 50bp, to a collection of 
many motifs that are bound by a variety of TFs over a large distance. Large regions 
of DNA with a high concentration of TF binding controlling highly expressed genes 
are called ‘super-enhancers’. Super enhancers are often associated with higher than 
normal amount of chromatin modification (reviewed in section 1.7) as well as 
binding of BRD4, and the multiprotein complex Mediator, both important 
transcriptional coactivators (Pott & Lieb 2015; Olley et al. 2018). 
  
Research by Whyte et. al. (2013) identified the first group of super-enhancers at key 
cell identity genes. They were able to show that the ‘master’ transcription factors, 
OCT4, SOX2 and NANOG bind to enhancers within embryonic stem cells that are 
then able to control much of the gene expression changes and cell fate decisions of 
these early cells. 
 
The role of super-enhancers in the many aspects of development became apparent 
within patients with Cornelia de Lange-like syndrome. This congenital syndrome is 
unsurprisingly similar to Cornelia de Lange syndrome, which presents as a global 
developmental delay via generalised de-regulation of developmental genes 
affecting many body systems (Kline et al. 2007). It is most often associated with 
mutations in genes important for the cohesin complex. Cohesin is an essential 
protein complex, with its main role being mediating the separation of sister 
chromatids during cell division. It has also been shown to be important for DNA 
damage repair pathways, as well as regulating gene expression (Peters et al. 2008). 
Mutations in genes involved in the cohesion complex, such as NIPBL can result in 
the loss of cohesin dependent chromatin looping important for transcription (Boyle 
et al. 2015; Boudaoud et al. 2017, Deardorff 2007). A recent gene to be identified 




part of the cohesin complex, but is important for ‘reading’ the acetylation status of 
histone associated lysine, and is found at high levels at many super-enhancers 
(Hnisz et al. 2013). Analysis of BRD4 and NIPBL through ChIP demonstrated they 
bound at similar locations at super enhancers. In the BRD4 mutants however, this 
binding was reduced, indicating it was unable to regulate the super-enhancers 
when mutated (Olley et al. 2018). The authors propose that CdL-like syndrome and 







1.5 Trans interactions 
Usually, mammalian enhancers are studied for their ability to regulate the 
expression of genes in cis. In Drosophila however, the presence of trans enhancer-
promoter interactions have been well characterised, and this phenomenon has been 
termed transvection. The first reported gene to undergo this process was Ubx, 
whereby regulatory regions located on a non-protein producing copy of Ubx (Ubx1) 
could still influence the expression of the functional Ubx gene, found on a separate 
chromosome (Micol et al. 1990; Lewis et al. 1954). Since this discovery, many more 
genes in Drosophila have been shown to have both trans and cis interactions 
between enhancers and promoters, suggesting this may be a commonly used 
mechanism, at least within flies (Sipos & Gyurkovics 2005; Mahmoudi et al. 2002; 
Mellert & Truman 2012; Kennison & Southworth 2002). While these studies are able 
to show partial genetic complementation, they were unable to quantify the levels of 
cis and trans interactions occurring at the loci, often due to the complexity of 
regulatory sequences. In an effort to understand this, a set of experiments were 
performed using fluorescent reporter alleles with complete enhancer-less and 
promoter-less constructs of the eye-specific enhancer, GMR (Bateman et al. 2012). 
Interestingly, when only cis interactions could occur, the Drosophila GMR enhancer 
could drive expression of GFP to the eye-discs as expected. However, when only 
trans interactions were allowed to occur, this expression became uneven and 
variegated suggesting it was not acting in the same manner as the cis-enhancer due 
to reduced interactions. Through a series of genetic crosses, the authors were able 
to show that the promoters in cis and trans will both compete for the activity of an 
enhancer, but expression is cis-biased possibly due to the proximity of the enhancer 
and promoter. It is not known whether these results are generally applicable to all 
enhancer-promoter interactions but they do provide an elegant experimental 





Recently, a study of the IgH super-enhancer has shown its capability for trans 
interactions within mouse models (Le Noir et al. 2017). The IgH super enhancer is a 
well characterised region, with many individual enhancer elements, high levels of 
enhancer RNA (eRNA) transcription (reviewed in section 1.6) and high levels of 
active chromatin marks (Le Noir et al. 2017; Pinaud et al. 2011). The authors 
generated transgenic mice carrying either one copy of the IgH regulatory region at 
the endogenous location, or three copies on another chromosome. Through 
analysis with 3D FISH the interactions between the transgene and endogenous Igh 
alleles could be visualised, and demonstrated that trans interactions can occur 
independently of chromosomal context.  
 
Although some mammalian systems have now been shown to interact in trans 
(Alvarez-Dominguez et al. 2017; Le Noir et al. 2017), this has not yet been shown to 
be a common feature like in Drosophila. In fact, a study within mammalian immune 
cells has proposed that there is no evidence of trans interactions during their 
development, and that their lineage identity is purely driven by cis interactions 
(Johanson et al. 2018). As further studies are performed in mammalian systems, it 
will be interesting to see how pervasive the trans interactions are, and if they are 






Figure 3 Proposed model of Trans interactions 
Trans interactions have not been well characterized in mammalian systems. The 
enhancer promoter interactions are usually thought to occur in cis as shown in (A) 
whereby the enhancer one allele interacts with the promoter, influencing 
transcription (top allele). If the enhancer is lost (bottom allele), the promoter may 
be able to generate basal levels of expression, but this does not reach wildtype. In 
(B), the theory of trans interactions states that the TF bound enhancer of one allele 
(top) can interact with the enhancer-lacking allele (bottom) to influence expression, 









The b-globin enhancer is one of the most well studied enhancer regions, and in 
1990 RNAs transcribed at this enhancer were identified (Collis et al. 1990; Tuan et 
al. 1992). Transcripts have since been noted at many enhancers and are termed 
enhancer RNAs (eRNAs). During the FANTOM and ENCODE projects it was 
confirmed that RNA synthesis occurs at almost all active enhancers sites (Lizio et al. 
2015; ENCODE Project Consortium 2012; Feingold et al. 2004). There is currently 
no clear answer as to whether eRNAs are a functional component of an enhancer, or 
simply an artefact due to the high concentration of RNA Pol II which is present at 
active enhancers. These transcripts are usually quite unstable, and are not spliced 
like a protein coding or functional RNA (Smith & Shilatifard 2014).  It has been 
proposed that eRNAs are important in keeping the enhancer within an active and 
open chromatin state to allow for TF binding at the enhancer, or to facilitate 






1.7 Enhancer States & Their Chromatin Signatures 
When DNA is not being actively transcribed, it is usually tightly bound by 
nucleosomes. Nucleosomes are formed of four core histones (H2A, H2B, H3, H4) 
around which the DNA is “wrapped” (Kornberg 1977). Nucleosomes are then 
bound by linker histones, condensing the DNA further and making it inaccessible to 
most TFs (Zhou et al. 1998). However, TFs need to have a way of accessing bound 
chromatin to enable enhancer activation. The histone variants H2AZ, and H3.3 have 
been found to be enriched at enhancer regions, and these are thought to be less 
stable, allowing for easier displacement of nucleosomes, allowing TF binding to 
occur (Jin & Felsenfeld 2007). Indeed, it has been shown that H2AZ knock-down in 
mouse ES cells leads to the mis-regulation of developmental and pluripotency 
genes, possibly due to the inability of TF binding to occur allowing tissue specific 
expression (Creyghton et al. 2008). 
 
Adams and Workman et al. (1995) were able to show that whilst a single TF is often 
insufficient to displace nucleosomes to allow accessible chromatin, the co-operation 
of a group of TF is able to overcome this threshold, allowing DNA binding and 
gene activation. However, another way in which the chromatin can become 
accessible is through the action of a pioneer TF. Pioneer TFs have the ability to bind 
nucleosome condensed DNA before the enhancer is active, creating accessible 
chromatin for future TFs to bind when necessary. An example of this is the binding 
of the FOXA TFs to liver specific enhancer regions. Here it has been shown to 
displace the linker proteins between the nucleosomes, allowing for tissue specific 
TFs to bind and activate transcription during development (Chaya et al. 2001; 






Figure 4 modified from (Calo & Wysocka 2013) Epigenetic modification at different 
stages of enhancer activity. At active enhancers (A) there is high levels of H3K27ac, 
as well as the mediator complex, RNA polymerase and p300 binding; these often 
produce e-RNAs. Primed enhancers (B) are characterized by H3K4me1, as well as 





Histone modifications have become one of the most common ways to identify 
enhancers, and to determine their current states within tissues and at various time 
points. The H3K4me1 mark is one of the most commonly assessed modifications, 
and was found to be associated with enhancers in a pioneering study by Heintzman 
(2007) as part of the large ENCODE project. Whilst H3K4me1 marks are found at 
both active and primed enhancers, they have also been identified at promoters and 
covering broad 5’ regions of actively transcribed genes, so this should be used with 
other data to identify the enhancer state (Calo & Wysocka 2013).  It is thought that 
H3k4me1 methylation can help to promote the incorporation of the H2AZ 
nucleosomes which, as previously discussed, aid in chromatin remodelling and allow 
access by specific TFs. This mark is lost after enhancer decommissioning (Calo & 
Wysocka 2013). 
  
Active enhancers are those that have accessible chromatin, are bound by H3K4me1, 
and have specific TF binding leading to gene expression. These enhancers are 
enriched for the acetylation mark H3K27ac, which is able to differentiate between 
active and poised enhancers unlike H3K4me1 (Creyghton et al. 2010).  The ability 
for enhancers to activate transcription is dependent upon their ability to bind co-
factors, such as p300. These are histone acetyltransferases able to produce 
epigenetic modifications thought to destabilise the nucleosomes, allowing the 
surrounding chromatin flexibility to generate enhancer promoter interactions (Calo 
& Wysocka 2013). It has also been shown that acetylation of Histone H3 (H3K64ac 
and H3K122ac) are also markers of a new class of active enhancers that lacks 
H3K27ac (Pradeepa et al. 2016). These histone modifications are thought to 
function by modifying the chromatin structure to destabilise the nucleosome and 
stimulate transcription (Pradeepa 2017). Identification of these histone marks will 


















1.8 Identifying Enhancers 
Before undertaking functional analyses of enhancers and their activity on gene 
regulation, they must first be identified. One of the most common ways in which this 
is performed is through ChIP-Seq experiments ( Johnson et al. 2007). This involves 
an antibody specific to the transcription factor being studied added to the DNA to 
bind to the protein wherever it may be within the genome. These regions of DNA 
that have been bound by the antibody are cross-linked through incorporation of 
formaldehyde, and digested into smaller regions of DNA which can be sequenced. 
The sequenced regions can then be mapped to the genome to identify where the 
TF of interest was initially bound. Bioinformatic tools can then be used to identify 
common sequences within the identified regions, which can be compared to known 
motifs of TFs through various algorithms such as MEME-ChIP (Machanick & Bailey 
2011) and RSAT peak motifs (Thomas-Chollier et al. 2012). To further validate 
putative binding sites, the peak data can be overlapped with other data to help 
increase the probability of finding active or biologically significant regions (Bailey et 
al. 2013; Bailey & Machanick 2012). As mentioned previously, there are different 
histone modifications associated with varying enhancer states, and by using ChIP-
seq datasets of these modifications within a particular tissue or cell type, the 
enhancer state can be inferred. Other TFs that are known to bind simultaneously, or 
as partner factors can also be used. 
  
It is generally thought that the more conserved region of DNA is, the higher the 
likelihood it will be biologically significant. Through both PhyloP and PhastCons 
algorithms (Siepel et al. 2005), it is possible to assign each DNA bound region a 
score which determines it conservation across placental mammals. By using these 
scores in enhancer identification studies, it helps to narrow down often very large 




important to note that not all enhancers or biologically meaningful regions will be 
highly conserved or vice versa, however this is a useful tool when using large 
datasets. 
 
Whilst ChIP-seq will identify where a TF of interest is binding, it will not give any 
information as to which promoter it is regulating. Often, it is assumed that this will 
be the nearest gene if intergenic, or if intronic the gene in which it is located. While 
this often true, there appears to be many cases where genes are not regulated by 
their closest enhancers. It has been estimated that only 7% of enhancers that loop 
to contact a promoter are located proximally to the target gene (Sanyal et al. 2012).  
By assessing the chromatin loops formed when the enhancer interacts with other 
regions of DNA, a more comprehensive picture of regulation can be determined, 
and this is achieved by chromatin conformation capture technology. 
 
Chromatin conformation capture technology allows the quantification of interacting 
DNA regions within specific cells or tissue types (Gavrilov et al. 2009). This is 
accomplished through cross-linking of proteins with formaldehyde, followed by 
restriction enzyme digestion, and subsequent random ligation of the fragments. 
Interactions between cross-linked fragments are favoured over non-cross-linked, 
and these can then be quantified through PCR. It is important to note that through 
random chance many fragments will interact, so these must be able to reach 
statistical significance before any results can be inferred. The original incarnation of 
this method was 3C, in which two interacting regions can be assessed, such as a 
putative enhancer and its cognate promoter (Dekker et al. 2002). Further 
technologies have been built upon this method including 4C (one known candidate 
region, and unknown targets) (Zhao et al. 2006), 5C (all interacting regions within a 
certain region) (Dostie et al. 2006), and Hi-C (all interacting regions genome-wide) 





Incorporating this method with ChIP-Seq has also been done, leading to ChIA-Pet 
(chromatin immunoprecipitation with paired end tagging), which is able to identify 
long range and interchromosomal interactions between chromatin regions. An 
example of this was used in a study by McAninch (2014) in which an existing 
RNAPol II dataset was overlapped with a SOX3 ChIP-Seq dataset to determine 
interacting regions (Zhang et al. 2013). This was able to produce an interaction map 
identifying a region within the Tex14 gene which shows interactions with 263 other 
promoters and enhancers, implicating SOX3 within a large transcriptional hub with 







Figure 4 modified from Rodriguez-Ubreva (2013). The process of ChIP-Seq. DNA bound 
the protein being studied is cross-linked with formaldehyde. The cells are then lysed and 
DNA I fragmented into smaller pieces, before an antibody corresponding to the protein of 
interest is added. The DNA that is bound by an antibody is the purified, and these smaller 
fragments of DNA can be sequenced and mapped to the genome to determine where the 





1.9 Enhancers and Disease 
The importance of understanding enhancers, not just for controlling gene 
expression, but as regions of disease causing mutations, is an important area of 
research. The identification of these is often hampered, as many genome wide 
association studies (GWAS) and genome sequencing is often only performed on 
exomes (Gibson 2018). Although these regions are statistically much more likely to 
contain a disease-causing allele, and only looking at the exome reduces the cost 
significantly, cis-coding regions that contribute to disease will be missed when using 
this approach. 
 
The introduction of large-scale datasets such as the Gnomad database is helping to 
identify single nucleotide polymorphisms (SNPSs) and allelic variants that are 
present within the healthy population, through the combination of whole genome 
and exome sequencing (Lek et al. 2016, Karczewski 2019). This data can be used to 
analyse when mutations are found within a disease patient, whether this is 
correlated with the disease or if it is just natural variation. There are currently over 
100,000 and exome sequences, and 15,000 whole genome sequences, and this 







Figure 5 (Krijger & de Laat 2016) 
There are many ways in which enhancers can cause disease. If an enhancer has 
been deleted, gene expression may not occur, or if an individual binding site for a 
TF is mutated or lost, expression may be lost or reduced leading to disease. 
Enhancers can also be duplicated, or potentially introduced leading to disruption in 
gene expression. Enhancer hijacking has also been seen in some cancers whereby 







In response to this large amount of data being generated, and in an attempt to 
annotate human disease enhancers, the Human Enhancer Disease Database (HEDD) 
has recently been built and made freely available ( Wang et al. 2017). This database 
incorporates information from enhancer studies (ENCODE, FANTOM5), disease 
studies (DisGeNET, MalaCards), GWAS studies, histone modifications (UCSC) and 
TF Binding Sites (UCSC). 
 
As enhancers are responsible for such a large proportion of the finely controlled 
gene regulation during embryonic development, it is not surprising that the loss or 
mutation of these can lead to disease. However, it can be difficult to link enhancer 
mutations to diseases for a number of reasons. One of these is that many 
sequencing efforts or GWAS studies only focus on the exome, and oftentimes an 
enhancer does not control its nearest neighbouring gene. 
 
One congenital embryonic disorder that has been associated with a particular group 
of enhancers is holoprosencephaly. Holoprosencephaly is a brain malformation 
where the forebrain midline fails to undergo cleavage to form the bilateral cerebral 
hemispheres (Golden 1999). This disorder affects 1 in 250 foetuses (Matsunaga & 
Shiota 1977), but only 1 in 8000 live births (Leoncini et al. 2008), as it is often fatal 
before birth. 
 
Sonic hedgehog (Shh) is an essential gene which among other functions has been 
shown to be important in forming the ventral midline structures in the developing 
central nervous system (Chiang et al. 1996). When Shh levels are reduced to 50% in 
humans, holoprosencephaly is evident, however mouse models are less sensitive to 
this mutation, requiring homozygous loss of the gene to elicit the same effect 
(Roessler et al. 1996; Chiang et al. 1996). Three enhancer regions were identified in 
the 35Kb upstream of Shh (Epstein et al. 1999) and this was expanded to a total of 




enhancer trap assays utilising BAC clones, the upstream genomic DNA was 
assessed for reporter activity in mouse embryo forebrains. The discovery of these 
regions shows that there is complex and often redundant regulation of Shh from 
long-range and close-range enhancers, which when displaced can cause expression 
defects leading to holoprosencephaly. This is based on the evidence of two patients 
with chromosomal rearrangements at 7q36, where Shh is shown to map (Lettice et 
al. 2002; Albuisson et al. 2011). This rearrangement was not found to be within any 
coding region, so it was hypothesised that these rearrangements have interfered 





1.10 Validating Enhancers 
Within the last two decades, our ability to generate bioinformatic data has greatly 
expanded. Whilst this has increased our knowledge about enhancers, and has 
improved our ability to identify them, there is a wealth of putative enhancers and 
regulatory regions that have not yet been functionally analysed. The technology 
available to assess the biological significance of putative enhancers has not yet 
caught up with the amount of data being produced. However, recent advances in 
genome editing technology including CRISPR in animal models has proved to be an 






1.10.1 Traditional Techniques 
Historically, the most popular way to assess the functionality of enhancers was to 
use reporter assays. By placing the enhancer in question upstream of a minimal 
promoter and a reporter, such as luciferase, it can be transfected into a cell line that 
expresses the TFs thought to bind, and a read-out of activity can be assessed 
through quantification of the luciferase gene expression. This is done either 
episomally, or by integrating the reporter gene construct chromosomally. It has 
recently been found through a high throughput assay examining over 2000 liver 
specific putative enhancers, that for the most consistent and biologically 
reproducible data, chromosomal integration gives the best results (Inoue et al. 
2017). 
  
Even better than using a cell line reporter assay, is the use of LacZ reporter assays 
within developing mouse embryos. This technique was first pioneered by Mansour 
et al. (1990) to show the expression of int-2 was recapitulated by LacZ in the 
developing embryo. This uses the same general principle as the cell line reporter 
assay, but the plasmid construct is randomly integrated the chromosome of a 
single-cell zygote by microinjection. This ensures that all cells contain a copy of the 
‘test enhancer’ and that this will be bound by the endogenous TFs to produce a 
similar result to that of the endogenous gene expression. After transient embryo 
dissection, a b-galactosidase reaction is performed on the embryos, and all regions 
in which the LacZ is expressed will develop a deep blue pigment. The VISTA 
enhancer browser is an example of a large-scale effort to experimentally validate 
thousands of putative enhancers through these LacZ reporter assays in mice (Visel et 
al. 2007), and this has since expanded into assessing cardiac specific enhancers. 
This is still a widely used technique that can produce high confidence results 
showing if the region is sufficient for expression. However, this needs to be 




genome which can produce differing results depending on the chromatin 




Generation of LacZ transgenic mice for enhancer analysis. To test the activity of a 
putative enhancer it can be cloned upstream of the LacZ gene, and driven by a 
promoter. The DNA is microinjected into a fertilized zygote where it can randomly 
incorporate into the genome. The injected zygotes are transferred into a 
pseudopregnant foster mother and allowed to develop. Embryos are dissected at a 
timepoint when the enhancer is thought to be active, and are stained with an X-Gal 
solution. If the enhancer is active, the LacZ will be expressed, and will stain the 
embryo blue in the tissue it is expressed. In the diagram, the blue staining can be 
seen in the neural tube. The enhancer’s activity can be insinuated from the location 







1.10.2 CRISPR/Cas9 Technology  
Over the last 5 years, the field of genetic modification has grown considerably, 
largely due to the development of CRISPR/Cas9 technology. First discovered as a 
bacterial defence system in 1998 (van Belkum et al.), it wasn’t until 2013 that this 
system was adapted for use in mammalian systems to create specific mutations 
which has revolutionized genome editing (Cong et al. 2013). For a comprehensive 
review of CRISPR and its use in mouse models, see Appendix 1 for the publication 






1.10.2.1 Bacterial Defence System 
The use of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) to 
manipulate genomes has been developed based on the knowledge of the innate 
immunity system of the same name present in most prokaryotes. This system was 
discovered by van Belkum and colleagues(1998), when the CRISPR array of small 
DNA sequences located between repeat elements was found to correlate with 
regions of DNA in bacterial pathogens such as phage or virus DNA (Bolotin et al. 
2005). The finding that these regions of DNA, known as protospacers could be 
created after challenge with a pathogen, and then later be used to protect against 
further infection (Barrangou et al. 2007) was an important piece of knowledge that 
allowed the CRISPR system to be repurposed for genetic editing applications. 




1.10.2.2 Use in mammalian systems 
A significant advance in CRISPR technology occurred when Cong and colleagues 
(2013) were able to design a system incorporating the elements of the type II 
CRISPR system into an easily modifiable plasmid. Instead of two separate 
transcripts, the pre-crRNA and tracrRNA were combined into a single transcript, 
known as a single guide (sgRNA). This RNA molecule includes a 20 bp targeting 
sequence, which is able to direct Cas9 nuclease to the genomic site for 
mutagenesis.     
 
Whilst many regions of the genome can be targeted, the largest restriction with this 
system is the protospacer adjacent motif (PAM; corresponding to NGG for SpCas9), 
that must be at the 3’ end of the sequence, and is essential for the initial binding of 
Cas9 nuclease. Sternberg et al. (2014) showed this by analysing the binding of Cas9 
to target sequences, demonstrating the nuclease binds preferentially to PAM 
sequences within the genome, and rapidly dissociates from those not containing it. 
Only once the Cas9 has bound to the PAM is the DNA able to interrogate the gRNA 
for sequence complementarity (Sternberg et al. 2014). 
 
Once the double strand break has been generated at the target locus, various 
methods are available to modify the DNA. For the introduction of insertions or 
deletions, the non-homologous end joining repair mechanism native to the cell can 
be exploited (Ran et al. 2013). This will generally result in small deletions and is 






Figure 7 CRISPR CAS9 to introduce mutations in DNA (modified from Thomson et 
al. 2018) 
The single guide RNA, and Cas9 protein or mRNA can generate a variety of 
mutations. The simplest is an ‘indel’ where a double strand break is generated and 
repaired by the cell leaving only a small mutation, of wither an insertion or more 
commonly deletion. To generate a more defined deletion, two single guide RNAs 
can be combined with Cas9 to generate two double strand breaks which remove 
the intervening sequence. This is then repaired by NHEJ at the cut sites. Insertion 
can be generated through incorporation of a ssDNA repair template with 
homologous regions flanking the new mutation to be inserted. Plasmid based 







1.10.2.3 Further Enhancements of the System  
Since the series of landmark papers outlining the use of CRISPR for mouse model 
modification, further refinements of both the endonuclease enzymes and the 
targeting strategies have emerged producing a vast ‘toolbox’ for researchers to 
utilise. 
 
If off-target effects are a major concern, endonucleases that have higher specificity 
for on-target cutting have been developed, such Cas9-HF1 (Kleinstiver et al. 2016). 
Another way to achieve this is to use an endonuclease that does not cause a double 
strand break, but instead ‘nicks’ the DNA by cutting only a single strand, known as a 
‘nickase’ Cas9-n (Ran et al. 2013). When two of these are used close by, they are 
able to increase the specificity of the target whilst minimising the potential for off-
target effects as the ‘nick’ can be easily repaired by the cell.  
 
Cas9 from different bacterial species such as Staphylococcus aureus (Thakore et al. 
2018; Lee et al. 2016), Niesseria meningiditis and Streptococcus thermophilus 
(Müller et al. 2016; Kleinstiver et al. 2015) have been shown to have different PAM 
sequences, enabling a greater range of the genome to be targeted for editing. 
Addition of cytosine or adenine deaminase to a catalytically inactivated Cas9 
protein (dCas9) have been also been produced (Gaudelli et al. 2017; Komor et al. 
2016). Instead of introducing double strand breaks these are able to generate 
targeted SNPs, changing individual bases; either A-G or C-T. These are likely to be 
extremely beneficial for gene therapy targets in the future, however the off-target 
implications of these has not been studied in depth enough to know their specificity 




1.10.2.4 CRISPR for enhancer analysis  
CRISPR has become an extremely useful tool for enhancer analysis and validation. 
Whilst reporter assays can show when and where a putative enhancer can direct 
expression, this does not mean that in its native context this will occur. Many factors 
such as chromatin accessibility, and the number of transgene inserts can affect this 
expression, whereas simply removing the enhancer from the genome will give a 
better in vivo readout of its functionality. 
 
There are two main ways in which this CRISPR can be utilised for enhancer analysis. 
The first is to simply remove the putative binding sites. This is best achieved via two 
sgRNAs, which will often remove intervening sequence without generating larger 
unwanted deletions. Alternatively, the non-homologous end joining repair system 
can be exploited and used to insert a sequence containing a modified version of the 
region, to which the TF of choice will be unable to bind. In results chapters 2 and 3, 







 2 SOX Proteins  
One of the many transcription factor families that are active during embryonic 
development is the SOX family of transcription factors (Kiefer 2007). These 
transcription factors rely on binding to enhancer sequences throughout the genome 
to control many cell fate decisions that are important to development of the foetus, 
and postnatal life.  
 
 
Figure 8 Modified from (Bowles et al. 2000) 
The SOX Subgroups. All SOX proteins contain the conserved HMG Box, and are 
then sub-classified into 8 separate groups (A-G) based on their sequence structure 





2.1 The SOX Family  
SOX (Sry-Related HMG Box) proteins form a large 20 member protein family, with 
varied roles within embryonic and postnatal development in mammals, with 
homologues in other species such as Drosophila, Danio rerio (zebrafish) and 
Xenopus laevis (frog) (Crémazy et al. 2000; Okuda et al. 2010). They encode a set of 
transcription factors which are categorised based on their homology to each other, 
and all contain a HMG Box DNA binding domain, first characterised in the founding 
member Sry (Sinclair et al. 1990). Many of these factors have been implicated in a 






2.1.1 The HMG Box  
The first SOX protein to be discovered was encoded by the mouse Sry gene 
(Gubbay et al. 1990; Sinclair et al. 1990) found to be the elusive testis determining 
factor located on the Y chromosome, and is responsible for differentiation of the 
gonad towards a male fate (Koopman et al. 1991). This is a single exon gene, with 
the only known functional domain being the HMG Box, involved in DNA binding, 
protein interactions and nuclear import (Wilson & Koopman 2002). HMG Box 
domains are present within a large variety of proteins across species, but the SOX 
group represents the largest cohort of these in humans and mouse (Štros et al. 
2007). 
  
Transcription factors act by their ability to bind DNA, leading to either activation or 
repression of target genes. In the SOX proteins, this is the function of the HMG Box, 
whose structure is shown to be comprised of three alpha-helices and a hydrophobic 
core in an inverted L-shape (van Houte et al. 1995). This is the most conserved 
region amongst the SOX factors, and all share a very similar consensus DNA 
binding motif (5′-(A/T)(A/T)CAA(A/T)G-3′) (Kamachi et al. 1999; Mertin et al. 1999). 
Unlike most TFs, the SOX HMG Box binds to the minor groove of the DNA, rather 
than the major groove (van de Wetering & Clevers 1992). It has been proposed that 
by binding to this region, and generating a 70-85 degree bend in the DNA, the 
protein is able to come into close contact to other TFs, and possibly could play an 
architectural role in multiprotein enhancer complexes or chromatin accessibility 





2.1.2 Subgroups and Homology  
SOX proteins are classified into 9 distinct subgroups, with every member sharing at 
least 50% homology to the HMG Box of the original SOX member, Sry. Sub 
classification is then allocated based on homology to other SOX proteins, with 
those having at least 85% homology to each other forming a subgroup; these often 
also contain similar structural motifs and functional properties (Sarkar & 
Hochedlinger 2013; Chew & Gallo 2009).   
  
  
The SOX subgroups, whilst varied in their roles are broadly defined as 
developmental transcription factors. They can be both activating and repressing, 
sometimes with different members showing distinctly opposing functions. The 
SOXB1 factors (which will be the main focus of this thesis) are active during early 
embryonic neural development, and their main role is to inhibit neurogenesis by 
maintaining stem cells within a progenitor state (Bylund et al. 2003), while the 
SOXB2 member SOX21 actively promotes neurogenesis by counteracting the 




2.2 SOXB1 Subgroup  
The SOXB1 subgroup is made up of three proteins, SOX1, SOX2 and SOX3. SOX3 
was discovered soon after Sry, and the high level of similarity along with its location 
on the X chromosome has led to the hypothesis that SOX3 was the original SOX 
member, from which Sry is thought to have evolved (Waters et al. 2007; Nagai 
2001). Indeed, ectopic expression of SOX3 in the developing female gonad can 
induce XX male sex reversal in mice and probably humans (Sutton et al. 2011). 
Along with the highly similar SOX1 and SOX2, these genes are responsible for the 
regulation of neurogenesis during early development, as well as having their own 
tissue specific functions in other aspects of embryogenesis. 
 
While the function of these proteins is known, the exact mechanisms by which they 
perform their function is an active area of research. These TFs are thought to control 
the expression of a multitude of genes, but exactly what these genes are and when 
this control is needed is unknown. This question is the main focus of this thesis, 
understanding where in the genome SOXB1s are binding and exerting their effect 






2.2.1 SOXB1 within Neural Tissues 
The SOXB1s are mainly expressed in the central nervous system and have very 
similar patterns of expression. Wood & Episkopou (1999) published a 
comprehensive comparison of SoxB1 expression from pre-gastrulation embryos to 
the early somite stage (Figure 6).  Sox2 is expressed earlier than either Sox1 or 
Sox3, at 2.5 dpc within the morula, and at 3.5 dpc can be detected within the inner 
cell mass of the blastocyst. After implantation, expression continues throughout the 
epiblast and becomes restricted to the presumptive neuroectoderm during 
gastrulation. By 9.5 dpc, Sox2 is expressed throughout the developing brain and 
neural tube. Sox3 is the second SoxB1 gene to be expressed and is first detected 
immediately after implantation at 5.5 dpc in the epiblast. At 7.0 dpc, expression is 
restricted to the anterior neural plate. By 9.5 dpc, expression is detected 
throughout the neuroaxis (Uchikawa et al. 2011; Wood & Episkopou 1999). Sox1 is 
the last of the family to be expressed. The first mRNA is detected at low levels in 
the neural plate ectoderm during the late head fold stage (Wood & Episkopou 
1999), and expression continues in all neuroepithelial cells of the anteroposterior 
axis (8-8.5dpc), which forms the neural tube at 9.5 dpc. 
 
The overarching function of the SOXB1 subgroup of proteins is to maintain neural 
progenitor cells (NPCs) of the CNS within a stem-like state, while also inhibiting the 
differentiation of these into other cell types. This was shown by Bylund et. al. (2003) 
using electroporated chick embryos whereby the presence of SOX1, SOX2 and 
SOX3 countered the activity of proneural proteins, and the ability to differentiate 
was reliant upon suppression of these SOXB1 proteins (Bylund et al. 2003). 
Inhibition of SOX2 however, leads to their early exit from the cells cycle, resulting in 
early differentiation (Graham et al. 2003). Rescue of this phenotype was achieved 
with co-expression of SOX1, indicating the functional similarities and overlapping 






Figure 9  (Wood & Episkopou 1999) 
Whole mount in situ hybridization of SOX1, 2 and 3 in mouse embryos.  A. Dorsal 
view of embryos at the 1-3 and 6 somite stage for each of the TFs (SOX1, SOX2 
and SOX3), with primitive streak shown by arrowheads. B. The hindbrain of the 6, 
8-10 and 12-14 somite embryos , s; somite, r; rhombomere, I; first branchial arch,  
II; second branchial arch.  C. Transverse sections of embryos. R; rhombomere, d; 
dorsal, v; ventral, h;heart, fg; foregut, se; surface ectoderm, ov; optic vesicle, np; 




2.2.2 SOXB1s in Testes Development  
 
SRY and SOX9 are essential for the progression of the undifferentiated gonads to 
into the male testes (Koopman et al. 1991; Sekido & Lovell-Badge 2008; Barrinuevo 
2006). While the SOXB1 members are not required for sex determination, SOX3 is 
essential for proper postnatal development of the testes and is the only SOXB1 
protein expressed at these stages.  
 
Spermatogenesis is the developmental process that male germ cells undergo to 
form mature sperm within the testes. The cells transition from spermatogonia to 
primary and secondary spermatocytes, then spermatids to eventually create 
spermatozoa able to fertilise the female oocyte (Griswold 2016). SOX3 is expressed 
within the early stages of this process, found within the early spermatogonia, As, 
Apr and Al (Raverot et al. 2005; Rizzoti et al. 2004).  As will be discussed in section 
2.3.2, SOX3 null mice are unable to properly undergo spermatogenesis, leading to 
an accumulation of spermatocytes with reduced spermatocytes (Laronda & Jameson 
2011). It has been proposed that SOX3 is essential for spermatogenesis in a 
developmental pathway that also involves the transcription factor Neurog3 (Raverot 
et al. 2005). This link is further explored in Chapter 4, where a ChIP-Seq experiment 













2.3 Specific Targets  
The SOXB1 proteins appear to have many overlapping transcriptional targets 
throughout development, and all bind to the same or highly similar DNA motif 
through their HMG box. As mentioned previously, knockout or mutant models of 
each SOXB1 member still produces phenotypic effects indicating that they cannot 






2.3.1 SOX2  
Mouse Models  
 
As SOX2 is the first of the group to be expressed, it has many specific targets. As 
such, SOX2 knockout mouse models cause early embryonic lethality (Avilion et al. 
2003) that is unable to be rescued by either SOX1 or SOX3, as their expression is 
restricted until later time points. It has been proposed that SOX2 is able to act as a 
pioneer TF in the early inner cell mass from which the embryo is derived (Zaret & 
Carroll 2011; Iwafuchi-Doi et al. 2016). 
  
By generating conditional knockout models of SOX2 which restrict expression to 
~5% of wild type levels within the developing brain from E14.5, preimplantation 
lethality can be avoided and specific SOX2 functions can be analysed in the 
developing CNS (Miyagi et al. 2008). Although these mice still die shortly after birth, 
it was shown that there is an essential role of SOX2 in generating the appropriate 
number of neural progenitor cells within the developing brain. It was noted that 
SOX3 levels were increased in these mice, presumably to compensate for the loss  
A recent study by Hagey et al (2018) undertook a large scale analysis of SOX2 
binding within various tissue and cell contexts, incorporating both RNA-Seq and 
ChIP-Seq analysis. By looking at the cortex, spinal cord, stomach and 
lung/esophagus they could show that SOX2 is able to regulate both tissue-specific 
and more global core transcriptional programs. SOX2 was shown to bind highly 
similar motifs within all contexts, although enrichment for known co-factors was also 







Human mutations in SOX2 have been identified, with phenotypic consequences 
mostly being restricted to the eye, with defects such as anophthalmia (absence of 
one or both eyes) and microphthalmia (significantly reduced eye size) (Driggers et 
al. 1999; Fantes et al. 2003; Faivre et al. 2006), and these are often coupled with 
delayed motor and general development. A study of 120 patients with congenital 
eye abnormalities identified 12 mutations within Sox2 (Bakrania et al. 2007). These 
mutations included missense, frameshift and whole gene deletions of Sox2, 
indicating that SOX2 haploinsufficiency is a cause of these eye defects. Whilst this 
correlation had been identified, it was not until a study in 2006 (Taranova et al.) 
where a mouse model that generated different gene-dosages of SOX2 to assess the 
effects on development of the eye that this was confirmed. When a SOX2 
conditional deletion was introduced, the NPCs within the retina lost the ability to 
divide and differentiate, whereas hypomorphic alleles led to aberrant differentiation 




2.3.2 SOX3  
Mouse Models  
Knockout mouse models of SOX3 do not have as severe a phenotype as those of 
SOX2, generating mice with relatively mild defects. Rizotti and colleagues (2004) 
generated SOX3 null mice, and the resulting mutation led to a variety of defects 
including craniofacial abnormalities, as well as fertility defects. They focused 
however on the pituitary, and were able to show that SOX3 is essential for 
development of the hypothalamic-pituitary axis and is not compensated for by other 
members of the SOX family. 
  
Spermatogenic defects have also been investigated in SOX3 null mice, which show 
that whilst Sox3 is evolutionarily very close to Sry, it is not important or required for 
sex determination in mammals but is needed for proper gonadal function ( Weiss et 
al. 2003). Through analysis of the postnatal testes, it was shown that loss of SOX3 
generates testes with greatly reduced weight, Sertoli cell vacuolization and loss of 
germ cells leading to sterility. This indicated that SOX3 is an important factor 
involved in spermatogenesis, the maturation of germ cells into functional sperm, 
and that it is specifically expressed within the As, Apr and Al spermatogonia 
(Raverot et al. 2005). Within this study, a functional link was proposed between 
SOX3 and NEUROG3, another TF expressed within both neural and endocrine 
progenitors, and the same spermatogonia subtypes as SOX3. Within results 
Chapter 3 of this thesis, a functional link between NEUROG3 and SOX3 in the 
progression of spermatogenesis is proposed. 
 
A SOX3 specific target within the spinal cord is the homeobox gene Dbx1 (Rogers 
et al. 2014). Intriguingly, this is one of the few SOX3 bound genes to be identified 
that is unable to be rescued by other SOX family members. This research suggests 











Human Mutations  
Phenotypes such as hypopituitarism, mental retardation and spermatogenic defects 
are the most common disorders of Sox3 mutation in humans. Polyalanine tract 
expansions within SOX3 have been identified as the causative mutation in a family 
with mental retardation and growth hormone deficiencies (Hamel et al. 1996) 
(Laumonnier et al. 2002). The association of the polyalanine tract expansions with 
hypopituitarism was further investigated in a chimeric mouse model by Hughes et 
al. (2013) where it was found that the expanded polyalanine tracts generate very 
low levels of SOX3 protein, not sufficient for proper development of the 
hypothalamus. 
 
Sex reversal has also been seen in patients carrying mutations which affect the 
regulation of SOX3. Analysis by Sutton et al. (2011) of patients that were 46, XX but 
phenotypically male, showed chromosomal rearrangements and duplications of 
SOX3 which were shown to alter the regulation of expression. As mentioned 
previously, when SOX3 is ectopically expressed within the developing gonad of 
mice, it can act in a similar way to SRY, and activate Sox9 leading to phenotypically 
male embryos. It is thought that these patient mutations are leading to modification 
of the regulation of SOX3 and allowing it to act as an SRY surrogate, producing 






2.3.3  SOX1 
Mouse Models 
Like SOX3, the loss of SOX1 is not as severe as that of SOX2, presumably because 
of the functional redundancy between the other members of the SOXB1 family. 
However, SOX1 is specifically expressed within certain regions which are unable to 
be compensated for. By generating SOX1 null mouse lines, Nishiguchi and 
colleagues (1998) were able to show the importance of SOX1 for proper 
development of the lens fiber within the eye. Whilst SOX2 is expressed within the 
sensory placode of which develops into the lens, it is replaced by SOX1 prior to the 
expression of γ-crystallin genes . SOX1 has been shown to partner with PAX6 to 
bind to regulate the suite of γ-crystallin genes leading to elongation of the lens 
fiber cells critical for lens development (Nishiguchi et al. 1998). These mice lacking 
SOX1, whilst only showing mild phenotypic effects of the eye; small eyes with 
opaque lenses, also showed signs of epileptic seizures. Whilst these mice develop 
brains without major malformations, there is a loss of neurons within the ventral 
striatum present from birth (Malas et al. 2003). The loss of these neurons disrupts 
the olfactory circuit, shown by abnormal electrophysiological recordings which can 







Whilst research in mouse shows the effects of SOX1 loss in a model system, human 
mutations in Sox1 have not yet been well explored. There are however patients that 
present with large deletions on chromosome 13, which encompass among other 
genes, Sox1 (Reinstein et al. 2016). The smallest of these deletions, 1.3Mb, has 
been found in 2 brothers who present with epilepsy and mild intellectual disability 
as well as genitourinary tract defects (Orsini et al. 2018). SOX1, along with 
ARHGEF7 have been implicated in this phenotype due to their associations in 





2.4 Functional Redundancy 
Highlighting the importance of the SOX factors, knockout mouse models of SOX2 
(the first to be expressed) exhibit early embryonic lethality (Avilion et al. 2003). 
Knockout models of SOX3 and SOX1 however, only show mild phenotypic effects, 
such as growth hormone deficiencies and microphthalmia, respectively (Rizzoti et al. 
2004; Nishiguchi et al. 1998). Given that the effects seen in SOX1 and SOX3 
knockout and mutant models are so mild when compared to SOX2 knockouts it was 
proposed that these three proteins are functionally redundant (Miyagi et al. 2009). 
Each of the proteins are very similar and each are capable of binding to the same 
TFBS within areas where they are all expressed, such as the neural progenitor cells. 
As Sox2 is the first of the group to be expressed, neither SOX1 or SOX3 is able to 
compensate for this loss and bind to the important SOX2 transcriptional targets 
leading to early lethality. Once Sox1 and Sox3 are expressed however, SOX2 
protein is already present and capable of binding to each of the others 
transcriptional targets, reducing the phenotypic effects seen. 
 
By utilising CRISPR technology, Adikusuma (2017) replaced the coding sequence of 
SOX3 with SOX2 and assessed its effect within the postnatal testes, a SOX3 specific 
region. This demonstrated that this gene swap was able to functionally compensate 
for the loss of SOX3 under the regulation of its endogenous promoter 




2.5 DNA Binding Partners  
While TFs are able to regulate expression of genes through binding to the DNA, an 
extra level of regulation can be imposed through partner factor binding. 
Throughout the 20 members of the SOX family, the DNA binding motif is highly 
similar- so how the individual TFs are able to bind to their own motif was not well 
understood. Kamachi et al (2000) has proposed a model of SOX binding, whereby 
an individual SOX TF alone is insufficient to activate gene expression and must be 
co-operatively binding with a partner to elicit an effect. Binding partners have not 
yet been identified for every SOX protein at every enhancer, but this has been seen 
at some loci. 
 
One of the most well studied partner factors of the SOXB1 proteins is the POU (Pit-
Oct-Unc) family. These are a group of transcription factors that contain the DNA 
binding POU domain, and are important for regulating cellular identify during 
development and are expressed within the developing CNS along with many SOX 
proteins (Latchman 1999). It has been estimated that SOX2 and Oct4 are able to 
bind together at thousands of enhancers within various tissue contexts, most 
prominently within neural stem/progenitor cells (Nishimoto et al. 1999; Tomioka et 
al. 2002). The importance of the regulation of many of these genes led to the theory 
that the two families may have co-evolved as cooperative regulators of many cell 




2.6 Identification of SOXB1-bound enhancers 
To identify enhancers bound by the SOXB1 proteins within the central nervous 
system, a ChIP-Seq experiment was performed on cultured mouse neural 
progenitor cells with a SOX3 antibody (McAninch & Thomas 2014). From this 
dataset over 8000 regions were identified as being bound by SOX3, so further ChIP 
data from SOX2 binding and p300 in similar cell types was used to identify a smaller 
subset of regions bound by each of these, that could be identified as putative 
enhancers. As well as evidence that the SOXB1 proteins bound to these regions of 
DNA, it also gave further insights into how and what SOXB1 is regulating and its 
specific roles within the NPCs. GO terms were generated from the binding regions 
which suggests that the SOXB1s are involved in various aspects of neural tube and 
brain development. Further evidence for SOXB1 and Oct protein partner binding 
was also shown when motifs were identified that incorporated the TFBS of both 






2.7 Project Aims 
All of the SOXB1 proteins are expressed within the neuroprogenitor cells of the 
CNS, while SOX3 is also found within the postnatal testes. The transcriptional 
targets of these proteins have not yet been fully elucidated, however previous work 
such as that by McAninch and Thomas (2014) described previously generated a list 
of putative enhancers bound by SOXB1s. The aims of this thesis have been to both 
identify and investigate putative enhancers bound by SOXB1 through both ChIP-
Seq data analysis as well as the generation of CRISPR mouse models to investigate 
gene expression and phenotypic effects. 
 
A previously described enhancer of the neurofilament gene Nes is shown to contain 
SOXB1 and POU TFBS, and Chapter 2 of this thesis examines the contribution of 
this enhancer to overall expression as well as the possibility that it is capable of 
trans interactions.  
 
FZD3 (Frizzled 3) is an essential protein that is important for brain development. In 
the SOXB1 ChIP-Seq analysis  a region of high conservation was identified with a 
Fzd3 intron that appeared to be bound by SOXB1 (McAninch & Thomas 2014). In 
Chapter 3, we deleted this putative enhancer and assess its role in Fzd3 expression 
though CRISPR modification and reporter mice.   
 
The final results chapter focuses on SOX3’s role within the postnatal mouse testes. 
A ChIP-Seq experiment was performed and the chapter analyses the results of the 
bound regions. This shows a potential role for SOX3 in the regulation of histone 
replacement in sperm as well as providing evidence that strengthens the link 






The Nestin neural enhancer is essential for 
normal levels of endogenous Nestin in 








This manuscript outlines the functional analysis of the SOXB1 bound enhancer 
region that controls expression of the neurofilament gene Nes. This enhancer has 
previously been identified as a CNS specific enhancer which can be used to direct 
transgene expression to neuroprogenitors, however the endogenous functionality 
of this region has not been assessed. 
 
By using CRISPR to generate deletions of the SOXB1 binding motifs we have been 
able to study the contribution of this enhancer to Nes expression throughout 
embryogenesis. We can show that this enhancer is active from 9.5dpc in the head, 
and at 10.5 dpc is responsible for up to 70% of Nes expression. 
 
We also generated 2 independent Nes null lines using CRISPR. Through breeding 
with enhancer deleted mice we show promising evidence of trans enhancer- 
promoter interactions, a relatively new field of mammalian enhancer research. 
 
Through these experiments we have shown the Nes enhancer is essential for proper 






















The Nestin neural enhancer is essential for normal levels of endogenous Nestin in 
neuroprogenitors but is not required for embryo development 
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Enhancers are vitally important during embryonic development to control the 
spatial and temporal expression of genes. Recently, large scale genome projects 
have identified a vast number of putative developmental regulatory elements. 
However the proportion of these that have been functionally assessed is relatively 
low. While enhancers have traditionally been studied using reporter assays, this 
approach does not characterize their contribution to endogenous gene expression. 
We have studied the murine Nestin (Nes) intron 2 enhancer, which is widely used to 
direct exogenous gene expression within neural progenitor cells in cultured cells 
and in vivo. We generated CRISPR deletions of the enhancer region in mice 
assessed their impact on Nes expression during embryonic development.  Loss of 
the Nes neural enhancer significantly reduced Nes expression in the developing 
CNS by as much as 82%. By assessing NES protein localization, we also show that 
this enhancer region contains repressor element(s) that inhibit Nes expression within 
the vasculature. Previous reports have stated that Nes is an essential gene, and its 
loss causes embryonic lethality. We also generated 2 independent Nes null lines, 
and show that both develop without any obvious phenotypic effects. Finally, 
through crossing of null and enhancer deletion mice we provide evidence of trans-







Embryonic development requires precise coordinated expression of thousands of 
genes across space and time. Regulatory elements such as enhancers have a critical 
role in coordinating spatio-temporal gene expression during embryogenesis. 
Enhancers are typically located within introns and intergenic regions and comprise 
DNA motifs that can be bound by transcription factors (TF). TF binding promotes 
interaction of the enhancer with the target promoter via DNA looping.  This 
process, which involves cohesins and the mediator complex (Kagey et al. 2010), 
allows TF-associated co-activators to engage the transcriptional machinery and 
stimulate RNA Pol II-mediated transcription of the target gene. While enhancers are 
generally regarded to function as cis-acting elements, recent evidence suggests 
that some enhancers can act in trans to influence expression of their target gene on 
the homologous chromosome. Trans enhancer-promoter interaction in Drosophila, 
termed transvection, is relatively well characterised and has recently been visualised 
within developing embryos (Lim et al. 2018). Few examples of trans interactions 
have been reported in vertebrates, although a recent analysis at the IGH super-
enhancer indicates that trans-enhancer activity can occur in mammals (Le Noir et al. 
2017).  
 
The Nestin gene (Nes) encodes an intermediate filament protein and is widely 
expressed during embryonic development including progenitor cells throughout 
the neuroaxis (Lendahl et al. 1990; Lothian & Lendahl 1997). Differing reports of 
NES functionality have been published, with research in 2011(Mohseni et al. 2011) 
suggesting Nes is not essential for development of the central nervous system, in 
contrast to an earlier paper (Park et al. 2010) indicating that loss of the gene results 
in embryonic lethality. The reasons for this disparity are unclear given the similarity 




(Zimmerman et al. 1994) is a highly conserved element located in intron 2 and is 
commonly used to activate exogenous gene expression in neural progenitor cells in 
vivo and in vitro (Dubois et al. 2006; Trumpp et al. 1999; Petersen et al. 2002). In 
vitro and transgenic data indicate the transcription factors belonging to the SOX 
and POU families bind the Nes enhancer and function synergistically to control the 
Nes expression in the CNS progenitors (Tanaka et al. 2004). Consistent with these 
data, ChIP-seq experiments have identified robust binding of endogenous SOX3 
protein at the Nes enhancer in cultured neuroprogenitor cells (McAninch & Thomas 
2014).  
 
Traditionally, enhancers have been identified and characterized using transgenic 
reporter assays (Kvon 2015). This has proven to be a useful approach to determine 
the contribution of specific enhancer elements to the spatiotemporal expression of 
its cognate gene.  However this strategy is incapable of recapitulating the 
endogenous genomic and chromatin environment in which the enhancer is usually 
located. The emergence of CRISPR gene editing technology (Cong et al. 2013) 
enables rapid and efficient deletion of enhancer sequences in vivo and provides the 
endogenous environment is maintained and allows for a better understanding of 
both enhancer activity and contribution to gene expression. This is an important 
advancement as the number of putative enhancers identified via bioinformatic and 
TF binding studies continues to grow, while functional studies are lagging.  
 
Despite widespread use of the Nes neural enhancer, the contribution of this 
enhancer to Nes expression during development has not been studied, nor have 
the effects of removing the enhancer on the developing CNS. Here we show that 
CRISPR-mediated deletion of the Nes enhancer results in a significant reduction in 
mRNA expression as well as altered protein levels within the developing mouse 




function mouse lines and show that NES KO mice are viable. Finally, we present 




Materials and Methods 
Mouse Generation  
CRISPR guides were designed using the crispr.mit.edu tool to determine off-target 
scores. Guide RNA sequences (enhancer deletion-TTTGCGGTCTGAAAAGGATT, 
AGAATCGGCCTCCCTCTCCG, nestin null lines - GGAGCTCAATCGACGCCTGG, 
GCACAGGAGACCCTACTAAA) were annealed and ligated into px330 (Addgene) 
after digestion with Bbs1 (NEB) using Rapid Ligation Kit (ThermoFisher Scientific), 
and transformed into E. Coli using standard protocols.  Plasmid was extracted from 
positive colonies using a Midi-Prep kit (Qiagen). Primers were designed to 
incorporate T7 promoter sequence and tracR sequence, and	PCR was performed on 
plasmid DNA with Phusion High Fidelity PCR Kit (NEB). PCR products were 
converted to RNA using the	T7 RNA Transcription Kit (NEB) and purified with 
RNEasy Kit (Qiagen) to generate sgRNA. Cas9 mRNA was synthesised from the XhoI 
(NEB) digested plasmid (Addgene) using the Mmessage Mmachine T7 Ultra 
Transcription Kit (ThermoFisher).  
 
BL6/2J females were superovulated with Pregnant Mare Serum Gonadotropin 
(PMSG) and human Chorionic Gonadotropin (hCG) prior to mating with BL6 males 
for zygote harvesting. Single cell zygotes were collected on the day of 
microinjection, and treated with hyaluronidase to remove surrounding cumulus cells. 
Cytoplasmic injection was performed with CRISPR reagents (50ng/uL Cas9 mRNA, 
100ng/uL sgRNA) before transfer into pseudopregnant CD1 females.  
 
Genomic DNA was extracted from 3 week old tail tips and ear clippings using KAPA 






Founder mice were	genotyped using FailSafe PCR Kit (EpiCentre) and run on a 12% 
polyacrylamide gel for heteroduplex assay. The genotype of the founder mice	was 
confirmed via	Sanger sequencing after BigDye Terminator v3.1 (Applied Biosystems) 
PCR reaction using reverse primer.  
 
Regular colony and embryo genotyping was performed with primers flanking 
deleted sequence (enhancer deletion line F-GCCCCAGTCAGTCTTCTGAG R- 
GCCACTGCAGGATCACTCTT, nes null FS F1 – CTGCTGAGCTGGGATGATGC F2 
– AGCTCAATCGACGCCTGGA R- GCATTCTTCTCCGCCTCGA, nes null BD F- 
CTGCTGAGCTGGGATGATGC R- CTGCTGAGCTGGGATGATGC) using 2G Fast 
MasterMix (KAPA), or Buffer J (EpiCentre) with Taq Polymerase (Roche).  
 
All mouse breeding and experimental work was performed at the University of 
Adelaide in accordance with relevant ethics approvals (S-201-2013 and S-173-2015). 
 
Tissue Preparation 
Heterozygous (wt/-255) males and females were set up as timed matings for embryo 
collection. Females were humanely killed via cervical dislocation and embryos 
removed and stored in cold 1x PBS until dissected. Tails were removed and kept at -
20ºC. Heads were removed and flash frozen on dry ice and kept at -80ºC for RNA 
extraction, or kept o/n in 4% paraformaldehyde in PBS, washed 3x in PBS and 
cryoprotected overnight in 30% sucrose before flash freezing in OCT and stored at -
20ºC for immunohistochemical analysis. 
 
Immunohistochemistry 
Trunks were sectioned at 16um on a cryostat (Leica CM1900) and slides washed 3x 




Triton-X, 10% Horse Serum), then stained o/n with 200uL primary antibody diluted 
in BS and kept in humidified chamber 4ºC. Primary antibody washed off with 3x 
10mins PBS. 200 uL of secondary antibody diluted in Blocking Solution was added 
to the slides and kept in a dark humidified chamber for 4hrs at room temperature. 
The secondary antibody was removed with 3x 10min washes in PBS, slides were 
dried and set with Prolong Gold Antifade + DAPI (Molecular Probes) and coverslip 
was	applied. Slides kept overnight in the dark before image acquisition Nikon 
Eclipse Ti  Microscope using ND2 Elements software. Images were modified for 
colour, brightness and contrast using Adobe Photoshop v7 (Adobe Systems). 
Antibodies used, Anti-SOX3 (R&D Systems, AF2568), Anti-Nestin (Abcam AB82375), 
Anti-CD31 (BD Pharmigen 550274). Secondary antibodies, Donkey anti-Goat-Cy3 
(Jackson ImmunoResearch), Donkey anti-Rat-Cy5 (Jackson ImmunoResearch), 
Donkey anti-Rabbit-488 (Jackson ImmunoResearch).	
 
In situ Hybridization  
In situ probes were designed to target exon 4 of the Nes gene. Primers 
corresponding to the region were used to amplify the DNA from wildtype mouse 
DNA and incorporate a T7 promoter at the 5’ end. The DNA was converted to RNA 
using the T7 IVT Kit (NEB), followed by DNase I (NEB) treatment and purification 
with RNEasy kit (Qiagen).  
 
Embryo trunks were	sectioned at 16um on a cryostat (Leica CM1900) and stored at -
20º. Prior to in situ hybridisation, slides were defrosted for 1hr at room temperature. 
The RNA in situ probe was denatured at 72ºC for 2 minutes and kept on ice. 100ul 
hybridisation buffer containing 1uL diluted riboprobe/slide added to slides and kept 
in humidified chamber containing formamide overnight at 65ºC.  Slides were 




30mins washes in MABT (Maleic Acid Buffer + 0.1% Tween-20) at RT. Slides were 
blocked with 300uL Blocking Solution (Blocking Reagent, Sheep Serum, MABT) and 
kept in humidified chamber at RT for 2 hrs. 75uL of anti-DIG antibody diluted in 
Blocking Solution added to slides and kept o/n at RT in humidified chamber. anti-
DIG antibody was washed off with 4x 20min washes in MABT, then wash 2x 10mins 
in Alkaline Phosphatase Staining Buffer (4M NaCl, 1M MgCl2, 1M Tris pH 9.5). 
Slides were then stained with 95uL staining solution (NBT, BCIP, Alkaline 
Phosphatase Staining Buffer), coverslipped, and kept in the dark at RT overnight. 
Staining solution was removed by washing 3x 5mins in PBS, and fixed with 300uL 
4% PFA added to slides and incubated for 1hr in sealed contained. Fixative was 
washed off with 3x 10min PBS washes, and 50uL Mowiol added to each slide for 
mounting with coverslip. Slides were analysed using brightfield microscopy on 
Nikon Eclipse Ti Microscope using ND2 Elements software (Nikon). 
 
qRT-PCR 
RNA was	extracted from flash frozen embryo heads by Trizol. Briefly, heads were 
homogenised in 500uL Trizol, 100uL chloroform was added to mixture and 
centrifuged at 6000xg for 30mins. The aqueous layer was removed and equal 
amount of 70% EtOH added. Then placed in RNEasy spin column and centrifuged 
at 13000 rpm for 1 minute. Column was washed with 2x Buffer RLT (Qiagen), and 
purified RNA eluted in 30uL of RNAse free H20, and stored at -20C. RNA samples 
converted to cDNA using AB Systems High Capacity RNA to cDNA Kit. SYBR Fast 
standard protocols used for qPCR, samples run in quadruplicate. B-actin (F-
CTGCCTGA CGGCCAGG, R- GATTCCATACCCAAGAAGGAAGG) used to 
normalise cDNA levels across samples, and Nes primers used to measure 
expression levels across timepoints and samples (F-GCTTCTCTTGGCTTTCCTGA; R- 




of qPCR data. Unpaired t-tests were performed to determine if wildtype Nes 





Generating a Nes Enhancer Deletion Mouse Model 
To investigate the role of the	Nes enhancer in directing endogenous expression in 
vivo, we generated an enhancer deletion mouse model using CRISPR-Cas9 
mutagenesis. Two gRNAs flanking the Nes enhancer were microinjected into mouse 
zygotes with Cas9 mRNA. 21 founder mice were generated with a range of 
deletions that partially or completely deleted the Nes enhancer. We selected a 
single founder animal containing both 255bp and 208bp deletion alleles that 
encompassed all SOXB1 binding sites identified in the ChIP-Seq analysis for these 
experiments (Figure 1A). Independent lines were generated for each deletion 
(hereafter referred to as -255 and -208). The -255 line was used for subsequent 
analysis of the enhancer deletion. Heterozygous and homozygous pups and 
embryos were generated at expected ratios indicating that viability was not 
compromised by the deletion mutation (Figure 1B) No morphological abnormalities 
were identified in either line indicating that the enhancer deletion did not overtly 






Nes mRNA expression is reduced in enhancer deletion mice 
To determine the impact of enhancer deletion on Nes expression, qPCR was 
performed on -255 homozygous whole embryos (8.5 dpc) and embryonic heads (9.5 
dpc-15.5 dpc), as seen in Figure 2A. No significant difference in Nes expression was 
detected in mutant embryos at 8.5 dpc. However, from 9.5 dpc significantly 
reduced levels of Nes mRNA were detected in the embryonic cranium.  Notably, 
the greatest reduction in Nes expression was detected at 10.5 dpc, with mutant 
embryos expressing just 18% of Nes mRNA compared with wild type controls. From 
11.5 dpc, a gradual increase in expression was detected in mutants which by 15.5 
dpc had recovered to 60% of wild type expression. A reduction in Nes expression 
was also observed in -208 homozygotes at 11.5 dpc (Supplementary Fig. 1). 
  
Next, we determined the spatial impact of enhancer deletion on Nes expression in 
the developing CNS (Figure 2B). For this experiment we analysed the spinal cord at 
11.5 dpc as Nes is robustly expressed in a steriotypical pattern throughout the trunk 
at this stage due to the abundance of neural progenitors (Dahlstrand et al. 1995). In 
situ hybridization was performed on the trunk sections of wild type (wt) and 
homozygous enhancer deletion (-255) embryos. As expected, expression of Nes was 
detected throughout the spinal cord, with the highest levels confined to the lateral 
regions and the floor plate. In contrast, the spinal cord of enhancer-deleted 
embryos was virtually devoid of Nes mRNA, except for restricted expression in the 
floor plate and the lateral regions. Notably, lateral expression in the mesoderm was 
not noticeably diminished in mutant embryos, consistent with the neural-specific 
activity of the Nes enhancer in transgenic mice. Thus, deletion of the Nes neural 





Protein Expression within Enhancer Deleted Mice 
As mRNA expression was significantly reduced in both the embryonic head (qRT-
PCR analysis) and neural tube (in situ hybridization), we performed protein 
expression analysis in these regions to determine whether NES was similarly 
reduced. Both head and trunk transverse sections were taken from wildtype, 
heterozygous and homozygous embryos and co-stained with anti-NES and anti-
SOX3 antibodies (Figure 3). We theorised that as the enhancer is controlled by the 
SOXB1 proteins binding to the region, that we would see little to no NES 
expression throughout the SOX3 expressing zones of the neural tube and brain. 
  
The wildtype brain sections show the telencephalon is densely stained for Nestin, 
showing a long filamentous structure without nuclear staining (Figure 3A). The SOX3 
is shown to be overlapping the NES in most regions. There is a small area along the 
telencephalon that is NES positive and SOX3 negative. In the heterozygous 
sections, the NES reactivity is lower, but still shows a similar pattern to wildtype and 
no apparent difference in expression are seen within the SOX3 expressing zones. In 
the homozygous enhancer deletion however, there are obvious differences in the 
staining pattern of the NES protein, as it is duller throughput the telencephalon, but 
shows regions of high reactivity that appear to be surrounding the vasculature. This 
effect is not seen in either wildtype or heterozygous samples. 
 
This experiment was repeated using neural tube sections, and similar results were 
seen (Figure 3B). The wildtype embryos show NES forming a smooth filamentous 
structure from the lateral edges, towards the midline. Whilst the SOX3 is confined 
to the ventricular zone with no expression seen in the intermediate zones or the 
floor plate. Interestingly, the base of the neural tube in the -255 embryos shows a 




wildtype samples. The NES reactive structures/stripe phenotype seen in the brain is 
recapitulated again in the neural tube, with these seen throughout the whole neural 
tube, and not just the SOX3 expressing regions. The somites, lateral to the neural 
tube show NES staining in all 3 genotypes, with no apparent differences in intensity 
or pattern. It is important to note that these are not SOX3 positive zones, and can 






Ectopic Nestin expression in vasculature of enhancer deleted embryos  
Whilst analysing -255 embryos for NES protein expression, we noted specific 
staining in discrete structures within the neural tube and cortex that appeared to be 
the developing vasculature. Notably, this signal was not present in wildtype or 
heterozygous embryos. To further investigate this finding, we co-stained 10.5 dpc 
embryo heads with CD31 (endothelial cell marker) and NES antibodies (Figure 4A). 
Images captured using an inverted fluorescence microscope indicated colocalisation 
of NES and CD31 in -255/-255 embryos but not in WT controls. Additional analysis 
using confocal microscopy revealed widespread expression of NES in endothelial 
cells lining the developing vasculature of  -255/-255 embryos.  In contrast, NES 
expression was rarely detected in wild type endothelial cells. Together, these data 







Nes is not required for CNS development 
It has previously been reported that deletion of Nes causes extensive cell death in 
the developing CNS and embryonic lethality at approximately 8.5 dpc (Park et al 
2010). Given that -255/-255 mutants do not exhibit overt developmental defects, it 
appears that the level of Nes in these enhancer-deleted embryos exceeds the 
threshold required for normal development. We were therefore interested in 
assessing whether further reduction of Nes levels in -255/KO compound 
heterozygous embryos would compromise CNS development. To generate Nes 
knockout mice, we employed a dual gRNA deletion strategy (Figure 5). The 
proximal gRNA targeted exon 1 immediately downstream of the start codon and 
the distal gRNA cut immediately upstream of the stop codon in exon 4. The 
rationale for this approach was that null alleles could be generated via frameshifting 
indels at the proximal cut site or from deletion of the ~8.7 kb intervening sequence 
between the proximal and distal cut sites. This approach also provided the 
necessary alleles for the trans enhancer interaction experiment (see below). PCR 
genotyping indicated that four of the six founder animals contained at least one 
large deletion allele. Sanger sequencing confirmed that the founder used for 
subsequent breeding carried the expected 8672 bp deletion that encompassed 
almost all of the coding region and introns of the Nes gene, including the neural 
enhancer in intron 2.  
 
This null allele, Nes g.54_4518/p.L19_V1506del/p.L19fsX,  termed BD, encodes 
only the first 18AA of the NES open reading frame, and a frameshift causes the last 
30AA of exon 4 to be incorrect. This founder also carried an 8bp frameshifting 
deletion, g.50_57del/p.R17fsX75, termed FS, at the proximal cut site that 
terminated the protein after 13 amino acids. Breeding colonies for each mutation 
were generated. Surprisingly, BD and FS homozygous mice were viable and did not 




FS/BD mice were also phenotypically normal. To confirm that NES protein was not 
generated from the FS allele, we stained FS/FS embryonic brain sections with anti-
NESTIN antibody. In contrast to WT control tissue, no discernible expression was 
detected in mutant tissue.  We therefore conclude that Nes is not required for CNS 






Trans Interactions of the Nes neural Enhancer 
While enhancers are generally considered to be cis-regulatory elements, previous 
studies have provided evidence for interchromosomal trans interaction between 
enhancers and their cognate promoters (Bateman et al. 2012). To investigate 
possible interchromosomal activity of the Nes neural enhancer in vivo, we used 
qPCR to assay allele-specific expression in a series of compound heterozygous 
embryos. For this experiment, we exploited the presence of the Nes enhancer in the 
FS allele but not the BD allele. Thus, the difference in Nes expression from the WT 
allele in FS/WT and BD/WT embryos will reflect trans activity of the (FS) Nes 
enhancer. Similarly, the difference in Nes expression from the -255 allele in FS/-255 
and BD/-255 embryos will reflect trans activity of the (FS) Nestin enhancer. No 
discernible signal was generated from FS/BD embryos indicating that Nes mRNA is 
not generated from either null allele (presumably due to nonsense mediated decay 
for the FS allele).  -255/-255 Nes expression was 23% of WT expression, consistent 
with Fig. 2A.  Comparison of FS/-255 and BD/-255 expression revealed a significant 
increase in the former (17% vs 11%; p< 0.01).  Similarly, WT/FS Nes expression was 
higher than WT/BD, however this did not reach significance (64% vs 49%; p< 0.07). 







While enhancers are routinely used to drive spatio-temporally restricted expression 
of heterologous genes, their functional role in coordinating cognate gene 
expression remains poorly understood. Using CRISPR/Cas9 technology, we show 
that deletion of the Nes neural enhancer has a profound impact on endogenous 
Nes expression in the developing nervous system. Our data also indicate that this 
region also contains a repressor element that inhibits expression in endothelial cells, 
underlining the ability of deletion analysis to identify both positive negative 
regulatory interactions. 
 
Nes is expressed within the incipient neural progenitor cells during early 
embryogenesis and is maintained during expansion of this cell population. Upon 
differentiation, Nes is downregulated and is replaced by other members of the 
intermediate filament family (Michalczyk & Ziman 2005). At 8.5 dpc, Nes expression 
is not significantly different in -255 homozygous embryos indicating that the neural 
enhancer is not functionally required for initiation of Nes expression.  Given that 
there is robust SOXB1 expression in neuroprogenitors at this stage, it appears that 
putative binding of these factors to the Nes enhancer at this stage is not required 
for expression, but may nevertheless play a role in maintaining the locus in an “open 
for business” conformation (Bergsland et al. 2011). From 9.5 dpc, Nes expression is 
significantly lower in -255 homozygous embryos-indeed, at 9.5 dpc, the neural 
enhancer is required for approximately 80% of the Nes expression within the head. 
The activity of the enhancer remains functionally significant until at least 15.5dpc, 
although the differential between -255 and WT expression becomes less 
pronounced, suggesting that other neural enhancer(s) have increasingly important 
roles as the nervous system develops. It is interesting to compare our data with 




majority of examples, deletion of a single conserved enhancer element has no 
impact on cognate gene expression (Osterwalder et al. 2018;Cadiz-Rivera et al. 
2014). The Nestin enhancer therefore appears to be unusual in having such a 
profound impact on Nes expression. The mechanism that underpins this unusually 
high activity remains to be determined. 
 
The expression of Nes mRNA throughout the neural tube is considerably affected in 
mutants lacking the 255bp enhancer, as seen in both in situ hybridization and qRT-
PCR experiments. However, when protein expression is analysed via 
immunohistochemistry for these same mutants, there is not the same significant loss 
as would be expected. It is usually predicted when there is a large decrease in 
mRNA, the resulting protein expression would also be compromised. Decreased 
protein reactivity is seen in the -255 embryos, however the staining is still present 
throughout the neural tube where the mRNA is not visualized. This is possibly due 
to very low levels of Nestin expression within these cells, undetectable through in 
situ hybridization. It is also expected that Nes expression is controlled by other 
transcription factors other than SOX or POU proteins that are expressed within non-
SOX/POU regions. 
 
An unexpected finding of this study was that deletion of the Nes enhancer resulted 
in ectopic expression within the vasculature. Through confocal microscopy, NES was 
shown to co-localise with the endothelial cell marker CD31. Previously, NES has 
been reported to be expressed within the vasculature of different tissues such as 
developing kidneys, and also shown to be upregulated within vasculature following 
focal cerebral ischemia (Suzuki et al. 2010; Wagner et al. 2006; Shin et al. 2013), 
indicating a role in development and repair. Whilst the mechanism is unclear, it 
appears that the -255 deleted region also contains a repressor element that 




required to determine the protein-sequence interaction(s) that mediate this 
repressor activity, it is worth noting that unmasking of repressor elements cannot be 
achieved using traditional enhancer activity assays such as transgenic reporter 
analysis. 
 
Within the literature there are conflicting reports as to whether Nes is an essential 
gene in mice (Park et al. 2010; Mohseni et al. 2011; Dickinson et al. 2016). Through 
generation of two independent CRISPR KO mouse lines, we have shown that NES 
null mice are viable and do not exhibit overt deleterious phenotypes, consistent 
with two previous reports (Mohseni et al. 2011). In contrast, the NES null mice 
reported by Park et al (2010) exhibit embryonic lethality. The reason for this 
inconsistency remains unclear.  Although not explored in this study, mild 
phenotypes such as impaired motor coordination (Mohseni et al. 2011) in KO mice 
suggest that NES function cannot be entirely replaced by other members of the IF 
family. 
 
It is often assumed that all enhancers are cis-acting. However, it remains unclear 
whether some enhancers can also function in trans to activate cognate target 
gene(s).  Trans enhancer interactions or transvection is well characterised in 
Drosophila, (Lim et al. 2018; Mellert & Truman 2012) but has rarely been observed 
in mammalian cells (Le Noir et al. 2017). Utilising a genetic approach, we provide 
evidence that the Nestin enhancer can undergo functional trans interactions in vivo.  
While the effect is relatively weak, these data raise the possibility that transvection 
of developmental enhancers may be more common than is currently recognised. 
Further investigation using chromatin capture technology would be beneficial in 









Generation of Nes Enhancer deletion (-255/-255) mouse line 
A . Guide RNAs (scissors) were designed to flank the six SOXB1 sites (red) and the 
POU site (yellow) within the second intron of the Nestin gene. Arrow indicates start 
codon, asterisk indicates stop codon, pink square denotes promoter region and 
dark blue, the 5’ and 3’ UTRs. This generated a 255bp deletion encompassing all 
SOXB1 sites identified by ChIP-seq. Observed/Expected tables of both live pups 
born (B) and transient embryos (C) show there is no embryonic lethality or sex bias 








Loss of Nestin mRNA during embryonic development 
A . Analysis of embryonic heads from aged 8.5 to 15.5 by qRT-PCR. All values are 
normalized to wildtype samples of the same developmental stage. Due to size 
constraints, whole 8.5 dpc embryos were used rather than embryonic heads. From 
9.5dpc the level of Nes decreases in the -255/-255 embryos, and progressively 




indicates p-value <0.001, **** indicates p-value <0.0001. Error bars represent the 
standard deviation of the mean. B. In Situ hybridization of Nes mRNA in an 11.5dpc 
neural tube section shows large amounts Nes mRNA throughout the neural tube in 
the wildtype sample. In the -255/-255 section, the majority of the staining is lost, 
although somite staining outside the neural tube remains as well as a small region 
at the base of the neural tube. NT denotes neural tube, FP denotes floor plate and 





Immunohistochemical analysis of brain and trunk sections  
Wildtype (wt/wt), heterozygous (-255/wt) and homozygous (-255/-255) transverse 
cortex (A) and trunk (B) sections labelled with anti-SOX3 and anti-NESTIN 
antibodies. The Nestin reactivity is decreased in both wt/-255 and -255/-255 









Immunohistochemical analysis of Nestin reactivity within vasculature of 10.5 dpc 
cortex sections 
Confocal microscopy of wt/wt and -255/-255 10.5 dpc cortex sections labelled with 
NESTIN and CD31 to mark epithelial cells of the vasculature. Co-localisation (white) 








Generation of Nes null lines 
A. CRISPR guide sequences (scissors) designed to cut within exon 1 and exon 4 of 
the Nes gene. The FS allele generated a frameshift mutation at codon 50, while the 
BD allele removed the 8.7 kb of intervening sequence. qRT-PCR primers indicated 
by the arrows amplify the FS, wt and -255 alleles. Pink box indicates the promoter, 
dark blue is 5’ and 3’ UTR, pale blue is coding regions, red circle is Nes enhancer, 
arrow is transcriptional start site and asterix is the stop codon.  
B. Immunohistochemical staining with NES antibody on ‘frameshift’ embryonic 












Interchromosomal Interactions of the Nestin enhancer and promoter 
A . Control crosses to determine trans interactions. The first will determine if 
nonsense mediated decay occurs in the ‘big deletion’ (BD) allele. The second 
determines the baseline level of ‘promoter only’ activity when no enhancer is 
present. The third will confirm is a single allele produces exactly half of the total 
wildtype mRNA. qRT-PCR primers indicated by the arrows amplify the FS, wt and -
255 alleles. Pink box indicates promoter, dark blue is 5’ and 3’ UTR, pale blue is 
coding regions, red circle is Nes enhancer, arrow is transcriptional start site and 
asterix is the stop codon.  
B. Experimental workflow to determine trans interactions. The first will determine 
whether both copies of the Nes enhancer are capable of influencing only one 
functional promoter. The second will determine if an enhancer on one allele can 
compensate for the loss of the enhancer on another allele.  qRT-PCR primers 
indicated by the arrows amplify the FS, wt and -255 alleles. Pink box indicates 
promoter, dark blue is 5’ and 3’ UTR, pale blue is coding regions, red circle is Nes 
enhancer, arrow is transcriptional start site and asterix is the stop codon. 
C. The qPCR results of the above experimental crosses and embryo analyses on 
11.5 dpc heads. By using various mating of FS, BD, wt and -255 alleles embryonic 
heads were analysed for changed in Nestin gene expression. The BD/-255 
produces significantly less Nestin mRNA that the FS/-255, indicating the presence 
of a single enhancer on one chromosome can interact with the promoter of 
another. Unpaired t-test between FS/-255 and BD/-255 show p-value of  0.0011, 
other t-test results not shown for clarity. Error bars represent the standard 













Supplementary Figure 1 
The -208 Nestin enhancer deletion line shows a reduction in Nes expression within 
the head similar to that of the -255 line. These preliminary findings were performed 
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Identification and in vivo validation of a 
Frizzled 3 neuroprogenitor enhancer bound 







This manuscript outlines the identification and validation of a SOXB1 bound 
enhancer controlling the expression of Fzd3 within neuroprogenitors of the CNS. 
Previous work within the laboratory identified a region bound by SOX3 and the co- 
activator protein p300 located within an intron of the Wnt-receptor Fzd3. 
 
To assess if the putative enhancer was functional, mouse models were generated 
using CRISPR that deleted the SOXB1 motif as well as 573bp of surrounding 
sequence. Through RNA expression analysis, we are able to show that this region 
influences Fzd3 expression within the developing neural tube. 
 
We also used traditional enhancer validation techniques to further understand the 
functionality of the putative enhancer. Through generation of LacZ transgenic 
embryos we could show the enhancer drives expression towards the floor plate of 
the neural tube, an important region required for axon development. 
 
Fzd3 is an essential gene. Homozygous loss leads to death soon after birth, however 
heterozygotes appear phenotypically normal. We generated our own Fzd3 null line, 
and used this in combination with the enhancer deletion allele to show that only 
40% of WT Fzd3 expression is sufficient for survival. 
 
Through these experiments we have provided the first evidence of an enhancer 
controlling Fzd3 expression within the CNS, as well as the first functional 















Enhancers are essential to direct gene expression during neural development. 
SOXB1 proteins (SOX1, SOX2 and SOX3) are important transcriptional regulators 
within neural progenitor cells, which act upon enhancers to maintain a stem-like 
state. While the transcriptional targets of these proteins are being elucidated 
through chromatin immunoprecipitation experiments such as ChIP-Seq, the vast 
majority of putative targets have not been validated. Here we identify a novel 
SOXB1 target in the Wnt protein receptor gene, Frizzled 3 (Fzd3). Located 
intronically, this 573bp region is highly conserved, and bound by both SOX2, SOX3 
and the enhancer co-activator p300 in neuroprogenitor cells. Using CRISPR, we 
generated mouse models lacking either the individual SOXB1 TFBS or the entire 
enhancer region. This shows that loss of an individual motif only causes very 
minimal reduction in Fzd3, whereas the larger deletion visibly reduced the Fzd3 
levels within both the floorplate and intermediate zone of the developing neural 
tube. Enhancer activity was assessed via generation of a LacZ reporter mouse 
carrying the putative 573bp enhancer. This showed enhancer activity in the floor 
plate, but interestingly not the intermediate zone. This raises an important issue in 
enhancer validation, whereby the endogenous chromatin and epigenetic landscape 
is needed to fully understand how the enhancer is acting upon target gene 
expression. Further to this, we generated an independent FZD3 KO mouse, known 
to cause perinatal lethality. This was used to create a compound heterozygote 
model (-573/KO), producing approximately 40% of wt Fzd3 mRNA. These mice do 
not appear to have any phenotypic effects, suggesting only a small proportion of 
the wildtype FZD3 is needed during development. Through these experiments we 
provide the first functional link between the SOXB1 proteins and the regulation of 





Neural development is a tightly controlled process that requires precise spatial and 
temporal activity of hundreds of genes. One of the ways in which this achieved is 
through the regulatory elements such as enhancers. Putative enhancers are 
increasingly being identified through chromatin immunoprecipitation approaches 
such as ChIP-Seq, which provide genome-wide assessment of TF binding (Mundade 
et al. 2014; Visel et al. 2009). Typically, these studies yield hundreds, if not 
thousands of sites but do not provide information about which interactions are 
biologically significant. For this reason, putative enhancers identified using these 
techniques must be functionally validated. Traditionally, enhancer testing was 
performed using transgenic mice carrying a reporter gene (e.g. LacZ) linked to a 
putative enhancer region (Kvon 2015). This is a useful approach and can identify the 
embryonic stage and regions where the enhancer is sufficient for expression. 
However, this approach does not functionally replicate the genomic or epigenomic 
context of the putative enhancer in vivo, and as such may yield limited or even 
misleading data. Recently, with the advent of new and simpler genome editing 
technologies such as CRISPR, fast and precise deletion of genomic regions in 
mouse zygotes is now possible (Cong et al, 2013; Mali et al. 2013). By removing the 
putative enhancer from its native context, its contribution to gene expression and 
the phenotypic effect of its loss can be tested in vivo, and can be analysed.  
 
The SOX (Sry-related High Mobility Group Box) family of TFs are expressed in 
virtually all developing tissues and in most cases are essential for normal embryonic 
development. The SOXB1 proteins (SOX1, SOX2 and SOX3) are a closely-related 
sub-group of SOX factors that function as transcriptional activators to maintain the 
undifferentiated state of neural stem/progenitor cell (Bergsland et al. 2011; Sarkar & 




seq experiments have identified a region within the second intron of Frizzled 3 
(Fzd3) as a putative developmental enhancer in neuroprogenitor cells (McAninch & 
Thomas 2014). Fzd3 encodes a Wnt protein receptor that is widely expressed in the 
developing nervous system including the neuroprogenitors throughout the CNS ( 
Wang et al. 2002; Sala et al. 2000). It has roles within the central nervous system, 
such as axon growth and guidance, and is also essential for the formation of many 
major fibre tracts within the brain ( Wang et al. 2002; Wang et al. 2006). 
Homozygous loss of Fzd3 leads to death shortly after birth, and the inability of the 
neural tube to fold. These mice also present with curly tails, an indicator of neural 
tube maldevelopment ( Wang et al. 2002).  
 
We hypothesised that SOXB1/p300 intronic binding demarcates a novel Fzd3 
neurodevelopmental enhancer. Using CRISPR, we generated a mouse model 
lacking the putative enhancer and showed that this region is essential for complete 
Fzd3 expression during CNS development. Further, we show that only 40% of Fzd3 
expression is required for normal brain development. This work establishes a direct 
link between Fzd3 regulation and the SOXB1 proteins and demonstrates the utility 






Materials and Methods 
Generation of Enhancer Deletion and Knockout Mouse 
Guides for CRISPR experiments were designed on the crispr.mit.edu web tool. 
Enhancer Deletion guide (TTAGCAAGGGTGTGAAAAG) Knockout guides (1- 
AGTTATAATGTAAAGGGCCG, 2- GCTCACTCTTACAACACTAC). Guides were 
cloned into the PX330 plasmid (Addgene) and the tracR sequence and T7 promoter 
were added via PCR (TTAATACGACTCACTATAGCTTAGCAAGGGTGTGAAAAG 
GTTTTAGAGCTAGAAATAGC). PCR products were transcribed to RNA using the T7 
RNA transcription kit (NEB) and purified with RNEasy Kit (QIAGEN) to generate 
sgRNA. Cas9 mRNA was synthesis from XhoI digested Cas9 plasmid (Addgene) 
using the Mmessage Mmachine T7 Ultra Transcription Kit.  
 
C57BL6/J females were superovulated with Pregnant Mare Serum Gonatropin 
(PMSG) and human Chorionic Gonatropin (hCG) prior to mating with C57BL6/J 
males for zygote harvesting. Single cell zygotes were collected on the day of 
microinjection, and treated with hyaluronidase to remove surrounding cumulus 
cells. Cytoplasmic injection performed with CRISPR reagents (50ng/uL Cas9 mRNA, 
100ng/uL sgRNA) before transfer into pseudopregnant CD1 females.  
 
Regular colony and embryo genotyping performed with primers flanking deleted 
sequence (enhancer deletion line F- AGGCTGTTCCACATTGGTTC, R- 
CATCTGCATAAACCCACACTC). Knockout genotyping performed using 3 primers 
to distinguish between alleles (F- AGCCCAGTGTTAGAGTATAGCCAG, M- 
TCCTAGCCCTTCCACCCTATG, R- CTGCCTCATCTTCCCAAATGC) using KAPA 2G 





All mouse breeding and experimental work was performed at the University of 
Adelaide in accordance with relevant ethics approvals (S-201-2013 and S-173-2015). 
Tissue Preparation 
Pregnant females were culled via cervical dislocation and embryos harvested from 
10-12dpc. Tails were removed for genotyping. If tissue was required for qRT-PCR 
analysis, it was immediately snap frozen on dry ice and stored at -80°C until RNA 
extraction. If tissue was required for staining, it was kept overnight in 4% PFA, 
washed 3 times in PBS and then stored in 30% sucrose as a cryoprotectant before 
flash freezing in OCT for storage at -20°C. 
qRT-PCR analysis 
RNA was extracted from flash frozen embryo heads using Trizol, according to 
manufacturer’s instructions. Briefly, heads were homogenised in 500uL Trizol, 100uL 
chloroform added to mixture and centrifuged at 6000xg for 30mins. The aqueous 
layer was removed and equal amount of 70% EtOH added. The solution was then 
placed in RNEasy spin column and centrifuged at 13000 rpm for 1 minute. Column 
washed with 2x Buffer RLT (Qiagen), and purified RNA eluted in 30uL of RNAse free 
H20, and stored at -20C. RNA samples converted to cDNA using AB Systems High 
Capacity RNA to cDNA Kit. SYBR Fast standard protocols used for qPCR with 
samples run in quadruplicate. B-actin (F-CTGCCTGACGGCCAGG, R- 
GATTCCATACCCAAGAAGGAAGG) was used to normalise cDNA levels across 
samples, and Fzd3 primers used to assess Fzd3 levels. For Fzd3 knockout samples, 





In situ hybridisation 
Probes for in situ hybridisation were designed to target the 5’ end of the Fzd3 gene 
primers (F- GACATGCTTTGAATGGGCCAG, R- CACATGGCACCAGCATGAACC) 
Primers corresponding to the region were used to amplify the DNA from wildtype 
mouse DNA and incorporate a T7 promoter at the 5’ end. The DNA was converted 
to RNA using the T7 In Vitro Transcription Kit (NEB), followed by DNase I (NEB) 
treatment and purification with RNEasy kit (Qiagen).  
 
Embryo trunks sectioned at 16um on a cryostat (Leica CM1900) and stored at -20º. 
Prior to in situ hybridisation, slides were defrosted for 1hr at RT. The RNA in situ 
probe was denatured at 72ºC for 2 minutes and kept on ice. 100ul hybridisation 
buffer containing 1uL diluted riboprobe/slide was added to the slides and kept in a 
humidified chamber containing formamide overnight at 65ºC.  Slides were washed 
3x 30 mins at 65ºC in Wash Buffer (50% formamide, 5% 20x SSC), then 330 minute 
washes in MABT (Maleic Acid Buffer + 0.1% Tween-20) at room temperature. Slides 
were blocked with 300uL Blocking Solution (Blocking Reagent, Sheep Serum, 
MABT) and kept in a humidified chamber at room temperature for 2 hours. 75uL of 
anti-DIG antibody was diluted in Blocking Solution and added to slides and kept 
overnight at room temperature in a humidified chamber. Antibody removed with 4 
20 minute washes in MABT, then wash 2 10 minutes washes in Alkaline Phosphatase 
Staining Buffer (4M NaCl, 1M MgCl2, 1M Tris pH 9.5). Slides were then stained with 
95uL staining solution (NBT, BCIP, Alkaline Phosphatase Staining Buffer), 
coverslipped, and kept in the dark at room temperature overnight. Staining 
removed by washing 3times for5mins in PBS, and fixed with 300uL 4% PFA added 
to slides and incubated for 1 hour in a sealed contained. Fixative was washed off 




coverslip. Slides were analysed using brightfield microscopy on Nikon Eclipse 
Ti  Microscope using ND2 Elements software. 
LacZ Reporter Mouse Generation 
A vector containing the Hsp68 minimal promoter followed by the LacZ gene (hsp-
LacZ) was digested with PstI and XhoI. Primers were designed to amplify the Fzd3 
enhancer fragment and incorporate PstI and XhoI restrictions sites (F- 
TAAGCACTGCAGCACTGTCCCCTTTTCACACCC, R – ACGAATCTCGAGGC 
ATGAGCAGAGAATGTGGAC). The PCR product was digested and ligated into the 
digested vector, generating the Fzd3-Hsp68-LacZ vector. Prior to injection, the 
plasmid digested with XhoI and NotI to release fragment. The fragment was gel 
extracted and purified with QIAGEN gel extraction kit. CRISPR components were 
also included in the injection, to generate a cut-site at the Rosa26 locus (guide RNA 
- ACTCCAGTCTTTCTAGAAGA) to help increase the chance of integration at a cut-
site.  
The injection mix (4ng/uL Fzd3-Hsp-LacZ, 25ng/uL Rosa26sgRNA, 0.05ug/uL Cas9 
protein) was injected into single cell zygotes and transferred at the 1 cell stage to 
pseudopregnant foster mothers. Where foster mothers were not available 
immediately post injection, injected embryos were cryopreserved until females 
available for transfer.  
 
Embryos were dissected at 11.5dpc and immediately fixed in 4% PFA for 45 mins, 
and washed 3 times in PBS. Embryos were stained in 1mL staining solution ( 2mM 
MgCl2, 5mM K3Fe(CN)6, 5mM K4Fe(CN)6, 0.01% sodium deoxycholate, 10% 
igepal, 1mg/mL X-gal) at 37C overnight in the dark. Embryos were imaged using a 
dissecting microscope and post-fixed again in 4% PFA overnight and cryopreserved 





Trunks and heads were sectioned at 16um on a cryostat (Leica CM1900) and slides 
washed 3 times for 10mins in PBT (1xPBS, 0.25% Triton-X), blocked for 30min in BS 
(1x PBS, 0.25% Triton-X, 10% Horse Serum), and stained overnight with 200uL 
primary antibodydiluted in BS and kept in humidified chamber 4ºC. Primary 
antibody removed with 3 10 minute PBS washes. 200 uL of secondary antibody was 
diluted in BS added to slides and kept in dark humidified chamber for 4hrs at room 
temperature. Secondary antibody removed with 310 minute washes in PBS. Slides 
were dried and set with Prolong Gold Antifade + DAPI (Molecular Probes) and 
coverslip applied. Slides kept overnight in the dark before image acquisition Nikon 
Eclipse Ti  Microscope using ND2 Elements software. Images modified for colour, 
brightness and contrast using Adobe Photoshop v7 (Adobe Systems). Primary 







Generating a putative Fzd3 enhancer deletion mouse model 
Through overlay of SOX3, SOX2 and p300 ChIP-Seq data from mouse 
neuroprogenitor cells, we identified a putative highly conserved enhancer in the 
second intron of the Fzd3 gene containing a single SOXB1 binding motif (McAninch 
& Thomas 2014). To investigate the role of the putative enhancer in vivo, we sought 
to generate mouse lines lacking the enhancer sequence. Using a CRISPR/Cas9 
gRNA that binds immediately upstream of the SOXB1 binding site, we generated 
two mouse lines containing an 8bp deletion (-8) (Supplementary Figure 1) and a 
573bp (-573) deletion (Figure 1). For the majority of experimental analysis, the -573 
line was used as this deleted the SOXB1 motif as well as downstream DNA, whereas 
the -8bp deletion only partially interrupts the SOXB1 motif. All mice generated from 







Fzd3 mRNA Expression is altered in Enhancer Deleted Mice 
To assess the impact of putative enhancer deletion on endogenous Fzd expression, 
we initially performed qRT-PCR of wild type (WT) and homozygous -573 (-573/-573) 
embryos (Figure 2). We compared Fzd3 expression in embryonic heads at ages 10.5 
dpc, 11.5 dpc and 12.5 dpc, when FZD3 and SOXB1 proteins are expressed within 
the neural progenitor population (Wang et al. 2016; Pevny & Placzek 2005). At each 
time point there is a significant reduction (20-40%) in Fzd3 expression, indicating 
that the enhancer is active during early brain development. A slight but significant 
reduction in Fzd3 expression was also detected in -8/-8 embryo heads at 11.5 dpc 
(Supplementary Figure 1). 
 
Next, we assessed Fzd3 expression in the 11.5 dpc neural tube, where 
neuroprogenitors undergo stereotypical positional-dependent differentiation with 
concomitant downregulation of Fzd3. In WT embryos, Fzd3 was expressed 
throughout the midline and ventricular zone, continuing into the floor plate, and 
was absent from the intermediate zones. This correlates almost perfectly to SOX2 
protein expression (Figure 2). In contrast, Fzd3 expression in -573 homozygotes was 
greatly reduced in the floor plate and ventricular zone and in the latter was retained 
only in the lateral edges. This is particularly obvious when compared with the SOX2 
staining (which is unchanged between WT and -573-deletion embryos).  Together 







The -573bp region drives floor plate reporter expression in transgenic embryos 
To determine if the Fzd3 enhancer is sufficient for expression in neuroprogenitor 
cells in vivo, we generated 11.5dpc transgenic embryos containing the -573 
element linked to a minimal promoter driving LacZ.  Whole mount staining revealed 
that the 7 transient transgenic embryos were positive for LacZ reporter activity 
(Figure 3). Whilst some variation was observed, staining was consistently detected in 
the midline region throughout the extent of the neuroaxis, as well as the eye ad 
midbrain. Section analysis revealed robust LacZ activity in the floor plate in all 6 
embryos that were sectioned (Supplementary Figure 2). Expression in the neural 
tube progenitors was generally absent apart from one embryo with patchy staining. 
These data suggest that the -573 enhancer can function in isolation to drive 







It has been shown previously that Fzd3 null mice have significant 
neurodevelopmental defects and die shortly after birth while heterozygotes are 
apparently unaffected. Given the (~30%) reduction in Fzd3 expression in -573/-573 
embryos, it is possible that neural development in -573/null compound 
heterozygotes will be compromised due to Fzd3 levels not exceeding a critical 
threshold. To test this hypothesis, we first sought to generate a Fzd3 null (KO) 
allele.  We identified 2 high-scoring gRNAs targeting intronic sequences flanking 
exon 3, deletion of which is predicted to cause an early frameshifting mutation 
(Figure 4). Of the 24 founder pups born from zygotic injections, 11 died soon after 
birth with 9 having a curly tail.  This phenotype is indicative of neural tube defects 
and has been observed previously in Fzd3 null mice ( Wang et al. 2002). PCR 
genotyping of the dead pups revealed large deletions of exon 3 and the 
surrounding genomic DNA (Supplementary Figure 3). The 13 surviving pups also 
showed a variety of deletions indicating the CRISPR guides cut at each site and 
possibly removed exon 3, but each could amplify at least one exon 3 allele with 
specific primers. A breeding colony was established from a founder harbouring a 
1261bp deletion that encompassed exon 3 and flanking intronic regions (referred to 
hereafter as KO mice). As expected, KO/KO mice had curly tails and died 
perinatally. 18.5 dpc null (KO/KO) embryos had severe fibre tracts abnormalities as 





Compound Het Morphology 
Next, we crossed KO and -573 mice to generate -573/KO compound heterozygous 
11.5 embryos and assessed Fzd3 expression. Initial qRT-PCR analysis indicated that 
the KO allele was not subject to nonsense mediated decay. To avoid amplification 
of the KO allele, we used primers binding to exon 3. Comparison of the KO/WT and 
KO/-573 11.5 heads revealed a significant 20% decrease in the latter (Figure 5).  
Despite their reduced Fzd3 expression, 573/KO pups were born at the expected 
frequency, did not exhibit curly tails and had a normal physical appearance. Fibre 
tract development in 573/KO embryos also appeared normal (Supplementary 
Figure 4).  Thus, a Fzd3 expression level of ~40% is sufficient to rescue the 
neurodevelopmental defects that occur in FZD3 null pups, however comprehensive 






Bioinformatic and chromatin capture studies have estimated that there are 
hundreds of thousands of enhancers scattered throughout mammalian genomes 
(ENCODE Project Consortium 2012). However, functional assessment of enhancer 
activity in the vast majority of these predicted elements is lacking. Using CRISPR, we 
have identified and validated a novel enhancer that is essential for normal levels of 
endogenous Fzd3 expression in neural progenitor cells in vivo.   
 
Although the Fzd3 enhancer region is bound by SOXB1 proteins (McAninch & 
Thomas 2014) deletion of the single canonical SOXB1 binding site resulted in only a 
small reduction in Fzd3 expression. This suggests that SOXB1 binding is essential 
for normal Fzd3 expression, but only makes a modest contribution to overall 
expression levels in neuroprogenitor cells. As deletion of the 573bp enhancer 
region resulted in a much greater (30%) reduction in Fzd3 expression, it appears 
that binding of additional transcription factors is a feature of this element, consistent 
with the idea that enhancers are made up many different transcription factor 
binding sites, and are rarely composed of just a single motif. Bioinformatic analyses 
of the region indicates the motifs known to be bound by SP1, IRF3, NR2E3 and 
PRDM4 are present, however these would need to be assessed by ChIP or 
immunoprecipitation to confirm binding.  
 
Traditional enhancer tests utilize transgenic reporter assays, which permit 
visualisation of a reporter in regions where the enhancer is active (Kvon 2015; Visel 
et al. 2007). However, one of the disadvantages of this approach is that it does not 
recapitulate the enhancer activity in its in vivo context where the epigenetic 
landscape and interaction with neighbouring sequences may be crucial. Further, 




to the influence of flanking sequences, described as a “position effect” (Guy et al. 
1997). Thus, although rarely performed, comparing the impact of enhancer deletion 
and transgenic reporter studies provides valuable insight into the physiological role 
of a particular enhancer. Our experiments revealed some interesting differences in 
the activity of the Fzd3 enhancer in each of these assays. Enhancer deletion showed 
that the 573 region was required for complete Fzd3 expression in the floor plate 
and intermediate zone of the neural tube. In contrast, the reporter assay showed 
consistent robust LacZ expression in the floor plate but not the intermediate zone. 
This suggests that the 573 region is sufficient for the floor plate expression but may 
interact with other enhancers/regions to drive intermediate zone expression. This 
data suggest that this enhancer acts as part of a ‘billboard’ model – whereby many 
smaller regions (or individual TFBS) make up the larger enhancer (Arnosti & Kulkarni 
2005; Kulkarni & Arnosti 2003). 
 
A previous study has reported that Fzd3 null homozygous pups die shortly after 
birth with fibre tract abnormalities and curly tails, an indicator of defective neural 
tube development ( Wang et al. 2002; Peeters et al. 1998). We generated an 
independent Fzd3 KO line and observed the same phenotype, with heterozygous 
animals appearing normal as previously reported ( Wang et al. 2002). It was 
hypothesised that the Fzd3 phenotype may become apparent at expression levels 
between 0-50%. To test this we generated -573/KO mice in which the endogenous 
Fzd3 expression was approximately 40% of WT levels. However, these mice 
appeared normal and did not display curly tails or fibre tract abnormalities. Whilst 
the Fzd3 compound heterozygote did not show a phenotype, given the ease with 
which CRISPR deletion mutations can be generated in mice, this will likely be a 
useful approach to determine the developmental consequences of enhancer 
mutation. Although these mice produced no observable phenotype, this is not an 




redundant, with combinatorial deletions required to induce morphological defects 
(Osterwalder et al. 2018) and reporter assay-positive enhancer regions often 
producing no phenotype or expression change (Cunningham et al. 2018). 
 
In conclusion, we have identified a novel intronic Fzd3 enhancer, likely activated by 
SOXB1 transcription factors in neuroprogenitors that is responsible for up to ~30% 
of Fzd3 mRNA levels. It is highly likely that other TFs bind either within this region, 
or working in complex with this enhancer to regulate the expression of Fzd3 during 
development. The 573 element may also be a useful tool to drive transgene 
expression within the floorplate, especially given that this area functions as a 
signalling centre for neural tube patterning (Yu et al. 2013; Ribes et al. 2010). Given 
the increasing rate at which bioinformatic studies are identifying putative enhancer 
elements, the approach we describe herein provides a valuable template for their 






Figure  1 
Generation of the -573 Fzd3 Enhancer Deletion Line 
A SOXB1 putative enhancer was identified in a region of high conservation within 
intron 2 of the mouse Fzd3 gene (red box and circle). This region was mutated 
using CRISPR and generated a 573bp deletion (red text) incorporating the majority 
of the proposed TFBS (bold red text). The resultant allele does not contain the 























Analysis of mRNA expression in embryonic -573 lines  
A. qRT-PCR was performed on embryonic heads to assess the levels of Fzd3 
expression of -573 embryos compared to wildtype. Expression of Fzd3 is reduced 
at each time point. Students t-test performed, 10.5 dpc samples show p-value of 
0.0088, 11.5dpc samples show p-value of <0.0001 and 12.5 dpc sample show p-
value of <0.0001. Error bars indicate the standard error from the mean B. 
Expression patterns of Fzd3 mRNA were assessed using in situ hybridization on 
11.5dpc trunk sections to visualize the neural tube (1A and 2A). These were 
compared to SOX2 protein(1B and 2B) The Fzd3  can be seen to be reduced 
throughout the ventricular zones and the floor plate of the neural tube, consistent 
with regions of SOX2 staining. C. A schematic of the neural tube outlining the 












Figure  3 
LacZ staining of -573 enhancer transgenic mice 
Representative images of the 7 LacZ positively stained embryos, out of 7 embryos 
analysed. Staining can be visualized in the midbrain, eye and neural tube regions 











Figure  4 
Generation of Fzd3 knockout mouse line 
A. To generate Fzd3 knockout mice, exon 3 was targeted as it would produce a 
frameshift mutation if deleted. CRISPR guides were designed to flank exon 3 and 
this generated a large deletion encompassing the region. Dark blue boxes 
indicates 5’ and 3’ UTR, light blue represent coding exons, and the red circle 
indicates the Fzd3 putative enhancer. The asterisk represents the stop codon, 
within the wildtype allele this is in the last coding exon, while in the new knockout 
allele this occurs within exon 3 due to a frameshift mutation.  B. Representative 





Figure  5 
Analysis of compound heterozygote (-573/ko) embryos 
A. Diagrams showing each of the alleles used for the crosses. Dark blue boxes 
indicate the 5’ and 3’ UTR, light blue represent coding exons, and the red circle 
indicates the Fzd3 putative enhancer. The asterisk represents the stop codon 1. 
The wildtype allele contains both the -573 enhancer (red circle) as well as exon 3 
producing wildtype levels of Fzd3. 2. The -573 allele does not contain the 
enhancer, but all exons are present. 3. The ko allele contains the enhancer but no 
exon 3 of the Fzd3  gene. The primers used for mRNA analysis amplify exon 3 to 
avoid amplifying product from the wt allele which does not undergo nonsense 
mediated decay. 
B. The expression levels of Fzd3 were compared between a wt/ko and ko/-573 
allele. This will only measure expression of a single allele that is not ko as the 
primers do not amplify this. The compound heterozygote (-573/ko) show a 20% 
reduction in expression from the -573 allele consistent with previous results. 
Unpaired t-test between wt/ko and ko/-573 samples generates a p value of 0.0038. 
Error bars represent the standard error of the mean. 
C. Table showing the numbers of live born pups that are able to survive from 
intercrosses. Fzd3 knockout pups (ko/ko) die shortly after birth, but compound 
heterozygote (-573/ko) and Fzd3 heterozygous (wt/ko) pups appear healthy and 






Supplementary Figure 1 
Generation and analysis of the Fzd3 -8 line. A shows the Fzd3 putative enhancer 
region. The red text has been deleted, while the bold black text is the remaining 
portion of the SOXB1 consensus motif. B shows qRT-PCR analysis of 11.5dpc heads 






Supplementary Figure 2 
6 transgenic Fzd3 enhancer embryo trunks were sectioned after whole mount 
staining to determine the location of the neural tube staining (E-F) The seventh 
embryo was not sectioned due to damage. Consistent expression can be seen 








Supplementary figure 3 
Genotyping Gel of F1 generation of Fzd3 KO  pups. The band at 900bp indicates 
the presence of a wildtype allele. The pups in lanes 1-11 were found dead soon 
after birth, and genotyping indicates most of them do not have a wildtype allele 
and are homozygous for a embryonic lethal mutation. The pups that survived ‘live 
pups’ almost all show a band at approximately 900bp indicating the presence of a 






Supplementary Figure 4 
Neurofilament staining of 18.5 dpc Fzd3 ko and enhancer deletion mutations shows 
that the loss of fibre tract phenotype within mice lacking Fzd3 does not occur in 
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Identification of SOX3 bound putative 











SOX3 is the only member of the SOXB1 family of transcription factors that is 
expressed within the postnatal testes. Located within only the germ cells  
(spermatogonial stem cells and early spermatocytes) it is thought to play a role in 
spermatogenesis, although the mechanisms of this have not yet been fully 
elucidated (J. Weiss et al. 2003).  
 
Due to the similarities of SOX3 and the sex determining gene Sry, widely thought to 
have evolved from Sox3 (Graves 1998), previous research sought to determine if 
Sox3 also plays a role in early testis or ovary development ( Weiss et al. 2003). It has 
since been shown that SOX3 is not required for sex determination, as SOX3 null 
males appear phenotypically normal during gonad differentiation and throughout 
embryogenesis ( Weiss et al. 2003; Raverot et al. 2005). Postnatally however, SOX3 
null mice have impaired spermatogenesis and lack mature sperm, affecting fertility 
(Raverot et al. 2005).  
 
After the bipotential gonad has its male fate determined by Sry expression, Sox9 is 
activated, leading to the downregulation of female specific genes and upregulation 
of genes that drive testes development (Sekido & Lovell-Badge 2008). The 
primordial germ cells become encased within Sertoli cell precursors and form 
gonocytes which, after rapid proliferation, eventually halt at G0/G1 phase until 
birth, when they begin to again undergo mitosis/meiosis after 2/3 days (Griswold 
2016). It is at this stage when the Sox3 null testes phenotype becomes apparent (J. 
Weiss et al. 2003). After birth, a subset of the gonocytes within the testicular cords 
will transform into the spermatogonial stem cell population, whilst the remaining 
gonocytes will undergo apoptosis. This transformation is essential to allow a 




as these provide cells to enter the spermatogenic cell cycle eventually undergoing 
spermatogenesis and becoming mature sperm. During this process there is a 
tremendous amount of chromatin remodeling occurring, whereby the histones 
which bind the DNA are replaced by testes specific histones, and subsequently 
protamines, another form of chromatin condensing protein (Rathke et al. 2014). 
Various knockout studies performed in mice have shown that altered regulation of 
the histone and protamine genes causes defects in spermatogenesis leading to 
infertility; indicating that this is an essential process that must be undertaken for 
viable sperm production (Ueda et al. 2017). 
 
Histones consist of the 4 core histone (H2A, H2B, H3, H4) proteins along with a 
linker histone protein (H1). The genes for each of these proteins are found in 
clusters throughout the genome, with many variants of each found. In mice, there 
are 3 main clusters found on chromosome 13 (51 Hist1 genes), chromosome 3 (6 
Hist2 genes) and chromosome 11 (3 Hist3 genes) (Marzluff et al. 2002). Other 
important histone genes, such as H2afx are not found in clusters but located 
throughout the genome as isolated genes. The regulation of these genes is largely 
cell cycle dependent due to the need of large amounts of histone expression during 
replication phases (Mei 2016). Histones and testes specific histone variants are an 
essential component of effective gene regulation during spermatogenesis, without 
which lead to fertility and sperm defects (Hoghoughi et al. 2017). 
 
In this chapter we have analysed a SOX3 binding in mouse postnatal testes using 
ChIP-Seq. We identify almost 800 putative SOXB1 binding regions, including those 
close to Neurog3, H3t and Th2b, thought to be important genes regulating sperm 
development. Further, we show SOX3 binding near a large number of histone 
genes, suggesting it may have a regulatory role in chromatin and nuclear 




Materials and Methods 
Animal Work 
Animal experiments were subject to approval by the Animal Ethics Committees of 
the University of Adelaide. All studies were conducted within the principles of 
animal replacement and reduction and experimental refinement. Animals were 
monitored daily for evidence of illness and, if distressed, were culled immediately 
by cervical dislocation by an experienced investigator/animal technician. 
 
Chromatin Immunoprecipitation 
Testes from postnatal day 7 wildtype mice (129/SvJ) were collected transferred to 
ice cold 1xPBS containing protease inhibitors. Testes were mechanically dissociated 
before crosslinking in 1% freshly prepared formaldehyde for 8 minutes at room 
temperature. Fixed testes tissue was then lysed and sonicated (Bioruptor, 
Diagenode) for 15 minutes in 30 second pulses on ice. SOX3 bound chromatin was 
immunoprecipitated by a goat polyclonal antibody raised against human SOX3 
(R&D systems, AF2569). DNA was recovered by reversing crosslinks, and purified by 
PCR clean-up kit (QIAGEN). Three independent DNA libraries were produced from 
testis from three independent mice with the Illumina TrueSeq library kit as per 
manufacturer's instructions, and libraries were sequenced on the Illumina HiSeq 
producing 50 bp single end reads. A control sample (without SOX3 antibody) was 
run as input for background control.  
 
Peak Calling 
As published in McAninch & Thomas 2014, Bowtie (Langmead 2010) was used to 
align reads to the mouse genome (mm9). Peaks were called for each biological 




using input sample as background control, and a p-value threshold of 1e-5. Only 
peaks present in at least 2 of 3 biological replicates were retained. 
 
Gene Ontology 
Gene ontology was performed using the GREAT webtool {McLean:2010iq) using the 
mouse mm9 genome. The default settings of ‘basal plus’ were used to define the 
genomic regions and the whole genome was used for background regions.  
 
de novo  Motif Analysis  
The RSAT Peak Motifs program (Thomas-Chollier et al. 2012) was used for de novo 
motif analysis for each group of peak sequences analysed. Default parameters were 
used and the JASPAR core non-redundant vertebrates was used to compare to 
known motifs. 
 
FIMO (Find Individual Motif Occurrences), part of MEME-Suite was used to confirm 
peak regions containing the motifs identified previously (Grant et al. 2011; Bailey et 
al. 2015).   
 
Conservation Analysis 
PhastCons scores were generated for each peak sequence (ref). These were then 
ranked, and sorted into high, moderate and low conservation based on their mean 
0 score (Siepel et al. 2005).  
 
Published ChIP-Seq data 
SOX3 ChIP-Seq data from NPCs was obtained from McAninch (2014b). Microarray 






Genomic location of SOX3 bound regions 
To identify the regions of the genome bound by SOX3 within the postnatal mouse 
testes, the three independent ChIP-Seq experiments were performed using a 
previously validated SOX3 specific antibody (McAninch & Thomas 2014). Postnatal 
day 7 testes were used, as SOX3 is known to be expressed at this time, however the 
effects of germ cell loss are not yet evident (Raverot et al. 2005). Independent 
replicate datasets were overlaid and overlapping regions identified from the peak 
sequences. Across the three experiments, 2209, 1991 and 2017 peaks were 
identified. Only 241 regions were present in all samples, whereas 778 regions were 
present in at least 2 of 3 samples. This group of 778 was used for further 
downstream analysis.  
 
To determine the genomic context of SOX3-bound regions, HOMER ChIP-Seq 
analysis was performed (Figure 1). This revealed that 50% of the sites were 
intergenic (388/778), while 31% are intronic (243/778), followed by 11% within the 
promoter region (86/778), 2% transcriptional start and stop sites (18/778) and 2% 







The genomic context of all peak regions from SOX3 peaks identified within at least 
2 or more ChIP-Seq experiments. This data shows the majority of peaks were 
present within intergenic and intronic regions, followed by promoter, exons, 





GO Terms associated with peak regions 
To determine if there is any known functional associations of these peak regions, 
Gene Ontology (GO) Term analysis was performed using GREAT (Genomic Regions 
Enrichment of Annotations Tool). This tool interprets the functional significance of 
given non-coding genomic regions through analysis of the annotations of nearby 
and neighboring genes (McLean et al. 2010). As seen in Figure 2, the top 5 terms 
produced were “negative regulation of megakaryocyte differentiation”, 
“nucleosome assembly”, “nucleosome organization”, “chromatin assembly” and 
“chromatin assembly or disassembly”. From this it can be seen that there is a highly 
significant enrichment for functional association with nucleosomes and chromatin 
environment. Looking further into what regions are responsible for these terms, it is 
interesting to see that the majority of the peaks are located close to various histone, 
and histone regulation genes such as Brd2, Setd2 and H2afx. The full list of region 
and gene associations for each of the GO Terms produced is shown in Appendix 2.  
 
To determine if the high level of ‘chromatin’ GO terms were masking the presence 
of less represented functional associations the data was reanalyzed. All histone 
associated peak regions were removed from the dataset, and this was assessed via 
GREAT. Interestingly, no significant GO terms were found from this data, 
suggesting that the histone and chromatin related gene regulation is the key role of 






GREAT Analysis identified the most highly represented significant gene ontology 
terms associated with the 778 peak regions. The most highly significant term is 










Conservation of peak regions 
A feature of many known enhancers is their high level of evolutionary sequence 
conservation. We assessed the conservation of SOX3 bound regions using 
phastCons, which generates a conservation score for input sequences based on the 
conservation between 30 placental mammals (< 0.1 low conservation, 0.1- 0.5 
moderate conservation, and >0.5 high conservation) (Figure 3A). The majority of the 
sequences were lowly conserved (65%), with 23% moderately conserved, whilst 12% 
were highly conserved.  
 
To determine the genomic location of these highly conserved regions, we 
performed HOMER analysis on this subset. This revealed that the majority of these 
lie within the promoter region (defined as 1kb upstream of start site) or overlap an 
exon. While these still may be functional enhancers, it is likely that these regions are 
highly conserved due to the fact they are closer to coding regions; as these are 
generally more conserved than an intron.  The genomic regions and their nearest 
genes are outlined in Appendix 2.  
 
Interestingly, among this group of highly conserved peaks, a notable region was 
found within an intergenic regions (Fig 3B) whose neighboring gene is known to be 
developmentally important in the progenitor cells of the testes, Neurogenin3 
(Kaucher et al. 2012). This peak region appears to be part of a much larger region of 
conservation suggesting the peak we have identified could be part of a larger 











Conservation analysis of the peak regions as assessed by PhastCons scores. A 
shows the conservation distribution of all 778 testes peak regions, most regions 
show low conservation. B shows the genomic location of the 12% of peaks from 3A 
that are highly conserved. C shows the SOX3 ChIP-Seq binding peak in the ‘testes’ 
track is present within a region of high conservation (blue, mammal cons track) and 
is located adjacent to the Neurog3 gene in mouse. Image is taken from the UCSC 





Identification of SOX Motifs 
The 20 different SOX proteins have been shown to bind to a consensus SOX core 
motif, (G1A2C3A4A5A6G7) (Hou et al. 2017). We wanted to determine if the sequences 
within our peak regions contained this core motif or variations of it. To identify 
putative SOX3 binding motifs, we performed de novo motif analysis using RSAT 
peak motifs.  
 
We identified 3 similar “SOX” motifs that were enriched within the peak sequences 
at similar frequencies (Figure 4A-C). Motif 1 and 2 are highly similar, but differ at  
the core position 6, corresponding to A9 in Motif 1, and T9 in Motif 2. The third 
motif appears to be similar to the ‘core’ sequence, however does not show a 
preference for the first G at position 1 (core).  
 
As these motifs vary, each of the groups were assessed via GREAT to determine if 
the different binding motifs may be indicative of function. However, for each of the 
three groups, as well as when combined, did not produce any significant GO Terms. 
The binding locations and nearest genes of the peak sequences containing a SOX 
motif can be found in Appendix 2.  
 
Importantly, the distribution of each motif is highest at the center of the peak 
sequence, suggesting these are bona fide binding sequences.  Each of these motifs 
is present within different peaks (motif 1-124, motif 2-94, motif 3-93), although due 
to the nature of position-specific frequency matrix, some peak sequences contain 
more than one of the SOX motifs. From this, there are 204 individual peaks that 
contain a SOX like motif (Figure 4D). For downstream analysis of putative binding 
partners or co-regulators, each of the peak sequences that contained at least one of 







The three SOX-like motifs identified via RSAT Peak motifs are highly similar 
although differ in core position 6, corresponding to position 9 in A and B, and 7 in 
C. The proportion of peak sequences containing one of the shown SOX motifs is 





Identification of putative co-regulator proteins  
The motif identification program, RSAT Peak Motifs identified a further 8 possible 
motifs present within the set of sequences. These include motifs shown to be similar 
to Ahr/Arnt, SP, and HES families. SOX proteins have been shown to co-activate 
expression of target genes with varying partner factors, dependent upon the tissue 
context. However none of those identified in this search have been shown 
previously to be SOX-protein partners. Interestingly, the most common partner 
factor of SOXB1 proteins, POU family members, were not identified in any de novo 
analyses, or through manual searches using the POU motif.  
 
One motif that warranted further investigation was the SP1/SP2 like motif 
(CGCCTCC/CCGCCGC) as seen in Figure 5A (SP Motif) and 5B (identified motif in 
dataset). SP transcription factors are expressed throughout many tissues and cell 
types, including spermatogonia, and been shown to induce expression of histone 
genes (Wilkerson 2002). We show 27 regions in which both SP and SOX3 motif were 
identified, and whilst likely not a partner protein due to considerable variation in 







Figure  5 
De novo motif analysis of the peak regions identified a SP like motif. A shows the 
Transfac known SP1 motif while B shows the motif identified within the peak 
sequences. The proportion of peaks containing both SOX and SP motifs is shown in 





SOX3 bound regions present in both NPCs and Testes 
Previous ChIP-Seq analysis of mouse neural progenitor cells (NPCs) using the same 
SOX antibody (McAninch & Thomas 2014b) identified 8064 regions bound by 
SOX3. Comparison of the NPC and testes sequences identified a subset of 123 
regions bound by SOX3 in both tissues (Figure 6A). This suggests some overlap of 
SOX3 function in these distinct cellular contexts. GO Terms were generated for the 
common subset of SOX3-bound sequences to assess what functions may be 
consistent. Significant enrichment for terms involving DNA packaging, nucleosome 
and chromatin assembly, as well as the negative regulation of both megakaryocyte 
and hematopoietic cell differentiation were identified (Figure 6B). These terms are 
similar to those produced when all 778 testes peaks were assessed. A large 
proportion of the peaks located within clusters near histone genes were also shown 
to be overlapping in the NPC data (Figure 6 C-D). This suggests a potential 
common function of SOX3 at these regions, and may be what accounts for the 






























Comparison of the bound regions between the NPC and Testes cell types identified 
123 genomic regions that are bound within both ChIP-Seq data sets (A). The GO 
terms of this subset were assessed via GREAT, with the most significant enriched 
terms being shown in B. UCSC browser images of the histone gene clusters on 
chromosome 3 and 13 show the overlapping peak regions (C and D). The track 
‘NPC and Testes’ only identifies peaks present in both datasets, while Testes 2 Plus 
identifies peaks present within at least 2 of 3 ChIP samples from the testes. Other 
tracks from the browser are also show, such as gene annotations, spliced ESTs and 






Motif identification in peaks present in both NPCs and Testes 
As binding motifs often differ depending upon partner factor interaction and/or 
cellular context, we wanted to determine whether a specific motif was enriched in 
the common testes/NPC ChIP sequences. Analysis of the 123 peak subset identified 
a SOX-like motif, with preference for an A or C at ‘core’ position 6 (Figure 7). This is 
most similar to the SOX-like Motif 1 (Figure 4A). Again, similar to the complete 
testes dataset, an SP1-like motif was identified, albeit in a much larger proportion of 
peak regions (60%). As these are mostly not present within the same regions it is 
difficult to assign them as partner proteins and the motifs may be present as 






Figure  7 
Motif analysis of overlapping regions between NPC and Testes ChIP-Seq data 
identified a SOX-like motif (A) as well an SP1 like motif (B). C shows the overlap 
between SOX and SP1 motifs within the 123 peak sequences, with the majority of 







Peaks only present within Testes 
We were interested to determine if there was a different subset of motifs or 
functions associated with testes-specific peak regions. Within this group of 655 
peaks, we still identified a SOX-like motif and an Sp1 like motif – however these do 
differ slightly from those found in both the NPC overlap data and the complete 778 
region dataset. The SOX Motif is most similar to Motif 1 and 3 from the original 
dataset, maintaining an A at position 9 (core position 6) rather than a T. The GO 
Terms generated are highly focused on chromatin and nucleosome organisation 
and assembly (Figure 8B). Interestingly, the ‘negative regulation of megakaryocyte 
differentiation’ was not enriched in this dataset unlike the NPC/Testes overlap and 
compete testes dataset, suggesting this may have been associated with regions 
also active within a neural context. Again, many histone genes were associated with 
these GO Terms as can be seen in Appendix 2. 
 
Two peak regions of interest were located nearby to testes specific histone genes, 
Hist1h2b and H3t (GM12260) (located within another gene, Trim17). These peak 
regions can be seen in 8C and 8D, and are specific to only the testes dataset, and 






































Analysis of the 655 testes-specific bound peaks identified both a SOX like motif and 
SP1 like motif (A). The significantly enriched GO Terms generated using GREAT 
show chromatin organisation and assembly like terms, with chromatin organisation 
giving the highest score. C and D show UCSC browser images of regions only found 
within the SOX3 testes ChIP-Seq located near testes specific histone genes (C- 
Hist1h2aa and Hist1h2b, D- H3t). The tracks ‘testes’ indicates the peak is present in 
at least 2 of 3 ChIP samples. In D, the testes specific histone gene H3t is indicated 






Regions present in ChIP-Seq and Microarray  
A microarray performed on postnatal mouse testes of both wildtype and Sox3 null 
mice has previously been performed to elucidate SOX3 target genes (Adikusuma et 
al. 2017). From this data, only 18 genes were found to be significantly up or 
downregulated in response to the lack of SOX3 (Figure 9). To identify putative 
SOX3 direct target genes, we compared these regions to the ChIP-Seq data, and 
found that only 1 nearest-neighbour peak sequence appeared to have a 
dysregulated gene in response to SOX3, neurogenin3 (Neurog3, also known as 
Ngn3). In the microarray, Neurog3 is shown to be downregulated 2.9 fold, with only 
0.35 gene expression compared to wildtype. The peak sequence for Neurog3 can 
be seen approximately 3kb upstream of the TSS, and is within a larger region of 









Overlap of the testes ChIP-seq peaks nearest genes with microarray data from 
SOX3 null mice only produced one gene, Neurog3 (A). B shows the details of this 
peak regions, including genomic location in mm9, conservation score and SOX 
motif. C shows the UCSC browser image, with the peak sequence seen in green 
overlapping a large region of conservation (mammalian conservation track) 






SOX3 is expressed within the postnatal testes, and whilst it is known that loss of this 
transcription factor leads to spermatogenesis defects and sterility, its transcriptional 
targets are currently unknown (Raverot et al. 2005; K. M. Weiss et al. 2003). Through 
ChIP-Seq analysis we have shown that SOX3 binds to 778 genomic regions within 
postnatal testes, and through integration with other data have identified putative 
SOX3 bound regulator regions that may be important for the initiation and 
progression of spermatogenesis, as well as the regulation of histone gene 
expression. 
 
The highest scoring TF motifs identified by de novo analysis were consistent with 
known SOX binding motifs, namely the core SOX motif (G1A2C3A4A5A6G7) (Hou et al. 
2017). From the three closely-related motifs that were identified, the most obvious 
difference is the strong preference for a T at core position 6 rather than A (Motif 2).  
However it is worth noting that SOXB1 motifs have been identified with either A or 
T at this position, and it has previously been shown that SRY, which is closely related 
to SOX3, favors the T at this position rather than A  (Harley 1994). Previous ChIP-
Seq analysis of SOXB1 binding within neural progenitors identified this position as 
being equally favoured as either A or T (McAninch & Thomas 2014). Interestingly, 
each of these motif variants were enriched in specific subsets of peaks.  However, 
functional GO terms were not associated with each of these groups, so the 
significance of this remains to be determined. Another difference between the 
identified motifs (AAACAAAG, AAACAATG, ACAAAG) and the core motif 
(GACAAAG) is the lack of a G at position 1. In all motifs identified there was either 
an A at position 1, or no strong preference. This is not surprising as many SOX 
factors have shown preferences for A at this position, including SOX18, SOX9 and 





Together these data may indicate that a subset of SOX3 binding that occurs within 
the testes, preferentially binds to the AACAATG motif. While within the CNS, and 
targets that are common between testes and CNS SOX3 binds with the other 
SOXB1 factors to AACAAAG. However, until further analysis can be performed on 
these regions it is difficult to assign a functional reason for this preference.  
 
SOX TFs do not appear to require strict binding motifs and have been shown to 
bind to transcriptional targets of other family members when ectopically expressed. 
For example, SOX3 can bind to the SRY-target enhancer upstream of SOX9 
(TESCO) (Sekido & Lovell-Badge 2008a) when ectopically expressed in Sertoli cells 
(Sutton et al. 2011), and SOX2 is able to almost fully compensate for SOX3 when 
ectopically expressed in the testes using the endogenous Sox3 promoter 
(Adikusuma et al. 2017). It is thought that while all SOX proteins have a core motif 
that they need to bind, the presence of different flanking nucleotides is what allows 
the specificity of binding by each protein (Mertin et al. 1999). 
 
SOX proteins are often shown to bind co-operatively at target genes with a partner 
protein (Kamachi et al. 2000). These partner proteins are thought to help increase 
the specificity of TF binding, as often more than one SOX factor is present in a 
tissue type. None of the known SOXB1 partner binding proteins such as the POU or 
PAX family members were enriched in motif searches of the testes dataset. SOX3 
has been shown to bind co-operatively with OCT4/POU in the nervous system 
(Wilson & Koopman 2002; Tanaka et al. 2004; Ng et al. 2012), and this was 
observed within a SOXB1 ChIP-Seq dataset of mouse NPCs (McAninch & Thomas 
2014b). Although OCT4 is known to be expressed within the gonocytes and 
spermatogonial stem cells along with SOX3, we did not see any evidence of these 





In identifying the SOX3 motif within the peak regions, a SP1 motif was also found 
within a large proportion of these regions. SP1 is a zinc finger transcription factor 
with a large array of functions including apoptosis, cell growth and chromatin 
remodeling (Tan & Khachigian 2009; Cakouros et al. 2001). Sp1 is expressed 
throughout the early stages of spermatogenesis, decreasing at the pachytene 
stages (Panigrahi et al. 2012), while SOX3 is expressed throughout these same 
regions and timepoints (Raverot et al. 2005). In our analysis, we show that 27 peaks 
regions contain both a SOX3 motif and an SP1 motif, which may represent a 
subpopulation of genes that are regulated by both SOX3 and SP1/SP2 TFs. Whilst 
SP1 has not previously been shown to partner with SOX3, it has been implicated as 
a binding partner with other SOX proteins, such as those from the SOXE subgroup, 
as well as SRY, which is thought to have evolved from SOX3 ((Wissmüller et al. 2006; 
Nagai 2001). This subgroup of peak regions may represent a group of genes 
containing enhancers bound by both SOX3 and SP1. Whilst there is little evidence 
that these are partner factors, they may regulate the same genes either as part of 
larger enhancer complexes, or could each control an aspect of the spatial or 
temporal expression of gene by acting separately at individual enhancer regions.  
 
Although only 204 of the 778 peaks were identified as containing at least one of the 
three SOX motifs, this may not be a complete representation of SOX3 binding. 
There is often flexibility in TF binding motifs, which can be influenced by partner 
factor binding. It is possible that there are some motifs which were not found via the 
motif searching algorithms due to low occurrence within our datasets. It is also 
possible that some of the peak regions generated are not bound by SOX3, but are 
a consequence of the looping interactions generated between enhancers and other 
TFs or promoters. Protein:Protein, rather than Protein:DNA interactions can be 




there would not be a SOX3 motif found as it would be binding a protein not 
identified in the ChIP-Seq. Chromatin capture experiments or ChIP combined with 
mass spectrometry could be applied to these regions, and help determine any 
partner factors that may bind at the same targets with SOX3, potentially regulating 
gene expression.  
 
The peaks identified  from the testes ChIP-seq are mostly found within intergenic 
and intronic regions, consistent with other ChIP-seq analyses (Ohba et al. 2015; C.-
F. Liu & Lefebvre 2015; McAninch & Thomas 2014b). This suggests a regulatory role 
such as enhancer binding. Conservation analysis via PhastCons scoring showed that 
12% of bound regions had high conservation, indicative of their importance within 
the mammalian genome. When only the highest conservation peaks are assessed, 
the genomic location of these changes significantly, with a higher percentage of 
exon and promoter associated regions now seen. The subset of exon-bound 
regions within the ‘high conservation’ group could be due to the generally much 
higher level of conservation of exonic regions compared to non-coding regions, and 
the high percentage of promoter bound regions may also be a symptom of this, 
albeit more functional. Recent evidence does however suggest that exons can 
function as tissue-specific enhancers (Birnbaum et al. 2012).  
 
SOX3 is present within both the CNS and the testes, and it is unknown id they share 
common targets. Using a ChIP-Seq dataset of SOX3 binding in NPC we could 
identify if binding regions and TF motifs were shared. The 15% of testes peak 
regions also identified as bound in NPCs, show GO terms again suggestive of 
nucleosome and chromatin regulation and assembly. This indicates that SOX3 may 
be an important regulator of histone expression throughout tissues types, and 
further experiments to investigate if this occurs within other tissues or at different 




produced from the peak data appear to be due to the proximity of binding closely 
to histone and histone related genes, the 3 most common SOX motifs identified in 
the initial searches are not found in these regions.  
 
During the progression of spermatogonia through spermatogenesis there is 
complete reorganisation of the chromatin structure within the nucleus (Bošković & 
Torres-Padilla 2013). Whilst almost all cells use histones to “bundle” their DNA, 
sperm cells are unique in that histones are replaced by protamines during 
maturation. In our analysis of SOX3 binding, we saw many peaks at the hist1 and 
hist2 clusters, as well as other key histone genes, H2afx and Hist1h2ba. Testes-
specific peaks were detected near histone 3 genes, although not in the same 
cluster-like formation seen at hist1 and hist2 regions.  These genes are responsible 
for the majority of the GO terms associated with the peak dataset due to their 
importance in regulation of chromatin and nucleosome organisation. The vast 
majority of these did not however contain identifiable SOX binding site motifs 
within the peak sequences, and it may be that SOX is binding with an unidentified 
partner at these regions. Further investigation into the expression regulation of 
these genes within each of the stages of spermatogenesis would again be beneficial 
to try and understand the relationship between SOX3 and regulation of histone 
genes.  
 
The binding of SOX3 close to many histone and chromatin-associated genes 
suggests that it could be playing a role in the regulation of histone expression 
throughout spermatogenesis; potentially during the essential histone to protamine 
transition that must occur for viable sperm. The lack of any significant differences in 
expression of these genes in SOX3 knockout testes suggests that although it may 
be involved, there are most likely redundancy pathway present, or the putative 




removing the potential enhancers in vivo and assessing both changes in gene 
expression as well as phenotypic analysis of the testes and sperm may help to 
determine if SOX3 is involved in these pathways.  
 
One of the most interesting regions identified within the ChIP-seq is a binding peak 
between the Hist1h2aa and Hist1h2ba genes, which encode TH2A and TH2B, and 
have been shown to utilize the same regulatory region {Huh:1991uz}. These are 
testis-specific histone variants that replace the canonical core histone proteins H2A 
and H2B within the early spermatocytes (Montellier et al. 2013). Depletion of Th2B 
in spermatocytes does not seem detrimental as compensatory mechanisms are 
induced allowing for an upregulation of the canonical H2b histone, allowing 
spermatogenesis to be completed. However, loss of both Th2b and Th2a which are 
controlled by the same regulatory region between the two genes does cause 
defects in spermatogenesis, leading to infertile males (Shinagawa et al. 2015).  
Another testes specific histone variant, H3t has been shown to be essential for the 
entry into spermatogenesis (Ueda et al. 2017). Whilst this gene is not an “officially-
named” gene within the mm9 database to which out ChIP-Seq data was mapped, a 
binding peak is located within the same region as the predicted gene, GM12260-
001 which is located within an intron of Trim17. The h3t histone variant is shown to 
be incorporated into the genome prior to spermatogenesis, displacing the 
canonical H3 variant. This replacement, although only 3 amino acids different to H3 
is thought to generate a more flexible and open chromatin structure, necessary for 
the progression into meiotic recombination (Ueda et al. 2017). Similar to SOX3 
knockout mouse models, loss of H3t leads to reduced testes weight and a loss of 
germ cells (Ueda et al. 2017). Further analysis of the SOX3 binding at this region is 
warranted, and could show a link between the loss of SOX3 leading to infertility 
through reduced or lack of H3t replacement of canonical H3 within the 





While SOX3 has not yet been shown to be involved in the regulation of these testes 
specific histone genes, the finding of SOX3 binding within the known promoter 
region, and overlapping an important gene is worth further investigation. Combined 
with the evidence of SOX3 binding near or at many other histone genes suggests it 
plays a role in their regulation. Although TH2B and TH2A do not replace the 
canonical histones until the early spermatocyte stage, and SOX3 is thought to be 
expressed within the earlier spermatogonia, it may be that SOX3 is acting as a 
pioneer transcription factor or is pre-binding genes prior to their expression, as 
other members of the SOXB1 family have been shown to do within neural contexts 
(Hagey et al. 2018; Bergsland et al. 2011; Klum et al. 2018). We would expect that if 
SOX3 was important in directly regulating either TH2A or TH2B, that this would be 
reflected in the microarray data of SOX3 KO testes, of which only 18 genes were 
shown to be differentially expressed. H3t was not identified as a functional gene 
when the microarray experiments were performed, and as such was not measured. 
Further experiments such as single cell RNA Seq of each stage of spermatogenesis 
would give a much better overall view of the changes in expression of these genes, 
when they are activated, and how long they are expressed for. If this was compared 
to a Sox3 null mouse model the nuanced changes in expression may be apparent 
and able to compared more closely.  
 
Another gene that may be regulated by SOX3, is Neurog3, which encodes a basic 
Helix Loop Helix transcription factor, and known mostly for its role in the 
differentiation of endocrine cells and NPCs (Gradwohl et al. 2000; Pelling et al. 
2011). NEUROG3 mirrors the expression pattern of SOX3 during early 
spermatogenesis, being found in As, Apr and Aal spermatogonia (Yoshida et al. 
2004; Yoshida et al. 2006), and has been shown that its expression is abolished in a 




members of the SOXB1 family are known to regulate the expression of other 
Neurogenin members during neuronal differentiation (Kan et al. 2004), led Raverot 
and colleagues (2005) to propose a functional link between SOX3 and NEUROG3 in 
the differentiation of spermatogonia. In the microarray data of Sox3 null testes 
(Adikusuma et al. 2017), its expression was reduced to 50% of normal levels, 
indicating a strong reliance on SOX3, whether through direct enhancer binding or a 
signaling pathway involving SOX3. We propose that the highly conserved binding 
site upstream of Neurog3 is an enhancer for NEUROG3 expression within SSCs and 
the early spermatogonial cell types; however functional analysis of this enhancer 
would need to occur before this can be fully validated. When looking at the putative 
enhancer region within the UCSC genome browser, it is evident there is 
approximately 1kb of highly conserved DNA surrounded by less conserved regions 
upstream of NEUROG3. As the SOX3 peak only covers a few hundred bp of this, it 
is highly likely that there is a number of other TF binding sites present that are 
working together to control expression. Determining if this region is an enhancer 
could first be examined through use of a reporter assay. By using the entire 
conserved region to drive expression of a LacZ reporter and assessing expression of 
this within the testes could show if this region is active and if it can drive expression 
to the expected regions. Further ChIP experiments with different TFs would be 
interesting to show what other factors are binding close to this peak, to see what 
factors are important in NEUROG3 expression. 
 
In summary, through ChIP-Seq analysis within the postnatal mouse testes, we have 
identified almost 800 regions that are bound by SOX3, including three putative 
enhancers implicated in spermatogenesis. These data provide a platform for further 
functional analysis to investigate the function of SOX3 within the testes. This work 
has provided the first evidence of a role for SOX3 in regulation of histone genes, 




show functional evidence of co-regulation or partner protein activity with SP1, ChIP 
combined with Mass Spectrometry would be a logical next step. Other experiments 
such as proximity ligation assays could provide visual confirmation of interaction 
between the two transcription factors. However this does not prove functional 
interaction but could show binding at the same locations. Single cell RNA Seq data 
on each stage of spermatogenesis, from spermatogonia to spermatocytes would be 
an invaluable resource for both this study and others to decipher gene expression 
changes during the complex progression of sperm development. This data would 
allow us to correlate the SOX3 binding with active or inactive genes, and help to 
determine if SOX3 is acting as a transcriptional activator, repressor or is pre-binding 











Widely used in transgenic mouse model research, the Nestin promoter and 
enhancer driven Cre recombinase, Nes-Cre, is known to direct expression of target 
genes to the neural stem and progenitor cells within the CNS ((Liang et al. 2012; 
Isaka et al. 1999; Trumpp et al. 1999; Petersen et al. 2002; Dubois et al. 2006). First 
discovered in 1994 in rat as a CNS-specific enhancer of expression (Zimmerman et 
al. 1994), further research on the region has identified a smaller 30bp section 
comprised of SOX and POU binding motifs that are essential for reporter gene 
expression (Tanaka et al. 2004). Although reporter assays are able to show the CNS-
specific activity of this enhancer, they are unable to demonstrate the contribution to 
endogenous Nestin gene expression during development.  
 
In Chapter 2, functional analysis of the SOXB1 bound Nestin enhancer was 
undertaken. From this, we wanted to ascertain the endogenous functionality of the 
enhancer, and whether it was required and/or essential for Nes expression within 
the neural progenitor cell population of the developing mouse CNS. Initially, we 
removed the enhancer using CRISPR and assessed two independent lines with 
slightly different deletions, both of which showed significant reduction in Nes 
expression via qPCR at 12.5dpc. Further investigation into the -255 line showed this 
reduction in expression was present from 9.5 until 15.5dpc, with the most dramatic 
change being a 70% reduction in Nes expression within the head.  
 
Our results confirmed previous assumptions that this enhancer is required for full 
expression of NES within the developing CNS. While spatial expression had been 
tested through LacZ reporters, the endogenous temporal expression of the 




In our analysis of the Nes enhancer, the earliest timepoint analysed for Nes 
expression within the head was 8.5dpc. At this timepoint, all 3 SOXB1s as well as 
POU proteins are present within the CNS in the NPCs (Uchikawa et al. 2011; Wood 
& Episkopou 1999). Gel supershift assays using OCT1, BRN1 and BRN2 antibodies 
indicate that OCT1 binds the Nes enhancer at 8.5dpc, followed by BRN1 and BRN2 
(Z. Jin et al. 2009). We were able to show that loss of this enhancer does not affect 
Nes mRNA expression at this early stage. However, from 9.5dpc Nes expression is 
reduced within the head, suggesting it is only active from this developmental stage 
onwards. This could be due to the requirement of other TFs to bind to the region. 
Indeed, binding sites for SF1 and NKX2.1 as well as hormone responsive elements 
have been identified within the enhancer, although the activity of these have not 
been tested in vivo (Pelizzoli et al. 2008; Z. G. Jin et al. 2009). There is large 
variation across enhancers in the number of TFs needed to bind for effective 
regulation of gene expression, making it difficult to know which or how many TFBS 
are functional at each enhancer. Further bioinformatic analysis along with 
integration of ChIP data could help to unravel which TFBS present are functional 
and required for Nes enhancer activity. In comparison with the endogenous 
enhancer activity, transgenic mouse models utilising the Nes enhancer to drive Cre 
recombinase, recombination begins to be seen between 8 and 10 dpc within the 
ectoderm, mesenchyme, somites and mesonephric cord (Dubois et al. 2006). This 
indicates that the activity may be regulated by the chromatin structure, which may 
be inaccessible endogenously, but easily bound within an open conformation 
transgene element.  
 
It is possible that the reduction in Nes expression when the enhancer region is 
removed is simply due to the change in the local chromatin structure, and not due 
to the removal of SOX and POU sites. The architecture of the chromatin 




chromatin and the need to form topologically associated domains (Kragesteen et al. 
2018; Spielmann & Mundlos 2013). As a way to overcome this issue in future 
experiments, point mutations that alter nucleotides critical for TF binding would be 
a more useful approach. In these more refined experiments, individual SOX and 
POU motifs that contribute to enhancer activity could be identified. This strategy 
could also be used to determine if this enhancer requires all TF to be bound for full 
activity, or if each individual TF is capable of a small contribution to overall 
expression. Enhancer deletion is becoming a widely used approach to assess the in 
vivo activity of these regulatory regions (Szafranski et al. 2017; Johnson et al. 2018; 
Dickel et al. 2018), aided by the continually improving CRISPR technologies which 
mean specific and precise mutation generation is becoming easier and more 
accessible. The newest form of genome editing, base editing, is now possible 
whereby individual adenine residues can be converted to guanine, and cytosine to 
thymine by dCas9 molecules fused to adenosine and cytidine deaminases, 
respectively, without inducing double strand breaks (Komor et al. 2016; Komor et al. 
2017; Gaudelli et al. 2017). This is an attractive strategy for modifying individual TF 
motifs without interrupting the 3D architecture, however recent reports have 
highlighted possible increases in off-target effects using this strategy (Zuo et al. 
2019) although these effects can potentially be mitigated in an established mouse 
line through breeding.    
 
Nestin was first discovered as a marker of neural stem cells, hence where its name is 
derived; Neuroepithelial Stem cells (Nes) (Lendahl et al. 1990). Nestin is an 
intermediate filament protein, although its exact function within the cell and during 
development are not completely understood. It is expressed in many cell types, 
mostly those during periods of active proliferation (Park et al. 2010; Wiese et al. 
2004), including neural precursor cells, muscle progenitors, newly formed blood 




Nestin caused embryonic lethality due to its role in the self-renewal of NSCs, rather 
than its role as a structural protein within these cells’ cytoskeleton. We then 
generated two independent NES null lines using CRISPR, an entire coding 
sequence deletion, and a frameshift mutation. Contrary to Park et al (2010) we 
showed that NES null mice and embryos are viable, fertile and show no obvious 
phenotypic effects. Other studies have also shown similar results with no defects 
(Austin et al. 2004), or with minor phenotypic defects such as impaired motor co-
ordination (Mohseni et al. 2011).  
 
Comprehensive phenotyping was not performed on our two NES null lines. If this 
was performed, it may show if similar motor coordination or subtle CNS defects are 
present and consistent with previous models. In the most recent knockout model by 
(Mohseni et al. 2011) and colleagues it was found that the number of acetylcholine 
receptor clusters and nerve length are significantly increased in mice lacking NES. 
These would be interesting to assess in both our knockout model of Nestin, as well 
as the enhancer deficient mice to ascertain if any of these phenotypes could be due 
to the loss of Nestin specifically within neural precursors. It is possible that the 
variation in phenotypes seen across these studies could be due to the use of 
different targeting vectors and recombination cassettes. Other factors such as 
differing mouse strains can lead to vastly different outcomes (Montagutelli 2000), 
however in this case, our experiments as well as those mentioned all used C57BL/6 
mice. This highlights the usefulness of CRISPR in generating ‘clean’ deletions, 
eliminating any potential side effects that may be caused due to selection cassettes 
left in the genome.  
 
During our analyses of Nestin expression, it could be seen that animals 
heterozygous for the enhancer deletion showed consistently higher expression than 




and trans to control gene expression. Generally, mammalian enhancers are viewed 
as cis-acting. In contrast, the phenomena of trans-activation of gene expression has 
been described for many decades in Drosophila models, where it is known as 
transvection (Lewis 1954). Our results are consistent with recent findings that some 
super enhancers such as those required for red blood cell development and IgH 
expression are capable of interchromosomal interactions between enhancer and 
promoter (Alvarez-Dominguez et al. 2017; Le Noir et al. 2017). These experiments 
are often difficult to perform in a wildtype mouse system as the mRNA expressed 
from each allele appears the same in qPCR based experiments. One way of 
overcoming this issue is to use two different strains of mice that contain SNPs 
between coding sequences, so individual alleles can be distinguished by sequence 
variation. These would need to bred with a enhancer deleted mouse line, and the 
resultant mRNA from each allele can then be analysed.  
 
In Drosophila, Lim and colleagues (2018) have demonstrated real time visualisation 
of trans enhancer-promoter interaction within the developing embryo (Lim et al. 
2018). They found that for the developmental enhancer Snail, gypsy insulators at 
each chromosome were critically important for the trans interactions to occur. This is 
thought to be due to their effect on stabilising the interactions between the two 
chromosomes (Kravchenko et al. 2005). In vertebrates, the only known insulator 
bound protein is the transcription factor CTCF, which is known to be critical for 
regulating the 3D structure of chromatin (Bell et al. 1999; Kim et al. 2015). Future 
experiments to understand the interchromosomal interactions of the Nes enhancer 
could focus on identification of putative insulator sequences. ChIP experiments 
assessing CTCF binding within NPCs at timepoints where the Nes enhancer is 
known to be active may show binding of CTCF flanking the enhancer. Previous 
genome-wide studies of CTCF binding have identified over 800 000 CTCF binding 




does not recognise any experimentally verified CTCF binding near the Nes gene 
(Ziebarth et al. 2013). This does not however take into account cell and tissue types. 
If found through ChIP binding, further experiments removing the CTCF binding 
regions and assessing trans enhancer activity could show its effect on expression 
from each allele.  
 
NES is known to be expressed within the endothelial cells of the blood vessels 
within various tissues, and can also be used as a marker of neovascularisation 
(Suzuki et al. 2010; Mokrý et al. 2008). We observed that when the Nes enhancer 
was deleted, ectopic expression of NES was seen within the vasculature of the 
neural tube. Whilst there is no identified enhancer responsible for this vascular 
expression, we proposed that by deleting the enhancer region other important 
regulatory elements may have been disrupted. As the expression was ectopic, 
rather downregulated, we reasoned a repressive element may be present within the 
255 bp enhancer. Repressive elements have been identified for other genes, such 
as GAP-43 where a 30bp region inhibits expression in non-neuronal cell types 
(Weber & Skene 1997), as well as the RE1/NRSE repressor that is found at a group 
of neural specific genes. There is not currently any evidence as to what other TF 
may be bound at the Nes enhancer, and future ChIP data would be needed to 
confirm any putative TF motifs identified. This result highlights the importance of 
endogenous enhancer analysis, as this effect would not be detected only using 
reporter assays or mouse models. As CRISPR deletions become the standard 
method for enhancer analysis, it is possible that more previously unknown 










FZD3 is a Wnt receptor protein involved in the Wnt/b-catenin canonical signaling 
pathway that controls many developmental programs (Sala et al. 2000). There has 
not previously been any link between the SOXB1 transcription factors and the 
regulation of Fzd3, apart from the fact that they are expressed within the same 
regions of the CNS during embryonic development. Whilst the SOXB1 proteins 
maintain the neural progenitor cells within a stem-like state, it appears that Fzd3 
along with other proteins is important for the cell fate decisions of NPCs through 
activation of Notch pathways (Wang et al. 2016).  
 
ChIP-Seq studies of the SOXB1 factors in NPCs identified the putative Fzd3 
enhancer within intron 2 of Fzd3 (McAninch & Thomas 2014). CRISPR mediated 
deletions of the SOXB1 motif and the larger putative enhancer enabled us to assess 
endogenous activity during embryonic development of the CNS. We detected a 
small but significant decrease in Fzd3 expression when only the SOXB1 motif was 
removed, and a more striking effect of a 30% expression reduction when 573bp of 
putative enhancer was removed. No previous enhancers or regulatory regions of 
Fzd3 have been identified within the literature. By generating two different 
deletions we were able to show that the SOXB1 motif is responsible for a small but 
significant proportion of this expression. The larger enhancer deletion (-573) 
provides evidence that it is highly likely other TFs are binding and controlling 
expression of Fzd3. To determine what these other TFs are, luciferase reporter 
assays using TFs known to be involved upstream of Fzd3 signaling pathways could 
identify initial targets. Alternatively, bioinformatic approaches such as integration of 





During our analyses, we were interested in the control of Fzd3 within the NPC 
population via SOXB1 proteins. However, Fzd3 is expressed within a variety of 
tissue and cell types including the thymus, testis, skin and hair follicles. 
(Romanowska et al. 2009; Papatheodorou et al. 2018). By utilising the Fzd3 
enhancer deletion model, the expression of Fzd3 can be measured in these other 
tissues to define the spatial and temporal activity of the enhancer. This could also 
help to identify any other TFs that may be regulating Fzd3 within these other 
contexts, through analysis of TFs known to be expressed in regions where Fzd3 
expression is modulated.   
 
Although removal of the 573bp putative enhancer showed a marked decrease in 
Fzd3 mRNA expression, no obvious phenotype was observed. FZD3 is an essential 
protein, without which mice die soon after birth due to brain and neural tube 
defects (Wang et al. 2002; Wang et al. 2006; Peeters et al. 1998), although 
heterozygotes develop normally. We generated a Fzd3 null line, which showed 
phenotypes consistent with previous reports, with pups displaying a curly tail and 
dying soon after birth. We used this line to generate compound heterozygote mice 
to determine the level of Fzd3 expression  sufficient for survival, and showed that 
only 40% of wildtype was sufficient. Although we could not detect any phenotypes 
with the compound heterozygote line, this is a useful approach to determine the 
levels of expression required for development of embryonic lethal genes. It is often 
difficult to generate mouse models with expression levels outside of 100%, 50% or 
0% expression, and this method can be applied to many genes with known 
enhancers.  
 
The lack of phenotype in the compound heterozygote Fzd3 mouse was not entirely 
unexpected, as genetic and functional redundancy has previously been shown 




Frizzled protein evolution (Huang & Klein 2004), and FZD3, along with FZD6 is 
known to be important in the closure of the neural tube. Mice lacking both these 
proteins die within minutes of being born due the failure of this essential process in 
CNS development, a more severe phenotype than seen in FZD3 or FZD6 single 
knockouts (Y. Wang et al. 2006; Stuebner et al. 2009). It may be that the SOXB1s 
are important in regulating the expression of Fzd3 within the neural tube for this 
closure to occur, but the phenotype could masked due to the functional 
redundancy with FZD6. FZD6 knockout mice are viable, showing hair patterning 
defects (Guo et al. 2004) but no CNS phenotype, presumably due to the presence 
of FZD3 within these areas. By generating mice lacking FZD6, and crossing these 
with mice homozygous for the Fzd3 enhancer deletion, possible effects of the Fzd3 
enhancer loss may become more apparent and be able to be studied in more 
detail. This functional redundancy has also been observed within the control of 
planar cells polarity of hair development as well as midbrain development which are 
potential further avenues to explore with Fzd6 null, Fzd3 enhancer deleted mice 
(Dong et al. 2018; Stuebner et al. 2009; Wang et al. 2006). 
 
As previously mentioned, throughout our experiments we were able to show 
reduction in Fzd3 mRNA, however no phenotype could be seen even when 
expression was reduced to 40% of wildtype levels. It is possible that this RNA loss is 
not recapitulated as a loss in protein expression. These two measures are not always 
proportional (Liu et al. 2016), and without a suitable antibody we are unable to 
visualize the effect on FZD3 protein. To overcome this, an endogenously tagged 
FZD3 mouse line with a HA or FLAG could be generated via CRISPR. This could 
then be used to again generate enhancer deletions, or for more refined targeted 
mutations of specific TFBS within the enhancer using CRISPR HDR-repair strategies. 
The effect of enhancer mutation or heterozygous loss of Fzd3 could then be 




of the regulatory regions on expression and how much these contribute to the 
overall expression of FZD3.  
 
We have shown that loss of the putative enhancer of Fzd3 can reduce mRNA 
expression within embryonic heads. We proposed that this was occurring in the 
NPCs under the control of SOXB1 factors, however the enhancer may be active 
elsewhere due to the influence of other TFs. We generated a LacZ reporter line 
using the 573bp enhancer region and assessed where this could drive expression 
within 12.5 dpc embryos. Expression could be seen in whole mount embryos 
throughout the neural tube, and specifically, within the floor plate. Similarly, in situ 
hybridization on wildtype mice results were able to identify expression of Fzd3 
throughout the neural tube, within both the midline, ventricular zone and the floor 
plate. Previous studies have assessed Fzd3 expression via RNA in situ hybridization, 
and these show similar results to ours with expression throughout the neural tube 
and brain at 12.5dpc (Visel et al. 2004). Deletion of the Fzd3 enhancer led to loss of 
expression mostly within the floor plate of the neural tube, with only minimal losses 
in the ventricular zone and no changes in the midline structures. This is in 
agreement with the LacZ reporter which consistently drove expression to the floor 
plate, where SOX2 is known to be expressed. During CNS development, neurons 
must extend their axons to generate neural circuits. Signaling molecules Netrin and 
Shh produced within the floor plate guide axons to extend, mediated by the growth 
cone on the elongating tip of the axon (Kennedy et al. 1994; Kennedy et al. 2006; 
Charron et al. 2003). Once at the floor plate, the axons cross the midline, followed 
by post-crossing rostral turning which is mediated by Wnt signaling and FZD3 
(Onishi & Zou 2017; Stoeckli 2018). Our LacZ reporter and enhancer deletion lines 
show evidence that the putative enhancer region is required for full Fzd3 expression 
within the floor plate. As previously mentioned, although we did not see any 




experiments assessing axon growth and guidance. Future experiments could be 
used to assess the guidance of axons along the rostro-caudal axis.  
 
The Fzd3 enhancer driven LacZ reporter mouse that was produced could be a useful 
tool for studying CNS development, particularly axon guidance. As axons are 
guided towards the floor plate due to the signaling gradients produced from this 
region, being able to specifically control expression within the floor plate could be 
beneficial. Using our enhancer region to drive a Cre-cassette could allow for 
conditional mutants to be made to study specific interactions within the neural tube 








Genome Editing to study Enhancers 
Throughout this thesis, we described the deletion and subsequent phenotypic 
evaluation of two enhancers thought to be controlled by SOXB1 proteins. These 
enhancers, one of which was previously known, the Nes intron 2 enhancer, and the 
previously undescribed Fzd3 enhancer were both identified within a SOX3 ChIP-Seq 
experiment of mouse neural progenitor cells (McAninch & Thomas 2014).  
 
Using ChIP-Seq combined with other bioinformatic data such as level of DNA 
conservation across species, DNase hypersensitivity and methylation status is a 
common way to identify putative enhancers. However, these do not always 
guarantee that region identified will be functional within the genome, or if the 
degree to which it is functional can be identified.  
 
For the two enhancers that were studied in this thesis, deletion of each showed no 
obvious phenotypic differences, despite previous evidence that each of the genes 
are essential for survival (Park et al. 2010; Y. Wang et al. 2006). Further analysis did 
show an appreciable reduction in expression of both Fzd3 and Nes during 
embryogenesis, however this did not appear to have an effect on overall CNS 
development. These results reflect a trend in enhancer deletion studies, where even 
highly conserved enhancers of developmental genes appear to have very little to no 
effect on overall development. One of the first reports of ultraconserved elements 
not being as essential as previously predicted was published in 2007. 
Ultraconserved elements upstream of the developmentally important gene, Arx 
were deleted and both individual and combinatorial deletion produced viable mice 
with no obvious phenotypes. However, in 2018 when these kind of experiments 
were reproduced, it was shown that although mice could survive, deficits were seen 




that may reduce overall evolutionary fitness (Dickel et al. 2018). Our results are 
consistent with these reports that enhancers are only responsible for small amounts 
of expression, and that these are possibly additive with other enhancers or 
regulatory regions to control endogenous gene expression. Future experiments for 
enhancers of both Nes and Fzd3 could focus on combinatorial enhancer deletions 
to determine the precise effects of each enhancer, and to understand if enhancer 
redundancy is a factor. There is some evidence that shows enhancers may be 
redundant, and indeed this was the original theory for the Arx enhancers, however 
the evidence of combinatorial enhancer deletions leading to additive effects 
phenotypically disputes this idea. Other reports, such as those by Oosterwalder 
(2018) showed a high level of functional redundancy between tissue-specific limb, 
brain and heart enhancers. It will be interesting in the future to determine if this is 
locus dependent, or if all enhancers are responsible for a certain subset of 
expression with no redundancy between regulatory regions.    
 
Reporter assays, such as LacZ transgenic mice have been used for decades to assess 
the spatiotemporal activity of putative enhancers. Until the development of 
CRISPR/Cas genome editing, this was seen as the best evidence for enhancer 
functionality. We generated a LacZ transgenic mouse using the 573 bp Fzd3 
enhancer which consistently showed expression throughout the neural tube and 
specifically within the floor plate. While this correlated well with our previous result 
of Fzd3 mRNA loss in the floor plate when the enhancer was deleted in vivo, it did 
not completely recapitulate the expression pattern. As CRISPR editing of enhancers 
is becoming more facile and accessible, these two methods should be used in 
conjunction. Consistent with this is a recent report of two putative Tbx5 enhancers 
thought to be required for limb development with substantial evidence from LacZ 
reporter mice showing expression in all expected regions (Cunningham et al. 2018). 




enhancers are non-functional endogenously, or there is a possible redundancy 
effect with another unknown enhancer. Another possibility is that small reductions in 
expression were present but these were not enough to cause a phenotype; however 
this was not analysed within the study. 
 
Our experiments assessing the endogenous enhancer activity of Nes and Fzd3 
enhancers used CRISPR to delete regions of DNA. This enabled us to show that 
each of the enhancers contain functional DNA that when lost, affects expression of 
the target gene. These kinds of enhancer deletion experiment are similar to those 
found within the recent literature (Cunningham et al. 2018; Dickel et al. 2018; Meyer 
et al. 2019), however like these, they do not identify the exact TFBS that are 
essential for target gene expression. As discussed previously, utilising HDR repair 
templates with CRISPR/Cas9 to modify the individual SOXB1 binding sites will be 
beneficial to understanding the function of the enhancer more. However, for the 
Fzd3 enhancer, deletion of single identified SOXB1 site yielded only very minimal 
changes in expression, indicating there are more functional regions throughout the 
573bp deleted enhancer. Bioinformatic analysis of this region identifies many 
putative TFBS which without further evidence is difficult to assign any functionality 
to. As more ChIP-Seq datasets become available these should be used to identify 
any overlapping binding peaks which could identify putative regulators of Fzd3 






SOX3 function within postnatal testes 
As well as being an important transcription factor during central nervous system 
development, SOX3 is also required for proper gonadal function (Weiss et al. 2003). 
Throughout Chapter 4 of this thesis, the putative transcriptional targets of SOX3 
within the postnatal testes was explored, and these results identified a number of 
testes-specific histone genes as well previously hypothesised interactors.  
 
The SOX3 ChIP-Seq on postnatal testes revealed a group of almost 800 putative 
binding targets. As no other ChIP-Seq had been performed on the testes, or within 
any other non-neural contexts, the extent to which SOX3 is binding in the testes 
was unknown. However, there were significantly less targets than within the neural 
progenitors where almost 8000 targets were identified (McAninch & Thomas 2014). 
These were identified through cultured neural progenitor cells, rather than tissue 
such as the experiments in this thesis and could account for the higher rate of 
protein binding as it is not within an endogenous context.  
 
Of the SOX3 binding targets identified within the testes, a large proportion with 
functional gene ontology annotations were consistent with nuclear organisation and 
chromatin regulation. The majority of genes proximal to these regions were either 
core histone genes clusters, or histone associated genes, or histone variants. 
Previous studies have not focused on SOX3 as a regulator of histone genes, 
although many of these genes are located close to peaks within the neural 
progenitor ChIP-Seq (McAninch & Thomas 2014), suggesting these may be a 
conserved binding site within different tissue contexts. Previous evidence 
implicating SOX3 in histone regulation comes from the sea urchin, where 
modification of a SOX motif upstream of H2A.Z was shown to decrease its 




is not observed near H2AZ, this adds evidence that the SOX proteins may be 
regulating histone variant expression.  Analysis of other SOX ChIP-Seq datasets, 
such as SOX3 within NPCs (McAninch & Thomas 2014) and SOX2 within cortex, 
spinal cord, and lung (Hagey et al. 2018) may identify a binding peak near the H2AZ 
gene or other histone variants. If these are consistently identified within other 
datasets, the TFBS could be modified or deleted via CRISPR and the effect histone 
expression and gene regulation could be assessed.   
 
Putative enhancers identified within the ChIP-Seq were located near two testes-
specific histone variants, TH2B and H3t. These histone variants are incorporated 
into the sperm DNA at different stages. H3t is expressed is from P8 as the 
differentiating spermatogonia emerge, while expression of TH2B is initiated at P10 
(Ueda et al. 2017). SOX3 expression is seen from P7 within the prospermatogonia, 
however defects in development are not observed until P10, when germ cell loss is 
apparent.  As previously discussed, the remodelling of chromatin within sperm is an 
essential process whereby histones are first replaced by transition histones to 
protect sensitive regions such as the telomeres and centromeres (Govin et al. 2007; 
Gill-Sharma et al. 2012). Protamines then replace these to form the chromatin into a 
toroidal conformation modifying its epigenetic state (Hud et al. 1993; Mudrak et al. 
2005) . The underlying mechanisms of histone displacement are not fully 
understood, and the finding of SOX3 binding near these genes within the postnatal 
testes may help to uncover regulatory regions involved. To further analyse the link 
between SOX3 and H3t prior to in vivo deletion, protein expression analysis of the 
SOX3 knockout mouse could prove valuable. By performing Western blots at each 
stage of spermatogenesis from P7 through to P14, it could be determined if the loss 
of SOX3 that leads to infertility involves a reduction in H3t or TH2B. If this is 




defects is partially due to defects within chromatin structure, which possibly affects 
many aspects of gene regulation in the differentiating spermatogonia.  
 
During analysis of the ChIP-Seq dataset, a microarray performed on Sox3 null testes 
was used to determine if any of the putative SOX3 target genes were affected by 
loss of SOX3. The microarray revealed only 17 genes were dysregulated in response 
to SOX3 loss, and Neurog3 was the only gene implicated with both the microarray 
and ChIP data. This data is in agreement with previous work showing Neurog3 
expression to be dependent upon SOX3 within the testes (Raverot et al. 2005). 
These genes are thought to interact within the same pathway however a functional 
link between the two has not yet been proposed. Previous enhancers of Neurog3 
have been proposed within the large region of conservation where we identified 
SOX3 binding. STAT3 bound approximately 4kb upstream of Neurog3 identified via 
a ChIP on undifferentiated spermatogonia, and was also able to activate expression 
of a luciferase reporter of the 4kb upstream of Neurog3 (Kaucher et al. 2012). These 
data indicate the SOX3 binding peak we identified is part of an enhancer, and 
further experiments to identify is SOX3 is active within it are warranted. This could 
be initially determined using luciferase reporter assays analysing SOX3 and STAT3 
activation via the putative enhancer region. 
 
Our SOX3 ChIP-Seq was performed on whole P7 testes to obtain a genome-wide 
view of SOX3 binding. To refine these experiments, and determine where SOX3 is 
binding within specific cell types, ChIP could be performed on individual 
subpopulations of spermatogonial stages. Previous work has identified ways to 
individually sort spermatogonial stem cells from whole testis using fluorescence and 
magnetic activated cell sorting (FACS and MACS) (Valli et al. 2014). Unfortunately, 
there is not currently a way to sort the As, Apr, and Aal spermatogonia as they are 




would be interesting to perform ChIP experiments on each developmental stage to 
determine which genes SOX3 is potentially regulating across spermatogonial 
development.  
 
For each of the putative SOX3 enhancers identified within the ChIP-Seq 
experiments, no functional analysis could be performed due to time constraints. 
This is an important next step that will define whether these are true regulatory 
regions active within the postnatal testes. The best way to assess this will be to 
generate in vivo deletions using CRISPR and assess the impact on target gene 
expression as well as identifying if there are any spermatogenic defects present. For 
the Neurog3 enhancer, mutation of the SOX3 TFBS as well as the larger enhancer 
region will show the endogenous contribution of both SOX3, and the larger 
enhancer.  
 
No SOX motif could be identified for many of the histone associated genes, 
including H3t and TH2B. It is possible that SOX3 is instead binding to another 
protein, itself which is bound to the DNA. If this is occurring, no TFBS motif would 
be identified via ChIP. A way to confirm this could be to perform ChIP combined 
with Mass Spectrometry (Bensaddek & Lamond 2016). This allows the identification 
of protein:protein interactions occurring with the protein of interest (ie SOX3) which 
can be performed within a specific contexts (postnatal testes tissue). SOX3 is known 
to partner with other factors to regulate gene expression, such as POU at the Nes 
enhancer (Tanaka et al. 2004), however protein:protein interactions at enhancers 
have not yet been shown.  
 
If a putative partner factor is identified throughout the further analysis, proximity 
ligation (PLA) assays will be a useful tool. This an immunohistochemistry based assay 




are bound by antibodies conjugated to oligonucleotides, they are able to connect, 
forming circular DNA. This DNA can then be amplified by a DNA polymerase and 
subsequently visualised by fluorescence signals (Bellucci et al. 2014). At many of the 
SOX3 bound DNA regions an SP motif was also identified. Although these were not 
a consistent distance apart, or connected, as would be expected for partner protein 
binding, it is possible that they both act at some of the same enhancers to control 
expression of target genes. SP proteins are expressed throughout many body 
systems to regulate gene expression, but they are also important regulators during 
sperm development (Lania et al. 1997). Gene set enrichment analysis performed on 
different stages of spermatogenesis identified SP1 as being one of the key 
regulators in spermatogonial stem cells, spermatocytes and spermatids (Zhu et al. 
2016). From this, it is predicted that of the SP1 is the most likely SP factor to be 
bound to the SP motif. By using the PLA approach on testes tissue with SOX3 and 
SP1 antibodies it is possible that some regions may show an interaction between 
the two proteins. The downside of this assay is that the specific locations this is 
occurring is not able to be identified, however this would be informative for any 
further studies. 
 
Although we identified putative enhancers bound by SOX3 from the ChIP-Seq data, 
most of the proposed target genes did not appear dysregulated when overlapped 
with SOX3 null microarray data. This may be due to the different timepoints being 
analysed, or due to subtle expression differences that may only be seen in a single 
cell type, such as the SSCs which only account for 0.03% of the germ cells in rodent 
testes (Tegelenbosch & de Rooij 1993; Phillips et al. 2010). The recent generation of 
a single cell RNA-Seq dataset encompassing each stage and cell type of 
spermatogenesis will be a useful resource for future ChIP studies (Chen et al. 2018). 
Extending this to RNA-Seq of SOX null testes would show the impact of SOX3 at a 




with the SOX3 bound regions in the testes will help to decipher functional targets 






This thesis focused on the SOXB1 proteins throughout different developmental 
stages, within embryonic CNS development as well as the postnatal development 
of the testes.  
 
Chapter 2 showed the functional analysis and endogenous function of the 
previously described Nes enhancer during embryogenesis. We were able to show 
this is able to contribute for up to 70% of Nes expression when active in the CNS. 
The third chapter both identified and validated an enhancer of the Wnt-receptor 
protein Fzd3. Through both CRISPR mouse models and transgenic LacZ models we 
were able to identify its activity within the neural tube of the developing embryo. 
The final chapter of this thesis focussed on the role of SOX3 within the postnatal 
testes. Through bioinformatic analysis of a SOX3 ChIP-Seq dataset we have been 
able to identify putative enhancers thought to be involved in the progression of 
spermatogenesis. We also provide evidence that SOX3 is involved in the complex 
chromatin organisation via regulation the of histone genes.  
 
CRISPR modification of the genome was an important aspect of these studies. As 
the bioinformatic identification of regulatory elements grows, it is important these 
are functionally validated. We have shown methods on how to do this, and 
incorporated with traditional techniques, this will help to elucidate the role of many 
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11.1 Introduction
Mice are one of the most widely usedmodel organisms for dissectingmammalian
gene function and human disease modeling. Targeted mutagenesis in mice has
traditionally been performed using “gene targeting,” in which mutations of
interest are initially generated in embryonic stem (ES) cells by homologous
recombination, which are then used to produce mutant mouse lines (Griep
et al., 2011). While this technique has been widely used, it is lengthy (1–2 years
are often required to produce a mutant), labor-intensive, expensive and prone to
failure. More recently, genome editing technologies such as zinc-finger nucleases
(ZFNs) (Carbery et al., 2010) and transcription activator-like effector nucleases
(TALENs) (Davies et al., 2013) have been successfully used to generate mutant
mice via zygotic injection, although high expense and relatively cumbersome
production methods have limited their use.
A paradigm shift in the field of genome editing occurred in 2013 when a group
of landmark papers were published demonstrating that the clustered regularly
interspaced short palindromic repeats (CRISPR) bacterial defense mechanism
could be used to introduce specific mutations at precise locations within eukar-
yotic cells (Cong et al., 2013; Jinek et al., 2012; Mali et al., 2013). This sparked
enormous interest from the scientific community, and soon many laboratories
around the world were using this system tomodify a diverse variety of organisms,
including plants (Xing et al., 2014), yeast (DiCarlo et al., 2013), zebrafish (Hwang
et al., 2013), fruit flies (Basset et al., 2013) and monkeys (Niu et al., 2014), among
others (Onuma et al., 2016; Wang et al., 2016). This chapter focuses on the
development and application of CRISPR mutagenesis in mice.
Over the past few years, CRISPR has been used extensively by our research
group, allowing the generation of a variety ofmutations inmice, including floxed
alleles, null alleles, enhancer deletions, epitope FLAG-TAG insertions and promo-
ter modifications. Based on our experience with this technique, we also provide
insights into which strategies are the most efficient, as well as highlighting
significant, but less well-known issues that can arise. 165
11.2 System Components and Activity
Establishing themechanismbywhich theCRISPR systemcleaves specific sequences
in bacteria provided the groundwork for its rapid development as a genome editing
tool in eukaryotes (Bolotin et al., 2005; Brouns et al., 2008; Cong et al., 2013; Jinek
et al., 2012; Mali et al. 2013; Sorek et al., 2013). The endonuclease in the CRISPR
system is Cas9, which can be directed to bind and cleave specific genomic target
sites through complementary base pairing of its single-guide RNA (sgRNA) to the
DNA (Brouns et al., 2008). By modifying the sequence of the sgRNA, Cas9 can be
directed to precise locations within the genome, causing a double-strand break
(DSB) in the DNA, the repair of which can be used to produce a variety ofmutation
types (Cong et al., 2013). The flexibility and practicability of this approach provides
a significant advantage over other genomeeditingplatforms andhas contributed to
the massive uptake of CRISPR across the research community.
Despite its utility, it is important to note that the CRISPR–Cas9 system cannot
be used to target every sequence in the genome due to the absolute requirement
for a protospacer adjacent motif (PAM) sequence immediately 3′ to the targeting
region of the sgRNA (Sternberg et al., 2014). For themost widely used Cas9 variant
(from Streptococcus pyogenes), the PAMcorresponds to anNGG sequence, which on
average will occur every 8 bp across the genome. Structural studies indicate that
Cas9 binds directly to the PAM followed by DNA strand separation and “sam-
pling” of the neighboring sequence for complementarity by the sgRNA (Sternberg
et al., 2014). Accordingly, mutation of the PAM will completely abolish cleavage
by the Cas9, regardless of whether or not the sgRNA is a perfect match to the
adjacent sequence (Jinek et al., 2012; Sternberg et al., 2014).
The mechanism by which Cas9 cleaves DNA is reasonably well understood and
is covered in some detail in other chapters. Briefly, Cas9 has two active nuclease
sites: the RuvC domain at the amino terminus and theHNHdomain in the central
region (Nishimasu et al., 2014). Both of these active sites generate site-specific
nicks on opposing DNA strands to create a blunt-ended double-strand break 3–4
nucleotides upstream of the PAM site (Jinek et al., 2012). Repair of the DSB by the
cell’s endogenous repairmachinery can result in the generation of alleles with the
desired functional consequence (e.g. loss of function). Unlike traditional gene
targeting, CRISPR mutagenesis permits directed modification of the zygotic gen-
ome through direct injection of sgRNA(s) designed to target the location of
interest along with Cas9 mRNA or protein. Surviving zygotes are then transferred
into pseudopregnant females for development to term when they can be geno-
typed to identify mutations of interest. Thus, remarkably, CRISPR mutagenesis
permits mutant founder mice to be generated within three weeks (summarized in
Figure 11.1)
11.3 Repair Mechanisms
CRISPRmutagenesis, like all forms of genome editing, relies on exploitation of the
cell’s endogenous repair mechanisms that ordinarily operate to protect the cell
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against DNA damage from sources such as replication error, fragile sites and ioniz-
ing radiation (Mehta andHaber, 2014). These repairmechanisms include canonical
non-homologous end joining (cNHEJ), microhomology-mediated end joining
(MMEJ), single-strand annealing (SSA) and homology-directed repair (HDR).
Utilization of a particular repair mechanism is determined by a number of factors,
such as cell cycle stage and flanking sequence, and, depending on the desired
outcome, each of these can be exploited to generate specific types of mutations in
mice, as outlined below and summarized in Figure 11.2 (Deriano and Roth, 2013).
11.3.1 Non-homologous End Joining
While cNHEJ repair is sensitive, rapid and precise, it can also result in mutations
and can therefore be harnessed in CRISPR mutagenesis. This repair mechanism
ligates and rejoins two blunt DNA ends without the use of a homologous template
and with limited resection or restoration of nucleotides around the break (Davis
and Chen, 2013; Dueva and Iliakis, 2013; Lieber, 1999; Matsuzaki et al., 2012).
The commonly held belief among users of CRISPR technology that NHEJ is highly
error-prone is unlikely to be true (Bétermier et al., 2014). This misconception
arises in part because of the difficulty in measuring the fidelity of repair and is
exacerbated by the fact that creation of DSBs and their repair will inevitably end
only when amistake is made. For example, in the context of CRISPRmutagenesis,
precise repair will result in restoration of the target sequence, meaning that
sequential rounds of cutting and repair will continue until misrepair destroys
either the sgRNA-binding sequence or the PAM (Bétermier et al., 2014). For this
reason, CRISPR mutagenesis in the absence of a repair template invariably results
in small insertions or deletions of nucleotides (indels) at the cut site. This property
has been used extensively to generate frame-shifting loss-of-function mutations













Figure 11.1 The process of using CRISPR in mice. (A) Female mice are superovulated by the
injection of hormones, PMSG and HCG, and bred with males to obtain 20–30 zygotes per female.
Cas9 mRNA and sgRNA are prepared through in vitro transcription from a plasmid template (B).
CRISPR reagents are then microinjected into the cytoplasm or pronucleus of zygotes (C). Injected
zygotes are transferred to pseudopregnant females that have been bred with vasectomized males
(D). After three weeks gestation, mutant founder mice are born (E).
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11.3.2 MMEJ and SSA (Alternative NHEJ)
Microhomology-mediated end joining (MMEJ) and single-strand annealing (SSA),
which are subsets of the alternative NHEJ pathway (aNHEJ), are inherently error-
prone, unlike cNHEJ (Dueva and Illakis, 2013; Simsek and Jasin 2010). Using
enzymes distinct from cNHEJ, aNHEJ pathways repair DSBs by catalyzing the
joining of DNA ends after resection, revealing small regions of homology on
the two strands (Chiruvella et al. 2013; Crespan et al. 2012). Base pairing of the
homologous regions is followed by trimming, extension and ligation to complete
the repair, which has the effect of generating defined small deletions to the
sequence (Crespan et al., 2012; McVey and Lee, 2008; Roth and Wilson, 1986).
SSA involves the annealing of larger repeat sequences, whereas MMEJ involves
much shorter sequences of homology (5–25 bp; Decottignies, 2013). Because
MMEJ and SSA rely on complementary base pairing of two homologous regions,
the resultant deletions are predictable, allowing them to be used to our advantage
in CRISPR genome editing.
11.3.3 Homology-directed Repair
Homology-directed repair (HDR) operates in competition with NHEJ to repair
DSBs. The main difference between these mechanisms is that HDR relies on
a repair template that is used to restore resected sequences at the break site and
therefore usually results in precise repair (Jasin and Rothstein, 2013). Cells can
undergo HDR when a homologous sequence of DNA is present, usually the
homologous chromosome or sister chromatid (Deriano and Roth, 2013; Heyer
et al., 2010; Mao et al., 2009). Importantly, exogenous DNA that is introduced to
the cell can be copied into the genome to introduce specific alterations using this
repair, by incorporating flanking regions of homology, which is amethod that has
historically been used in traditional gene-targeting methods. However the effi-
ciency of this approach is very low, as millions of ES cells are typically needed in
order to select for these rare recombination events (Hall et al., 2009). However,
when Cas9 is used to create the DSB, a remarkable increase in efficiency of
template incorporation is seen, making it possible to directly modify mouse
zygotes and avoid the use of ES cells entirely (Yang et al., 2014).
It should be noted that all of the discussed repair mechanisms work in competi-
tion with each other, and greater understanding of these pathways should lead to
an improved ability to control the type of repair used and hence the efficiency of
a desired mutational outcome.
11.4 Harnessing Endogenous Repair Mechanism for Desired
Mutational Outcomes
11.4.1 Single-cut Gene Disruption
The simplest way to utilize CRISPR in model organisms is to generate non-
functional copies of genes following indel mutations caused by imprecise NHEJ,
MMEJ or SSA.When themutation causes a frameshift, this can result in a null allele
due to loss of functional protein domain(s) (Isken andMaquat, 2007). Being able to
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create null mice in an efficient and reliable way is especially useful when none are
commercially available on the background of choice (Barbaric et al., 2007).
In 2013, Shen et al. published the first mutations to disrupt gene function in
mice using a single-guide CRISPR strategy when they targeted a GFP transgene.
They were successful in detecting mutations in 2 out of 12 founder mice. Since
this study, many examples of single-cut indel mutants have been published, with
mutations being found in almost all alleles (Qin et al., 2015; Yasue et al., 2014).
In addition, Wang and colleagues (2013) and subsequent studies have demon-
strated that this approach can be multiplexed to simultaneously generate muta-
tions in multiple genes using a single zygotic injection. The utility of this
approach was nicely demonstrated in a recent study of acute myeloid leukemia,
in which different combinations of genes were inactivated simultaneously to
allow for more accurate disease modeling (Heckl et al., 2014). The use of CRISPR
to generate nullmice is now routine in research and is already becoming a leading
genome editing technique (Singh et al., 2015).
In our experience, generating single-cut null (frameshift) mice has been
relatively simple. We use a strategy targeting an early exon to ensure incor-
poration of a stop codon soon after the translation start site. Although we have
been successful in generating null mouse lines using the single-cut method,
one of the disadvantages of this approach is the generation of in-frame dele-
tions that occur in approximately one-third of mutated alleles, which can
allow the resultant protein to retain significant function. In an attempt to
overcome this problem, we have since moved away from this approach to
a double-cut method, which also has the added benefit of easy genotyping
(discussed in detail below).
11.4.2 Genotyping Single-cut Mutants
Given that single-cut mutations are generally small insertions or small deletions,
they must be screened using a method that does not rely on discrimination based
on mutation size. Assays that involve heteroduplex formation can be used to
detect small changes to the sequence. Amplification around the mutated region
will generate two or more PCR products with at least one base mismatch, which,
after melting and annealing, will form DNA heteroduplexes. These heterodu-
plexes can either be visualized on a polyacrylamide gel, as they migrate much
more slowly than homoduplexes, or they can be detected through restriction
fragment length polymorphism (RFLP) in a T7E1 assay, where heteroduplexes
are cleaved to form two distinct products (Shen et al., 2013). These mutation
screening techniques allow specific samples to be selected for sequence analysis.
Sequencing chromatograms from foundermice frequently contain overlapping
distinct sequence reads from the cleavage site due to the presence of different
mutations on multiple alleles. These can sometimes be difficult to unravel, parti-
cularly if more than two alleles are present as a result of Cas9 endonuclease
activity post-zygotically. However, if necessary, mutant alleles can be discrimi-
nated by cloning of individual sequences. When the size difference between the
two products is sufficient, the easiest method is to gel purify the individual alleles
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and sequence separately. Importantly, we have found that standard PCR screen-
ing using products of 200–400 bp will often miss alleles that result from larger
deletions due to loss of the primer binding sequences. For this reason, it is
important to out-cross founders before starting any experimental work to ensure
that only the allele(s) of interest is present in the mutant line.
11.4.3 Double-cut Deletions
While frameshift mutations are very useful and relatively easy to make, the size
and functional impact of deletions generated by a single cut can be difficult to
predict. To overcome this issue, a double-cut strategy can be employed to gen-
erate deletions across a predetermined genomic region. The double-cut
approach uses two sgRNAs flanking the interval of interest, and, after generation
of the DSBs, rejoining of the blunt ends through NHEJ results in deletion of the
intervening sequence (Fujii et al., 2013; Mali et al., 2013). Mice with specific
deletions up to 10 kb were first reported by Fujii et al. (2013) and since, even
larger deletions (65 kb) have been generated using this approach (Zhang et al.,
2015). Our group has adopted a double-cut strategy to delete enhancer regions,
exons (around 200 bp) and whole genes (up to 9 kb). Exon deletions are now our
favored approach to generate non-functional alleles by targeting cuts flanking
a relatively short exon early in the transcript that contains a number of nucleo-
tides not divisible by three. This approach can also be extended to other untrans-
lated regions of the genome such as intronic and intergenic regions, promoters
and UTRs.
11.4.4 Genotyping Double-cut Mutants
When there is a larger deletion or insertion being made, it is relatively easy to
screen for the desiredmutation using a PCR-basedmethod, where a size difference
will be apparent on an agarose gel. However, it is important to remember that
whilst this is an efficient process, the DBS is not always at the precise predicted
location and therefore can be slightly larger than intended due to NHEJ-mediated
imperfect repair. For this reason, it is recommended to sequence all potential
founders to determine the exact mutation.
The importance of screening for regions of homology or microhomology
when designing the sgRNAs was emphasized to us when we observed a high
frequency of identical small deletions in multiple mice generated from cleavage
in a region of microhomology. This phenomenon has been reported previously
in the literature in the context of CRISPR (Wang et al., 2013) and indeed other
gene editing reagents, such as TALENs (Tesson et al., 2011). Microhomology can
be used to predict precise deletion events, which, in theory, could be used to the
advantage of the researcher (Bae et al., 2014). However, these mechanisms can
also result in a nasty surprise after mice have been generated, if repeat sequences
are not identified during sgRNA design. Widely used current design tools do not
always take this into account, but there are online tools available which can be
used to screen guides for microhomology independently (Bae et al., 2014;
Haeussler et al., 2016).
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11.4.5 Point Mutations and Small Insertions
By using HDR-mediated CRISPR mutagenesis, it is now possible to introduce spe-
cific point mutations and small insertions such as epitope tags (e.g. HA-FLAG)
relatively cheaply and rapidly compared to traditional methods (Wang et al.,
2013). These mutations are most easily achieved using a single-stranded oligonu-
cleotide (ssDNA) donor that contains regions of homology (50–80 bp) to the
endogenous locus flanking the donor sequence to be inserted at the cut site (Lee
andLloyd, 2014;Nakagawa et al., 2016;Wang et al., 2015; Yang et al., 2014). There is
ongoing optimization of the HDR-mediated CRISPR method to increase its low
efficiency, including changes to homology arm length and silencing or inhibition
of genes involved inNHEJ (Chu et al., 2015;Maruyama et al., 2015; Nakagawa et al.,
2016; Vartak and Raghavan, 2015). Substitution of a single base can also be used to
generate silent mutations, which can destroy the relevant PAM site to prevent
recutting after donor sequence insertion. From a practical standpoint we have
found it useful to either destroy or introduce a restriction site as a silent mutation
to aid in genotyping of founders.
Althoughwe have been successful in generating 12mouse lines with a variety of
HDR-mediated insertions, in all cases NHEJ repair predominated, resulting in
a relatively low efficiency of the desired insertion. In an attempt to increase the
frequency of NHEJ repair events, we trialled co-injection of the DNA ligase IV
inhibitor SCR7, which was previously shown to repress NHEJ and increase HDR
efficiency (Chu et al., 2015; Maruyama et al., 2015; Vartak and Raghavan, 2015),
although it did not increase insertion rates in our hands. Recently, it has been
hypothesized in the literature that low HDR efficiency may be due to the donor
oligonucleotides being degraded by the cell prior to the Cas9 mRNA being trans-
lated into functional protein (Ménoret et al., 2015). We have found that injection
of Cas9 protein rather than the mRNA directly into the zygote increases insertion
efficiency as previously shown in the literature (Ménoret et al., 2015). For the same
reason, using phosphorothioate-modified oligos has also proven to be a useful
approach to promote HDR insertion (Renaud et al., 2016).
11.4.6 Generating Reporter and Floxed Conditional Mouse Lines
Using CRISPR to create more complexmutations, such as reporter gene insertions
and floxed alleles, is possible, but generally much less efficient than the deletions
and HDR-mediated small insertions described above. However, these modifica-
tions are becoming easier to generate using emerging CRISPR technologies,
although strategies for longer or more complex insertions such as reporter genes
(e.g. EGFP and LacZ) or two LoxP sequences are still being optimized. Whilst
single-stranded oligonucleotides are an inexpensive and accessible option to
insert small sequences into the mouse genome, often a much larger insert is
required (Mali et al., 2013; Yang et al., 2013; 2014). Inserting longer sequences
can be achieved using a plasmid donor template containing the insertion
sequence flanked by large homology arms greater than 800 bp (Zhu et al., 2015).
This approach is similar in concept to targeting vectors that have been used in ES
cells for over 30 years, although there is no requirement for a drug selection
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cassette for zygotic injections. To generate a large insertion, sgRNAs targeting the
genomic region between the homology arms are injected along with the plasmid
donor template (in linearized or circular form). The long homology arms provided
by the donor template facilitate repair of the DSB via homologous recombination,
thereby resulting in targeted insertion of the intervening sequence. It is important
to note that the efficiency of this strategy is relatively low (8–10%) (Nakagawa
et al., 2016; Yang et al., 2013). We have used this approach to generate targeted
insertions of 750 bp–4 kb at three loci and, consistent with published reports, our
insertion rate is relatively low (2.5–12.5%).
Floxed conditional alleles are probably the most challenging type of mutation
to generate. Several alternative approaches have been used successfully, although
all remain relatively inefficient. The first published approach used an oligonucleo-
tide HDR repair strategy to simultaneously insert LoxP sequences either side of an
exon of interest (Bishop et al., 2016; Yang et al., 2013). Using this strategy, we
recently generated a floxed allele containing LoxP sites spaced 2 kb apart through
co-injection of gRNAs and single-stranded oligonucleotides repair templates with
60 bp homology arms. Of the 11 founder pups born, only one had both the LoxP
sequences inserted on the same allele, while themajority of the cut sites generated
indels or single LoxP insertions and one case of deletion of the 2 kb region
between the cuts. This relatively low efficiency is consistent with reports from
the literature (Maruyama et al., 2015; Nakagawa et al., 2016; Yang et al., 2013).
The alternative approach utilizes a dsDNA (plasmid) repair template (identical in
sequence to the intended floxed allele) that includes long homology arms (typi-
cally >1 kb). The floxed allele is generated by sgRNA-mediated cutting at one or
both of the LoxP insertion sites, followed by homologous recombination repair.
This approach has been used to insert LoxP sites separated by 71–600 bp albeit
with low efficiency (2.7–16%) (Maruyama et al., 2015; Yang et al., 2013). A dual
sgRNA Cas9-nickase approach has also been successfully used but with similarly
low efficiency (2.7%) (Ran et al., 2013; see below).
11.5 The CRISPR Toolbox
Since 2013, when the first mutant mouse lines were generated using the CRISPR
system (Shen et al., 2013; Wang et al., 2013), the number of tools available to
researchers has rapidly expanded to include modified versions of the wild-type
S. pyogenes Cas9 (wt SpCas9) with altered PAM specificity, Cas9 proteins from
a range of bacterial species and new programmable endonuclease enzymes (sum-
marized in Table 11.1). This section focuses on the ever-increasing “CRISPR
Toolbox” and some of the ways these new enzymes can be implemented to enable
increased flexibility of target site selection and reduce off-target cutting.
11.5.1 Off-target Reduction
One of the enduring concerns of CRISPR mutagenesis is the occurrence of off-
target endonuclease activity. Whilst breeding is a simple way to eliminate these
from a mutant line, it can be time-consuming and expensive to backcross to be























































































































































































































































































































































































































































































































































































































































































































































































































sure all off-targets have been segregated away. Targeted resequencing of potential
off-target sites in founder mice indicates that sgRNA binding sites that differ by
three or more nucleotides from the on-target sequence are very unlikely to be
mutated (Haeussler et al., 2016). Various online tools have been developed to
predict where the most likely off-target cuts will occur and guide sequences can
often be designed to avoid those within coding sequences (Haeussler et al., 2016).
In cases where there is limited flexibility in sgRNA targeting (e.g. generating
a point mutation via HDR-mediated repair), potentially problematic off-target
sgRNAs can now be paired withmodified endonucleases that are able tominimize
this occurrence (discussed below).
One of the first published solutions to off-target mutagenesis was the “dual
nickase” strategy (Ran et al., 2013). This approach uses a modified Cas9 protein
containing an inactivating mutation in the RuvC domain that functions as
a nickase. To create a mutation at the site of interest, a pair of sgRNAs (spaced
by <100 bp) are used to nick opposite strands to create a dsDNA with a large
5′ overhang (Ran et al., 2013). Through repair of this staggered break it is possible
to generate indels or localized targeted modifications such as point mutations
via HDR using a ssDNA repair template. Off-target nicks generated by a single
sgRNA/Cas9 complex will be repaired efficiently by the high fidelity base excision
repair method (Dianov and Hübscher, 2013), greatly minimizing the chances of
unwanted mutations elsewhere in the genome. The dual nickase approach has
been shown to be efficient in both cell lines and mouse models without any
apparent reduction in on-target DNA cutting (Cheng et al., 2014; Ran et al., 2013).
Off-target cleavage has also been addressed by fusing an endonuclease “dead”
Cas9 protein (dCas9) with a dimer-dependent FokI endonuclease domain to
create fCas9. The FokI endonuclease domain has been used extensively in zinc-
finger nuclease and TALEN genome editing, where pairs of DNA-binding proteins
bind to adjacent sequences to enable generation of a double-strand break at the
target site. A similar principle is used in the context of fCas9; two sgRNAs are
designed to target regions 15–20 bp apart, allowing the two FokImodules to create
the DSB in the intervening “spacer” region (Guilinger et al., 2014). In human cell
lines this approach was shown to have 140-fold higher specificity for target sites
compared to wt SpCas9 (Guilinger et al., 2014), and this has also been shown to be
an effective strategy for use in mouse models, with similar efficiencies to
Cas9 being reported (Hara et al., 2015). However, a disadvantage of this approach
is that regions that are able to be targeted via this method occur on average once
every 34 bp, compared to every 8 bp for a single sgRNA strategy with wt SpCas9
(Guilinger et al., 2014).
Structure-guided rational engineering has also been used to increase the fidelity
of Cas9. Two different versions of Cas9 recently published were eSpCas9
(Slaymaker et al., 2016) and SpCas9 HF-1 (Kleinstiver et al., 2016). It was shown
that these mutants are able to disproportionately decrease off-target binding with
respect to on-target binding and hence improve specificity without compromis-
ing on-target activity in human cell lines, although this has not yet been tested in
a mouse model.
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11.5.2 PAM Variants
PAM sites for wt SpCas9 (NGG) are relatively common throughout genomes,
although there are regions where it can be difficult to find a suitable sgRNA,
such as A-T-rich regions, or in regions of highly repetitive sequence.
Identification of Cas9 proteins that bind to different PAM sequenceswill therefore
provide increased flexibility in target site identification.
To generate SpCas9 enzymes that recognize alternative PAM sequences,
Kleinstiver et al. (2015) used a directed evolution approach targeting residues
within the PAM-recognizing region of the Cas9 enzyme. This approach yielded
a number of Cas9 mutants with altered PAM specificities: SpCas9 VQR, EQR and
VRER, which recognize NGAN/NGNG, NGAG and NGCG, respectively. As with
other Cas9 mutants, these have been tested in cell lines, but have not yet been
validated in mouse zygotes.
CRISPR/Cas9 defense systems are widely used in bacteria, providing consider-
able scope for the development of new genome editing platforms. Inspired by the
success of CRISPR/Cas9 from Streptococcus pyogenes, Cas9 orthologs from other
bacterial species including Staphylococcus aureus, Niessera meningiditis (Lee et al.,
2016) and Streptococcus thermophilus (Kleinstiver et al., 2015; Müller et al., 2016)
have recently been published, each of which utilizes a different PAM sequence.
So far, only the SaCas9 has been shown to work successfully in mice, although the
other strains are also likely to prove effective agents for generation ofmutantmice.
11.5.3 Non-Cas9 Endonuclease
Whilst Cas9 is the pioneer endonuclease used in mammalian CRISPR applica-
tions, a newly recognized endonuclease known as Cpf1 has similar properties,
and can also be harnessed for genome engineering (Zetsche et al., 2015).
By analyzing the CRISPR systems in hundreds of bacteria to determine if other
enzymes are also capable of cutting DNA, Cpf1 was found in the Acidaminococcus
and Lachnospiraceae families, and has been shown to be successful at creating
mutations in human cell lines and mouse models (Hur et al., 2016; Kim et al.,
2016).
Although they bothwork as part of a CRISPR bacterial defense system, Cas9 and
Cpf1 have different modes of action. Specifically, Cpf1 cleaves DNA asymmetri-
cally, such that rather than forming blunt ends, sticky ends are formed, creating
a 4 or 5 bp 5′ overhang (Zetsche et al., 2015). In addition, Cpf1 makes a staggered
cut, 23 bp upstream from the PAM on the non-targeted strand and 18 bp on the
targeted strand, rather than 3 bp upstream of the PAM site (Zetsche et al., 2015).
Due to the distance between the PAM site and the staggered DSB, repeated
cleavage of the repaired allele can readily occur if the gRNA binding or PAM
sequence is not altered. While this is tolerable for simple deletion strategies, it is
essential that donor fragment integration includes a PAM-destroying silent muta-
tion to eliminate the possibility of recutting after correct insertion.
In 2016 it was reported that the argonaute proteins from the bacterial species
Natronobacterium gregoryi (NgAgo) could be used as ssDNA-guided genome editing
agents in human cell lines (Gao et al., 2016). The NgAgo protein was reported to
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functionwithout the requirement for a PAM sequence, thereby bypassing one of
the key limitations of existing CRISPR genome editing platforms. However,
whilst this technology appeared to function efficiently in cell lines, replication
studies have not yet been published. Indeed, concerns have been expressed
about reproducibility of the published data. We recently compared the muta-
genesis efficiency of wt SpCas9 and NgAgo in mouse zygotes (n = 29) and mouse
ES cells and no evidence ofmutations were detected in theNgAgo samples. Thus,
the suitability of this platform for routine genome editing remains highly
questionable.
11.6 Conclusion
The advent of CRISPR technology for genome editing has greatly improved the
ease and affordability of creating mouse models for biological research.
By harnessing the cell’s endogenous repair mechanisms through this technology,
researchers can now reliably and efficiently generate a range of mutations for
a plethora of experimental applications. As the interest and use of CRISPR con-
tinues to escalate, it seems likely that new editing platforms and techniques will
continue to be developed thatwill circumvent existing limitations, and inevitably
increase the scope of research applications.
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Appendix Two 
Data from SOX3 ChIP-Seq experiments 
1 Peak regions identified in 2 or nore ChIP samples, and their nearest gene 
2 Top 5 GO Terms associated with the ChIP peak regions in 2 or more samples 
2.1 Negative regulation of Megakaryocyte Differentiation 
2.2 Nucleosome Assembly 
2.3 Nucleosome Organisation 
2.4 Chromatin Assembly 
2.5 Chromatin Assembly or Disassembly 




4 Regions containing atleast 1 SOX motif and their nearest genes 
5 Overlapping peak regions between NPC and Testes SOX3 ChIP datasets 
6 Peak regions only present within Testes ChIP (Testes Specific) 
7 Top 5 GO Terms associated with the Testes Specific peaks 
7.1 Nucleosome Organisation 
7.2 Nucleosome Assembly 
7.3 Chromatin Assembly or Dissassembly 
7.4 Chromatin Assembly 
7.5 Chromatin Organisation 
chromosome start stop nearest gene (distance to TSS)
chr7 3000020 3000235 Gm7353 (+111822)
chr7 4999282 4999547 Zfp580 (-3719)
chr7 4999598 4999859 Zfp580 (-3405)
chr7 5543821 5543962 Vmn1r62 (-82337), Vmn1r60 (-47161)
chr7 6147041 6147413 Galp (-1465)
chr7 11787109 11787324 Zscan4d (-35720), Zscan4e (+108814)
chr7 16994559 16994776 Tmem160 (-43460), Zc3h4 (+8438)
chr7 27031275 27031464 Vmn1r184 (-20480), Cyp2b9 (+72940)
chr7 29827407 29827755 Map4k1 (+59708), Ryr1 (+82589)
chr7 29958939 29959245 Ggn (+3853), Psmd8 (+6600)
chr7 31306647 31307327 Arhgap33 (+13092), Prodh2 (+28346)
chr7 31307390 31308185 Arhgap33 (+12291), Prodh2 (+29147)
chr7 39231479 39233273 Pop4 (-176009), Gm5591 (+80836)
chr7 39352222 39353766 Gm5591 (-39782)
chr7 50122401 50122572 Gm2381 (+117)
chr7 50509190 50509325 EU599041 (+30313), Zfp715 (+57598)
chr7 52964901 52965056 Rpl18 (-5848), Dbp (+4521)
chr7 52965206 52965362 Rpl18 (-5543), Dbp (+4826)
chr7 52965417 52966222 Rpl18 (-5007), Dbp (+5362)
chr7 72747499 72747658 Tjp1 (-231454), Tarsl2 (-42205)
chr7 72750212 72750303 Tjp1 (-234133), Tarsl2 (-39526)
chr7 87853701 87853957 Crtc3 (-20066), Iqgap1 (+94388)
chr7 88903178 88903348 Fam103a1 (-4548)
chr7 90974226 90974809 1700026D08Rik (-31128), Mesdc1 (+58333)
chr7 91561750 91562035 Arnt2 (-3424)
chr7 95678989 95679332 Rab38 (+100378), Tmem135 (+808136)
chr7 96802485 96802569 A230065N10Rik (-20893), Ccdc81 (+249601)
chr7 107520727 107520893 Ppme1 (-404), C2cd3 (+67)
chr7 108458149 108458626 Atg16l2 (-7786), Stard10 (-7212)
chr7 108789576 108789755 Art2b (-59991), Clpb (-22481)
chr7 115820499 115820711 Olfr512 (-36229), Olfr510 (+9673)
chr7 117817849 117818128 Ampd3 (-93731), Adm (+46814)
chr7 118226353 118226835 Eif4g2 (-50)
chr7 120444291 120444522 Btbd10 (+68446), Arntl (+93428)
chr7 121290447 121290617 Rras2 (-29237), Copb1 (+107662)
chr7 122814005 122814257 Gm6816 (-742891), Sox6 (+324469)
chr7 124444366 124444948 Xylt1 (-79836), Nucb2 (+796769)
chr7 130559517 130559817 Aqp8 (-46141), Lcmt1 (+38171)
chr7 133056871 133057003 Gsg1l (+168988), D430042O09Rik (+205508)
chr7 134171142 134171368 Maz (-1262)
chr7 138559852 138560095 Hmx3 (-126407), Acadsb (+5859)
chr7 141150079 141150413 Fank1 (+181702), Adam12 (+266534)
chr7 148151421 148151685 Ifitm1 (-2386)
chr6 3150680 3151774 Samd9l (+198344)
chr6 8115351 8115691 Col28a1 (+10873), C1galt1 (+320679)
1. Testes Peak Regions from 2 or More Samples
200
chr6 12106365 12106464 Gm6578 (-46832), Thsd7a (+592838)
chr6 17741408 17741763 St7 (+97554), Wnt2 (+238999)
chr6 17741787 17742080 St7 (+97902), Wnt2 (+238651)
chr6 22299685 22299898 Fam3c (+6374), Wnt16 (+61562)
chr6 30677243 30677546 Cep41 (-33646), Mest (-10668)
chr6 42445265 42445364 Olfr456 (-8102), Fam115e (+102056)
chr6 44742921 44743299 Cntnap2 (-266950)
chr6 47091238 47091832 Cul1 (-312784)
chr6 47110170 47110764 Cul1 (-293852)
chr6 50146919 50147262 Dfna5 (+66770), Mpp6 (+86851)
chr6 51419242 51419535 Hnrnpa2b1 (-1961), Cbx3 (-970)
chr6 51419690 51420373 Hnrnpa2b1 (-2604), Cbx3 (-327)
chr6 51936401 51936542 Skap2 (+26076), Snx10 (+462572)
chr6 54927446 54927856 Nod1 (-5045), Ggct (+15293)
chr6 54927977 54928346 Nod1 (-5556), Ggct (+14782)
chr6 58767579 58767663 Herc3 (-16073), Abcg2 (+220956)
chr6 58775563 58775687 Herc3 (-8069), Abcg2 (+228960)
chr6 66579484 66579697 Vmn1r33 (-13535), Vmn1r34 (+8155)
chr6 68200903 68201280 Tacstd2 (-715276), Igkv4-71 (+992347)
chr6 79075351 79075546 Lrrtm4 (-893422), Reg3g (-656583)
chr6 83417694 83418110 Tet3 (-26233), Dguok (+39061)
chr6 83530301 83530768 Stambp (-8037), Clec4f (+75646)
chr6 87931409 87931718 Gm5577 (-113), H1fx (-88)
chr6 88444425 88445476 Sec61a1 (+23948), Ruvbl1 (+29548)
chr6 89950379 89950539 Vmn1r47 (-21423), Vmn1r46 (+24294)
chr6 92356089 92356462 Trh (-161632), Prickle2 (+161084)
chr6 103599005 103599368 Cntn6 (-843729), Chl1 (+138317)
chr6 116201111 116202043 Zfand4 (-12663), Fam21 (+43526)
chr6 121600081 121600259 Mug1 (-188389), A2m (+13979)
chr6 126489214 126489669 Kcna5 (-3869)
chr6 132413674 132413881 Prh1 (-106049), Gm8882 (-99626)
chr6 143101173 143101323 C2cd5 (-52621), Etnk1 (-14502)
chr6 145881183 145881640 Sspn (-1230)
chr6 146525985 146526167 Fgfr1op2 (-305), Asun (+281)
chr6 147501623 147501803 Far2 (-494225), Ccdc91 (+77320)
chr5 11220304 11220562 4933402N22Rik (-374523), Gm5861 (+37361)
chr5 11220573 11220751 4933402N22Rik (-374294), Gm5861 (+37590)
chr5 11400416 11400736 4933402N22Rik (-194380), Gm5861 (+217504)
chr5 11829495 11829872 Sema3d (-553482), 4933402N22Rik (+234728)
chr5 11881170 11881428 Sema3d (-501867), 4933402N22Rik (+286343)
chr5 14918464 14922081 Gm9758 (-5374), Speer4e (+18156)
chr5 16889535 16889710 Speer4f (-92293), Gm3495 (+10597)
chr5 16974433 16975269 Speer4f (-7065), Gm3495 (+95825)
chr5 28661168 28661314 Evc2 (-9068497), Rbm33 (+17512), Shh (+132400)
chr5 54893762 54893923 Stim2 (+504187)
chr5 66330250 66330572 Chrna9 (-27952), Rhoh (+75603)
chr5 66375177 66375388 Chrna9 (+16920), 9130230L23Rik (+20241)
chr5 72438606 72438857 Commd8 (+120690), Gabrb1 (+347561)
201
chr5 76651154 76651299 Tmem165 (+38322), Clock (+82590)
chr5 76657257 76657453 Tmem165 (+44450), Clock (+76462)
chr5 78845888 78845995 NONE
chr5 102235572 102235858 Cds1 (+41566), Wdfy3 (+263225)
chr5 105855709 105855904 Lrrc8c (-92600), Lrrc8b (+11013)
chr5 108295958 108296386 Evi5 (+7954), Ube2d2b (+36900)
chr5 109111463 109111867 Fgfrl1 (-11583), Slc26a1 (-7077)
chr5 109176965 109177370 Rnf212 (+1299), Fgfrl1 (+53920)
chr5 109231240 109231381 Tmed11 (-6929), Vmn2r8 (+6462)
chr5 109722239 109722366 Vmn2r14 (-68662), Vmn2r15 (+4272)
chr5 113763814 113764285 Sgsm1 (-24244), Aym1 (-22264)
chr5 115939382 115939805 Sirt4 (-4860)
chr5 115940244 115940408 Pxn (-16491), Sirt4 (-5592)
chr5 123453058 123453399 Kdm2b (-14121), Orai1 (-11854)
chr5 123960959 123961289 B3gnt4 (+655)
chr5 123961314 123961799 B3gnt4 (+1088), Diablo (+12628)
chr5 129661847 129662082 Sfswap (-345141), Gpr133 (+59340)
chr5 129760523 129760777 Sfswap (-246456), Gpr133 (+158025)
chr5 135003226 135003818 Gtf2ird1 (-70941), Clip2 (+24782)
chr5 137540337 137540712 Ap1s1 (-18520), Serpine1 (+7617)
chr5 140277688 140278199 Mafk (+10477), Tmem184a (+12293)
chr5 143455156 143455542 Tnrc18 (+123717), Slc29a4 (+277294)
chr5 143579353 143579517 Tnrc18 (-369)
chr5 143579622 143579759 Tnrc18 (-625)
chr5 148910391 148910631 Mtus2 (+141615), Slc7a1 (+300969)
chr5 149864457 149864875 Hmgb1 (-50)
chr4 3429671 3429955 Vmn1r3 (-317308), Tmem68 (+72187)
chr4 3540699 3541766 Lyn (-64029), Tgs1 (+39211)
chr4 8154834 8155634 Car8 (+10954)
chr4 8619372 8619621 Clvs1 (-576967), Chd7 (+1429)
chr4 9133821 9134179 Clvs1 (-62464), Chd7 (+515932)
chr4 11324250 11324666 1110037F02Rik (-88647), Esrp1 (-10528)
chr4 17379647 17379762 Mmp16 (-400900)
chr4 37908025 37908169 NONE
chr4 41811878 41812712 Ccl27a (-91280), Gm20938 (-24489)
chr4 41925351 41926345 Gm2564 (+17616), Gm20938 (+89064)
chr4 41963771 41963931 Gm13304 (-21689), Gm2564 (-20387)
chr4 42023793 42024677 Gm13306 (-528)
chr4 42269110 42269783 Gm13305 (-230121), Il11ra2 (-69813)
chr4 42353908 42354512 Il11ra2 (+14950), Gm13298 (+187497)
chr4 42414654 42414814 Il11ra2 (+75474), Gm13298 (+126973)
chr4 42452240 42453234 Gm13298 (+88970), Il11ra2 (+113477)
chr4 42565486 42566480 4930578G10Rik (-183094), Gm13298 (-24276)
chr4 42603910 42604070 4930578G10Rik (-145087), Gm13298 (-62283)
chr4 42663761 42664645 Gm13298 (-122496), 4930578G10Rik (-84874)
chr4 42748677 42749163 4930578G10Rik (-157)
chr4 46596519 46596890 Trim14 (-47692), Coro2a (+18369)
chr4 50709855 50710061 Grin3a (-851537), Cylc2 (-519592)
202
chr4 51825350 51825590 Smc2 (-626645), Cylc2 (+595920)
chr4 80355629 80355771 Tyrp1 (-124434)
chr4 81597155 81597635 Mpdz (-508684), Nfib (+553817)
chr4 83269166 83269399 Ccdc171 (+97834)
chr4 101763903 101764474 Pde4b (-163419), Gm12789 (+104958)
chr4 107831578 107831728 Scp2 (-40516), Echdc2 (-6389)
chr4 108952605 108952986 Eps15 (-77)
chr4 114943768 114943896 Cyp4x1 (-137250), Cyp4a12a (-27819)
chr4 114986056 114986184 Cyp4a12b (-98109), Cyp4a12a (+14469)
chr4 115718594 115718991 Faah (-28262), Nsun4 (+7192)
chr4 115893683 115893927 Pik3r3 (-461)
chr4 116862455 116862794 Kif2c (-7381), Gm1661 (+61897)
chr4 116875066 116875292 Kif2c (-19935), Gm1661 (+49343)
chr4 116883412 116883551 Kif2c (-28238), Gm1661 (+41040)
chr4 117559595 117559777 B4galt2 (-3594), Atp6v0b (+248)
chr4 118110022 118110315 Cdc20 (-212)
chr4 118219655 118221372 Tmem125 (-4181)
chr4 120709969 120710060 Col9a2 (-1975)
chr4 123369561 123369835 Macf1 (-8095), Ndufs5 (+25747)
chr4 124617836 124618218 Cdca8 (-3910)
chr4 125568410 125568787 Csf3r (-133195), Grik3 (+400655)
chr4 131301601 131301835 Ptpru (+92428), Matn1 (+801418)
chr4 131673819 131674044 Epb4.1 (-42725), Oprd1 (+26469)
chr4 131825733 131826483 Taf12 (-4182)
chr4 132894275 132894409 Wdtc1 (+897)
chr4 132994761 132995022 Fam46b (-41155), Slc9a1 (+69271)
chr4 134024169 134024391 Stmn1 (+45)
chr4 141102627 141102930 Spen (-8267), Fblim1 (+53060)
chr4 146316224 146316405 Gm13150 (-29770), Zfp600 (+191224)
chr4 149185046 149185351 Slc25a33 (-36813), Spsb1 (+143953)
chr4 149612437 149612864 Rere (-43104), Eno1 (+1590)
chr4 153394885 153395163 Smim1 (+5237), Lrrc47 (+9184)
chr4 153527347 153527613 Tprgl (+7295), Wrap73 (+10999)
chr4 154231384 154231576 Mmel1 (-14258), Ttc34 (+1171)
chr4 154306287 154306408 Tnfrsf14 (-4162)
chr3 5860243 5860873 Pex2 (-284319), 1700008P02Rik (+759885)
chr3 22026150 22026308 Tbl1xr1 (+50655)
chr3 23209200 23209294 NONE
chr3 31260640 31260800 Kcnmb2 (-540709), Slc7a14 (-51420)
chr3 52059270 52059807 Maml3 (-150726), Foxo1 (-12720)
chr3 58469472 58469815 Fam194a (-28515), Siah2 (+26678)
chr3 58469948 58470228 Fam194a (-28959), Siah2 (+26234)
chr3 61949655 61949811 B430305J03Rik (-779860), Arhgef26 (-192533)
chr3 64230774 64230952 Vmn2r4 (-11645), Vmn2r5 (+82794)
chr3 68096244 68096863 Il12a (-398012), Schip1 (+227690)
chr3 69490627 69490976 B3galnt1 (-88019), Nmd3 (-35105)
chr3 77059606 77059705 NONE
chr3 93518698 93518941 Tdpoz4 (-81500), S100a10 (+159818)
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chr3 95276043 95276623 Ctsk (-26875), Arnt (+38023)
chr3 96024557 96024756 Hist2h2be (-387), Hist2h2ac (+146), Hist2h2ab (+869)
chr3 96042667 96043048 Hist2h3c2 (+192)
chr3 96043066 96043922 Hist2h3c2 (-444), Hist2h2aa2 (+722)
chr3 96043950 96044533 Hist2h3c2 (-1192), Hist2h2aa2 (-26)
chr3 96049190 96049726 Hist2h3c1 (-1216), Hist2h2aa1 (-3)
chr3 96049754 96050602 Hist2h3c1 (-496), Hist2h2aa1 (+717)
chr3 96050624 96051005 Hist2h3c1 (+141)
chr3 96072452 96072813 Hist2h2bb (-1042), Hist2h3b (+56)
chr3 96132007 96132599 Fcgr1 (-34411), BC107364 (+123926)
chr3 96163525 96164181 Fcgr1 (-65961), BC107364 (+92376)
chr3 96177802 96178458 Fcgr1 (-80238), BC107364 (+78099)
chr3 96226594 96226840 Fcgr1 (-128825), BC107364 (+29512)
chr3 96254032 96254704 Fcgr1 (-156476), BC107364 (+1861)
chr3 96263776 96264448 Hfe2 (-64996), BC107364 (-7883)
chr3 96290119 96291035 Hfe2 (-38531), BC107364 (-34348)
chr3 96292179 96293188 BC107364 (-36455), Hfe2 (-36424)
chr3 103897340 103897866 Phtf1 (+125570), Magi3 (+126423)
chr3 106243488 106243658 BC051070 (-34473), 2010016I18Rik (+42782)
chr3 109061732 109061903 Vav3 (-81753), Slc25a24 (+135751)
chr3 115609465 115610475 Dph5 (+18869), Slc30a7 (+100354)
chr3 124418625 124418909 Ndst4 (-688242), 1700003H04Rik (-134758)
chr3 142973853 142974253 Pkn2 (-429085), Lmo4 (+891228)
chr3 144408324 144408651 Sh3glb1 (-25201), Clca1 (+15317)
chr3 144467409 144467757 Clca1 (-43778), Clca2 (+14875)
chr3 146005710 146006075 Ssx2ip (-61713), Lpar3 (+121968)
chr3 152165618 152166329 Zzz3 (+107007), Ak5 (+165130)
chr3 152996314 152997030 St6galnac5 (-351462), St6galnac3 (+391354)
chr3 154085430 154086146 Tyw3 (+174271), Slc44a5 (+449388)
chr3 154136600 154137010 Tyw3 (+123254), Slc44a5 (+500405)
chr3 159218929 159219028 Rpe65 (-43218), Depdc1a (+60582)
chr2 3356844 3357148 Dclre1c (+15574), Suv39h2 (+35307)
chr2 16187859 16187954 Plxdc2 (-90024), Gm13318 (+224154)
chr2 18461040 18461299 Dnajc1 (-146713), Commd3 (-132880)
chr2 20196979 20197177 Etl4 (-244340), Otud1 (+617389)
chr2 20821416 20821899 Arhgap21 (+67689), Etl4 (+380240)
chr2 22443076 22443924 Gad2 (-34225), Myo3a (+294370)
chr2 25035800 25036694 Nrarp (-31)
chr2 28980310 28981010 Setx (+148)
chr2 34611014 34611361 Gapvd1 (-25021), Hspa5 (-16424)
chr2 51198320 51198829 Tas2r134 (-284456), Rnd3 (-193944)
chr2 57246848 57247325 Galnt5 (-603208), Gpd2 (+156379)
chr2 57481881 57482153 Galnt5 (-368278), Gpd2 (+391309)
chr2 80302072 80302264 Frzb (-14386), Nckap1 (+119369)
chr2 83373876 83374011 Zc3h15 (-110648), Fsip2 (+590153)
chr2 98502287 98503234 Gm10801 (+367)
chr2 98503710 98504293 Gm10801 (+1608), Gm10800 (+3456)
chr2 98505008 98505437 Gm10800 (+2235), Gm10801 (+2829)
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chr2 98506338 98507542 Gm10800 (+518)
chr2 99785651 99785785 NONE
chr2 105308425 105308582 Pax6 (-200549), Rcn1 (-69028)
chr2 111925966 111926040 Olfr1313 (-13263), Olfr1314 (+6853)
chr2 117059330 117059501 Fam98b (-16059), Spred1 (+112306)
chr2 121962909 121963298 Spg11 (-18982), B2m (-10318)
chr2 124986392 124986659 Dut (-86400), Slc12a1 (+8285)
chr2 125443221 125443497 Fbn1 (-111238), Cep152 (+7490)
chr2 131233744 131234170 Smox (-83722), Rnf24 (-55340)
chr2 142290456 142290537 Kif16b (+436770)
chr2 146335546 146336272 Ralgapa2 (+1831), Insm1 (+288252)
chr2 162688176 162688554 Ptprt (-201482), Srsf6 (-68899)
chr2 166065850 166066134 Sulf2 (-84829), Prex1 (+473340)
chr2 167702233 167702451 Ptpn1 (-55485), Cebpb (+187927)
chr2 167702530 167702802 Ptpn1 (-55161), Cebpb (+188251)
chr2 170945712 170946046 Dok5 (+388572), Cbln4 (+923087)
chr1 6638065 6638194 St18 (-82002), Fam150a (+288593)
chr1 8400880 8401020 Sntg1 (+59651)
chr1 12634806 12634963 Sulf1 (-73741)
chr1 16647040 16647245 Tceb1 (-197)
chr1 23067721 23067887 Rims1 (-464382), 4933415F23Rik (+41288)
chr1 24618332 24623038 Gm10222 (-1146)
chr1 30819114 30819315 Gm9898 (-42409), Phf3 (+100886)
chr1 33951484 33951619 Zfp451 (-80112), Bend6 (+13109)
chr1 33951622 33951859 Zfp451 (-80301), Bend6 (+12920)
chr1 35326119 35326392 Hs6st1 (-798989), Plekhb2 (+419419)
chr1 36425881 36426371 Kansl3 (-1267)
chr1 38461097 38461289 Rev1 (-274686), Aff3 (+135494)
chr1 39576302 39576542 Tbc1d8 (-40830), Cnot11 (-15415)
chr1 46910029 46910937 Slc39a10 (+408)
chr1 48519013 48519161 C230029F24Rik (-782373)
chr1 49014660 49014787 C230029F24Rik (-286736)
chr1 57513605 57513800 Spats2l (-318002), Tyw5 (-49758)
chr1 66863661 66863845 Kansl1l (+367)
chr1 69851276 69851438 Ikzf2 (-118823), Spag16 (-22205)
chr1 72283383 72283807 Mreg (-24714), Pecr (+47293)
chr1 72290738 72291074 Mreg (-32025), Pecr (+39982)
chr1 72301572 72301870 Mreg (-42840), Pecr (+29167)
chr1 83996431 83996610 Sphkap (-591746), Pid1 (+284699)
chr1 84836064 84836238 Trip12 (-272), Fbxo36 (-265)
chr1 88383859 88384257 Ptma (-39253), 1700019O17Rik (+61112)
chr1 88422999 88423418 Ptma (-102)
chr1 88617661 88617989 Dis3l2 (+17446), Alppl2 (+368678)
chr1 91355897 91356040 D130058E05Rik (-470840), Agap1 (+4583)
chr1 95841863 95842057 Gm6086 (-45126), Gm9994 (+17596)
chr1 99816002 99816317 Ppip5k2 (-149172), Pam (+176038)
chr1 105755854 105756011 Cdh20 (-909173)
chr1 115518268 115518479 NONE
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chr1 120355482 120355898 2900060B14Rik (-366)
chr1 130932071 130932291 Cxcr4 (-443314), Thsd7b (-237740)
chr1 133716876 133717034 Slc41a1 (-7599), Pm20d1 (+22997)
chr1 134318052 134318382 Rbbp5 (-55727), Dstyk (+4187)
chr1 136457209 136457415 Kdm5b (+564)
chr1 136457440 136457676 Kdm5b (+810)
chr1 136457717 136457907 Syt2 (-148065), Kdm5b (+1064)
chr1 136920453 136920843 Ube2t (+61506), Lgr6 (+81205)
chr1 138233122 138233315 Gpr25 (-75769), Camsap2 (+9462)
chr1 138235598 138235739 Gpr25 (-78219), Camsap2 (+7012)
chr1 141954325 141954737 Gm4788 (-276715), Cfh (+125457)
chr1 142869679 142869779 Kcnt2 (+726934)
chr1 159482429 159482704 Sec16b (+45708), Fam5b (+803824)
chr1 159661262 159661466 Sec16b (+224505), Fam5b (+625027)
chr1 162275331 162275404 Cacybp (-132460), Rabgap1l (+447701)
chr1 163027312 163027488 Cenpl (+26502), Klhl20 (+34242)
chr1 169270302 169270622 Aldh9a1 (-9660), Tmco1 (+31661)
chr1 169328474 169328599 Mgst3 (-4565)
chr1 169600816 169601057 Lmx1a (-18752), Rxrg (+72422)
chr1 172572750 172572955 Olfml2b (-1810)
chr1 172958057 172958306 Fcgr4 (+9131), Fcgr3 (+31352)
chr1 173001780 173005313 1700009P17Rik (-48245), Fcgr3 (-14013)
chr1 173012987 173014985 1700009P17Rik (-37806), Fcgr3 (-24452)
chr1 173432897 173433394 Alyref2 (-463)
chr1 173808683 173808857 Gm10521 (-17025), Cd84 (+38942)
chr1 174196993 174197081 Atp1a4 (-8492), Atp1a2 (+31158)
chr1 178744251 178744519 Sdccag8 (-406)
chr1 180250830 180251576 Cox20 (+1942), Hnrnpu (+16725)
chr1 180251592 180252051 Cox20 (+2561), Hnrnpu (+16106)
chr1 180252156 180252389 Cox20 (+3012), Hnrnpu (+15655)
chr1 180252951 180253209 Cox20 (+3819), Hnrnpu (+14848)
chr1 180266685 180267253 Hnrnpu (+959)
chr1 183634010 183634190 Ccdc121 (-192518), Dnahc14 (-37067)
chr1 186854896 186855388 Rab3gap2 (-172905), Mark1 (-31714)
chr1 192053952 192054194 Prox1 (-59514), Rps6kc1 (+681576)
chr1 194061545 194061791 Kcnh1 (+47002), Hhat (+535739)
chr1 197190299 197190481 Cr2 (-187481)
chrY 2869581 2872285 Gm10352 (+480543)
chr9 2999998 3002205 Gm10722 (+180)
chr9 3002257 3003490 Gm10720 (-12780), Gm10722 (+1952)
chr9 3003894 3004721 Gm10720 (-11346), Gm10722 (+3386)
chr9 3008887 3009792 Gm10720 (-6314), Gm10722 (+8418)
chr9 3011305 3013245 Gm10720 (-3379)
chr9 3013318 3014219 Gm10720 (-1885)
chr9 3015054 3015859 Gm10720 (-197)
chr9 3016808 3017613 Gm10718 (-6336), Gm10720 (+1557)
chr9 3017722 3018549 Gm10718 (-5411), Gm10720 (+2482)
chr9 3023697 3024501 Gm10718 (+552)
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chr9 3024619 3028825 Gm10718 (+3175), 4930433N12Rik (+173060)
chr9 3029353 3030835 Gm10718 (+6547), 4930433N12Rik (+169688)
chr9 3030999 3033810 Gm10718 (+8858), 4930433N12Rik (+167377)
chr9 3035278 3036770 Gm10718 (+12477), 4930433N12Rik (+163758)
chr9 3036840 3037472 Gm10718 (+13609), 4930433N12Rik (+162626)
chr9 3037542 3038423 Gm10718 (+14436), 4930433N12Rik (+161799)
chr9 9927813 9927959 Arhgap42 (-688873), Cntn5 (+976889)
chr9 10564871 10565170 Cntn5 (+339754)
chr9 13338640 13339469 Maml2 (-85379), Phxr4 (+104474)
chr9 19029130 19029345 Olfr843 (+24669), Olfr836 (+103837)
chr9 25059849 25060024 Sept7 (-232)
chr9 28182826 28182970 Opcml (+584366)
chr9 35112756 35113275 Cdon (-116166), Rpusd4 (+37566)
chr9 37980371 37980508 Olfr891 (+7966), Olfr890 (+29718)
chr9 41056175 41056341 Ubash3b (-90113), Sorl1 (+876122)
chr9 41780734 41780824 Ubash3b (-814634), Sorl1 (+151601)
chr9 44142700 44142969 H2afx (+37)
chr9 44689301 44689523 Mll1 (-33)
chr9 45064717 45064951 Tmprss4 (-52659), Il10ra (+12398)
chr9 45443886 45444033 Cep164 (+192814), Dscaml1 (+205584)
chr9 49183419 49183597 Drd2 (+34776), Ankk1 (+51618)
chr9 56071355 56071791 Tspan3 (-62977), C230081A13Rik (+194284)
chr9 58538904 58539073 2410076I21Rik (+50377), Nptn (+108890)
chr9 58743557 58744359 Hcn4 (+72639), Neo1 (+140290)
chr9 59505862 59506188 Gramd2 (-49419), Pkm (+1642)
chr9 65044185 65044584 Parp16 (-18569), Igdcc3 (+55424)
chr9 65049332 65049789 Parp16 (-13393), Igdcc3 (+60600)
chr9 67419497 67419783 C2cd4b (-187604), Tln2 (-12130)
chr9 70942604 70942770 Lipc (-160072), Aqp9 (+68409)
chr9 71908716 71909086 Cgnl1 (-289492), Tcf12 (+50725)
chr9 75471052 75471301 Lysmd2 (-2362)
chr9 82868925 82869191 Phip (+38)
chr9 82869297 82869515 Phip (-310)
chr9 96435662 96435871 Rnf7 (-56673), Rasa2 (+96269)
chr9 99341156 99341459 Mras (-4171)
chr9 100119352 100119755 Sox14 (-342891), Il20rb (+267653)
chr9 100119779 100119975 Sox14 (-343214), Il20rb (+267330)
chr9 108465913 108466233 Impdh2 (+3299), Ndufaf3 (+3600)
chr9 108466612 108467145 Ndufaf3 (+2794), Impdh2 (+4105)
chr9 110154884 110154975 Elp6 (-52766), Cspg5 (+8643)
chr9 110428162 110428353 Setd2 (-6843), Kif9 (+48760)
chr9 110428485 110429550 Setd2 (-6083), Kif9 (+49520)
chr9 110989678 110990024 Lrrfip2 (-30764), Ccrl2 (-30077)
chr9 112911176 112911399 Arpp21 (-776283), Pdcd6ip (+706074)
chr9 115695410 115695590 Stt3b (-475961), Gadl1 (-122182)
chr9 115695612 115695770 Stt3b (-476152), Gadl1 (-121991)
chr9 118647931 118648304 Ctdspl (-187453), Itga9 (+132310)
chr9 120058537 120058711 Mobp (-236)
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chr9 123370836 123371309 Limd1 (-16746), Lars2 (+95015)
chr8 4944835 4945023 Shcbp1 (-165395), Slc10a2 (+160303)
chr8 10676257 10676741 3930402G23Rik (+251958), Myo16 (+403927)
chr8 12651761 12651915 Tubgcp3 (+20410), Spaca7 (+78789)
chr8 15519762 15520194 Myom2 (+462325)
chr8 25462270 25462920 1810011O10Rik (+86823), A730045E13Rik (+178219)
chr8 31438279 31438743 Dusp26 (-761432)
chr8 48678169 48678670 Rwdd4a (+59402), Ing2 (+82092)
chr8 48799209 48799365 Cdkn2aip (-2)
chr8 53422254 53422419 NONE
chr8 62368986 62369151 Gm10283 (+612926), BC030500 (+978517)
chr8 68498956 68499055 March1 (+357082), Tma16 (+511412)
chr8 73222346 73223170 Jund (+1120), Gm11175 (+1221)
chr8 82479259 82479547 Hhip (+102502), Anapc10 (+243684)
chr8 83262886 83263555 Smarca5 (+175)
chr8 85884272 85884590 Clgn (-29346), 4933434I20Rik (+12061)
chr8 89571694 89572030 N4bp1 (-162705), Cbln1 (+424646)
chr8 93860665 93860961 Fto (+23382), Irx3 (+464740)
chr8 97794284 97794571 Kifc3 (-127988), Cngb1 (+13653)
chr8 107828141 107828923 Elmo3 (-969)
chr8 110220901 110221068 Psmd7 (-108603)
chr8 112302324 112302543 Ap1g1 (-20)
chr8 119567477 119567793 Gcsh (-50198), Pkd1l2 (+38714)
chr8 122124325 122124484 Taf1c (+4717), Dnaaf1 (+25270)
chr8 122125009 122125167 Taf1c (+4034), Dnaaf1 (+25953)
chr8 122126044 122126895 Taf1c (+2652), Dnaaf1 (+27335)
chr8 124494912 124495249 Gm22 (-298388), Banp (+20637)
chr8 125801296 125801869 Vps9d1 (-23335), Fanca (+40893)
chr8 127528426 127529090 Egln1 (-55604), Tsnax (-8139)
chr13 3026151 3026232 Gdi2 (-511129)
chr13 3179280 3179495 Gdi2 (-357933)
chr13 6134585 6134854 Pitrm1 (-412683), Klf6 (+273985)
chr13 9833500 9833762 Zmynd11 (-69225), Chrm3 (+44698)
chr13 12366712 12366965 Mtr (-16572), Actn2 (+66188)
chr13 16464769 16464850 Inhba (+361126)
chr13 20876498 20876763 Aoah (-9357), Elmo1 (+694143)
chr13 21809473 21809969 Hist1h2bm (-4192), Hist1h3h (+224)
chr13 21813489 21813714 Hist1h2bm (-311)
chr13 21826842 21827336 Hist1h4j (+186)
chr13 21842001 21842479 Hist1h4k (+134)
chr13 21846168 21846343 Hist1h4k (-3882), Hist1h2ak (-480)
chr13 21874791 21875299 Hist1h2bp (-4285), Hist1h1b (-2551), Hist1h3i (+221)
chr13 21879560 21879759 Hist1h3i (-4394), Hist1h2an (-573), Hist1h2bp (+330)
chr13 21901526 21901863 Hist1h4m (-1920), Hist1h2bq (+358)
chr13 21901911 21902528 Hist1h4m (-1395), Hist1h2bq (-167)
chr13 21903666 21904052 Hist1h2bq (-1806), Hist1h4m (+244)
chr13 21923627 21924238 Hist1h2br (-1694), Hist1h4n (+132)
chr13 21925147 21925768 Hist1h4n (-1393), Hist1h2br (-169)
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chr13 21925816 21926153 Hist1h4n (-1920), Hist1h2br (+358)
chr13 22127932 22128107 Hist1h2ah (-508), Hist1h2bk (+330)
chr13 22132822 22133297 Hist1h2bj (-2023), Hist1h4i (+161)
chr13 22135028 22135487 Hist1h4i (-2037), Hist1h2ag (-440), Hist1h2bj (+175)
chr13 23622999 23623365 Hist1h3g (-4109), Hist1h2af (-2593), Hist1h4h (+263)
chr13 23643135 23643389 Hist1h1d (-3639), Hist1h4f (+255)
chr13 23646975 23647201 Hist1h4f (-3571), Hist1h1d (+187)
chr13 23667674 23668022 Hist1h2ae (-4759), Hist1h2bf (-1783), Hist1h3d (+216)
chr13 23714034 23714302 Hist1h2be (-1175), Hist1h1e (+203)
chr13 23776051 23776229 Hist1h2ac (-323), Hist1h2bc (+72)
chr13 23789960 23790459 Hist1h4c (+113)
chr13 23830593 23831031 Hist1h1c (+136)
chr13 23838768 23839012 Hist1h2ab (-4067), Hist1h3c (-1419), Hist1h2bb (+287)
chr13 23844179 23844628 Hist1h4b (-4402), Hist1h3b (+268)
chr13 23848933 23849239 Hist1h4b (+280)
chr13 23852658 23853012 Hist1h1a (-2702), Hist1h4a (+264)
chr13 23853920 23854301 Hist1h1a (-1426), Hist1h4a (-1012), Hist1h3a (+144)
chr13 24025614 24026204 Hist1h2aa (-422), Hist1h2ba (+116)
chr13 24633416 24633684 Fam65b (-96967), Cmah (+214261)
chr13 42190662 42190816 Edn1 (-205900), Hivep1 (+43349)
chr13 44964885 44965059 Dtnbp1 (+132537), Jarid2 (+138780)
chr13 47046203 47046525 Kif13a (-21277), Nhlrc1 (+63855)
chr13 49494901 49495368 Ippk (-21545), Bicd2 (+58217)
chr13 51297951 51298500 Hist1h2al (+208)
chr13 51941709 51941925 Gadd45g (-230)
chr13 51941968 51942164 Gadd45g (+19)
chr13 52846109 52846573 Syk (+167799), Auh (+178689)
chr13 56199754 56200260 Pitx1 (-267221), H2afy (+36985)
chr13 58502820 58503374 Rmi1 (-861)
chr13 58503773 58503940 Rmi1 (-101), Hnrnpk (+847)
chr13 61052440 61052524 Tpbpa (-9186), Ctsj (+54795)
chr13 62460597 62460717 Gm10260 (-141328), Gm5141 (+12639)
chr13 65552554 65553189 Gm10139 (-60742), Zfp369 (+172750)
chr13 65967440 65968021 Gm10772 (-39856), Gm10139 (+354117)
chr13 66394389 66396325 Vmn2r-ps104 (+60964), 2610044O15Rik8 (+256118)
chr13 67299065 67299259 Zfp455 (+3720), Zfp458 (+70842)
chr13 67474005 67474254 Zfp953 (-12589), Zfp456 (+2616)
chr13 67497929 67498144 Zfp456 (-21291), Zfp429 (+2666)
chr13 68096842 68096930 BC048507 (+132612), Mtrr (+624112)
chr13 69733647 69733870 Papd7 (-61042), Srd5a1 (+16561)
chr13 70231949 70232253 Med10 (+283341), BC018507 (+544411)
chr13 91778066 91778279 Acot12 (-102944), Ssbp2 (+177518)
chr13 91778284 91778432 Acot12 (-102759), Ssbp2 (+177703)
chr13 92094003 92094177 Ckmt2 (-77600), Rasgrf2 (+807359)
chr13 97342467 97342837 Col4a3bp (+29962), Hmgcr (+98239)
chr13 101432401 101432811 Ccdc125 (-6830), Taf9 (+11308)
chr12 3036912 3037000 Rab10 (+273013)
chr12 4786211 4786418 0610009D07Rik (-38099), Pfn4 (+10214)
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chr12 5503370 5503761 2810032G03Rik (+85119)
chr12 9432167 9432451 Osr1 (-148939), Ttc32 (+395506)
chr12 12018484 12018858 Fam49a (-250274), Rad51ap2 (+555786)
chr12 12018866 12019112 Fam49a (-249956), Rad51ap2 (+556104)
chr12 13143011 13143206 Mycn (-194389), Ddx1 (+112910)
chr12 17539673 17540043 Odc1 (-11821), Nol10 (+184573)
chr12 19226266 19226526 Gm5784 (-167269), 5730507C01Rik (+704852)
chr12 20828925 20829099 1700030C10Rik (-7424), Zfp125 (+77716)
chr12 22990713 22991030 NONE
chr12 35958601 35958755 Snx13 (+226817), Ahr (+261032)
chr12 37392265 37392572 Meox2 (-442708), D630036H23Rik (-283651)
chr12 38091134 38091230 Dgkb (-516110), Agmo (+122954)
chr12 50712141 50712236 Gm9804 (+209925)
chr12 55797359 55798061 Eapp (-842)
chr12 55810882 55811993 Eapp (-14570), Snx6 (+85252)
chr12 55814849 55815664 Eapp (-18389), Snx6 (+81433)
chr12 55819723 55820200 Eapp (-23094), Snx6 (+76728)
chr12 55820236 55820781 Eapp (-23641), Snx6 (+76181)
chr12 55830120 55831178 Eapp (-33781), Snx6 (+66041)
chr12 55835205 55835592 Eapp (-38531), Snx6 (+61291)
chr12 55835629 55836060 Eapp (-38977), Snx6 (+60845)
chr12 55838910 55839950 Eapp (-42562), Snx6 (+57260)
chr12 59261099 59261197 Foxa1 (-614040), Sstr1 (-51611)
chr12 62477546 62477700 Lrfn5 (-147312)
chr12 71978715 71978914 Actr10 (-60029), Frmd6 (+52314)
chr12 79949073 79949263 Atp6v1d (+13457), Mpp5 (+99234)
chr12 92828267 92828427 Gtf2a1 (+102)
chr12 93036365 93036569 Ston2 (-11591), Sel1l (+51130)
chr12 98299606 98300037 NONE
chr12 103079306 103079937 Fbln5 (-22357), Trip11 (+71855)
chr12 111934120 111934354 Hsp90aa1 (+368)
chr12 112341390 112341756 Traf3 (-63101), Rcor1 (+63748)
chr12 112579306 112579480 Cdc42bpb (+36536), Amn (+70071)
chr12 113088150 113088677 Ppp1r13b (+22412), Zfyve21 (+36033)
chr12 113338413 113338652 BC048943 (-119571), Aspg (-6361)
chr11 3724658 3725260 Osbp2 (+38947), Morc2a (+175462)
chr11 3971581 3971778 Sec14l3 (+6836), Mtfp1 (+23768)
chr11 11397628 11398506 4930415F15Rik (+8798), 4930512M02Rik (+129760)
chr11 14977824 14977948 NONE
chr11 22170490 22170823 Otx1 (-269039), Ehbp1 (+15184)
chr11 23624548 23624891 Pex13 (-58761), Rel (+46250)
chr11 25000048 25000203 5730522E02Rik (+670444)
chr11 32076000 32076214 Il9r (+24129), Nsg2 (+175644)
chr11 40613689 40613785 Ccng1 (-44924)
chr11 50191163 50191410 Hnrnph1 (+16)
chr11 52099825 52100178 Tcf7 (-3929)
chr11 58775172 58775820 Trim17 (-1808)
chr11 60187409 60187676 Lrrc48 (+20712), Atpaf2 (+43010)
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chr11 62364915 62365180 Ubb (+375)
chr11 62365648 62366351 Trpv2 (-22040), Ubb (+1327)
chr11 69571960 69572257 Polr2a (+30)
chr11 70729707 70729900 Nup88 (+53660), Rabep1 (+71524)
chr11 73312282 73312397 Olfr381 (-7361), Olfr382 (+18359)
chr11 76148608 76148883 Glod4 (-91519), Nxn (+63896)
chr11 76191172 76191993 Glod4 (-134356), Nxn (+21059)
chr11 76191995 76192164 Glod4 (-134853), Nxn (+20562)
chr11 79398713 79398991 Evi2a (-54762), Rab11fip4 (-5862)
chr11 79687340 79687428 Utp6 (+88508), Rab11fip4 (+282670)
chr11 82841057 82841310 Slfn2 (-37430), Slfn8 (-6872)
chr11 83084948 83085270 Pex12 (+27370), Slfn3 (+80277)
chr11 86887233 86887808 Gdpd1 (+43)
chr11 87236084 87236908 Gm11492 (-143659), Tex14 (+17929)
chr11 87239984 87240835 Gm11492 (-139745), Tex14 (+21843)
chr11 87256352 87257209 Gm11492 (-123374), Tex14 (+38214)
chr11 87261721 87262640 Gm11492 (-117974), Tex14 (+43614)
chr11 87275408 87276317 Gm11492 (-104292), Tex14 (+57296)
chr11 87284520 87285299 Gm11492 (-95245), Tex14 (+66343)
chr11 95737123 95737400 Abi3 (-33539), B4galnt2 (+38943)
chr11 95893927 95894111 Snf8 (-2180)
chr11 98724900 98725256 Wipf2 (+126)
chr11 101466103 101466410 Rdm1 (-22999), Tmem106a (+22701)
chr11 101488622 101488966 Rdm1 (-462)
chr11 101502809 101503485 Arl4d (-23708), Rdm1 (+13891)
chr11 101506771 101507524 Arl4d (-19707), Rdm1 (+17892)
chr11 101519404 101519849 Arl4d (-7228), Rdm1 (+30371)
chr11 103268409 103268520 Arhgap27 (-46251), Plekhm1 (+5513)
chr11 105301298 105301520 March10 (+16640), Mrc2 (+147449)
chr11 106586494 106586742 Tex2 (-112374), Pecam1 (+25324)
chr11 108872866 108873417 Axin2 (+91479), E030025P04Rik (+132541)
chr11 115885512 115885926 Galk1 (-11686), H3f3b (+3557)
chr11 116928412 116928569 Sec14l1 (-47995), Mgat5b (+148314)
chr11 119320596 119321173 Endov (-31776), Rnf213 (+66471)
chr11 119720614 119720939 Chmp6 (-54347), Rptor (+256314)
chr11 120092832 120092980 Bahcc1 (-1355)
chr11 121518509 121519059 Zfp750 (-138137), B3gntl1 (+15683)
chr10 3831543 3831933 Rgs17 (-592417), Gm10945 (+246958)
chr10 4930547 4930938 Syne1 (+126216), Esr1 (+803777)
chr10 9467362 9467556 Samd5 (-72453), Stxbp5 (+153418)
chr10 11710100 11710246 Gm9797 (+381152), Utrn (+871360)
chr10 12273996 12274342 Utrn (+307364), Gm9797 (+945148)
chr10 17037210 17037294 Cited2 (-405782)
chr10 17044382 17044530 Cited2 (-398578)
chr10 21000123 21000287 Myb (-119415), Hbs1l (-15580)
chr10 26647120 26647204 Arhgap18 (+154879), Lama2 (+689586)
chr10 26655097 26655181 Arhgap18 (+162856), Lama2 (+681609)
chr10 35943971 35944136 Amd2 (-512357), Hs3st5 (-282566)
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chr10 37782321 37782472 Lama4 (-902924), 5930403N24Rik (+923033)
chr10 39691073 39691718 G630090E17Rik (-11437), BC021785 (+15049)
chr10 39978217 39978605 Gtf3c6 (-940)
chr10 49977195 49977294 Grik2 (-468673), Ascc3 (-335230)
chr10 59378436 59378712 Ddit4 (+35944), Dnajb12 (+36251)
chr10 61591506 61591858 Neurog3 (-4156)
chr10 76766491 76766846 Pofut2 (+44624), Adarb1 (+114346)
chr10 77152943 77153141 Gm10272 (-16347), Ube2g2 (+67961)
chr10 80827990 80829989 4930404N11Rik (-429)
chr10 81167324 81168170 Zfp873 (-353415), Ankrd24 (+76367)
chr10 81326463 81327279 Zfp873 (-194291), Ankrd24 (+235491)
chr10 81459541 81460166 Zfp873 (-61308), Ankrd24 (+368474)
chr10 89139305 89139721 Slc17a8 (-55515), Scyl2 (+9517)
chr10 110654809 110655409 Bbs10 (-80626), Osbpl8 (+53251)
chr10 115632868 115633040 Ptprb (-105476), 4933416C03Rik (-81981)
chr17 4626143 4626590 Nox3 (-930106), Arid1b (-368707)
chr17 5011512 5011895 Arid1b (+16630), Tmem242 (+428556)
chr17 10380494 10380692 Pabpc6 (-518024), Qk (+131633)
chr17 13743457 13746115 Mllt4 (-152769), Smok4a (+30464)
chr17 13911136 13911387 Gm7168 (-174118), Mllt4 (+13707)
chr17 14847569 14847759 Thbs2 (-16395), Wdr27 (+223994)
chr17 15098409 15099907 Phf10 (-921)
chr17 15115289 15116168 Gm3448 (-108), Gm3435 (-100)
chr17 15129992 15131491 Gm3435 (+14913), Gm3417 (+16406)
chr17 15146650 15147540 9030025P20Rik (-105), Gm3417 (+53)
chr17 15161360 15162859 9030025P20Rik (+14910), Tcte3 (+16413)
chr17 15178018 15178623 2210404J11Rik (-284), Tcte3 (+202)
chr17 15344966 15345538 2210404J11Rik (+166647), Dll1 (+167688)
chr17 15950608 15950912 Rgmb (+12790), Chd1 (+108829)
chr17 25896831 25897067 Narfl (-13772), Msln (-5677)
chr17 27298995 27299442 Mnf1 (-28358), Ip6k3 (+5490)
chr17 33811718 33812117 Hnrnpm (+11887), Pram1 (+36917)
chr17 34256094 34256550 Brd2 (+2370), H2-Oa (+27037)
chr17 35618079 35618232 Pou5f1 (-24826), H2-Q10 (+11122)
chr17 39979856 39985845 Gm7148 (-269450)
chr17 43892632 43892898 Rcan2 (-46035), Cyp39a1 (+88391)
chr17 56339395 56339517 D17Wsu104e (-16113), Dpp9 (+18856)
chr17 60653649 60653794 NONE
chr17 65987738 65987998 Vapa (-24973), Txndc2 (+3676)
chr17 66713720 66713971 Soga2 (+85244), Ddx11 (+240986)
chr17 69054628 69055037 Epb4.1l3 (-451317), L3mbtl4 (+431696)
chr17 69816419 69816669 Dlgap1 (-957590), A330050F15Rik (+27878)
chr17 71834308 71834443 Smchd1 (-9693), Ndc80 (+41821)
chr17 71834471 71834609 Smchd1 (-9857), Ndc80 (+41657)
chr17 75509211 75509527 Rasgrp3 (-355509), Ltbp1 (+104461)
chr17 80606236 80606439 Ttc39d (-462), Srsf7 (-318)
chr17 80606473 80606939 Srsf7 (-686), Ttc39d (-94)
chr17 84581105 84581330 Haao (-335088), Zfp36l2 (+6069)
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chr17 86824334 86824518 Gm10309 (+80146), Prkce (+257301)
chr17 87452962 87453212 Gm5499 (-24524), Cript (+28197)
chr17 87608182 87608477 Mcfd2 (+56945), Socs5 (+101311)
chr17 89174552 89174875 Lhcgr (+16602), Gtf2a1l (+106714)
chr16 3174030 3174196 Olfr161 (-418285)
chr16 4301021 4301518 Crebbp (-87866), Adcy9 (+118538)
chr16 9241776 9241912 1810013L24Rik (+411651), Grin2a (+753170)
chr16 11015717 11015936 Snn (-50564), Litaf (-22613)
chr16 11143902 11144496 Txndc11 (-9456), Zc3h7a (+32287)
chr16 17088054 17088368 Ypel1 (+18422), Ppil2 (+23114)
chr16 17088394 17089580 Ypel1 (+19198), Ppil2 (+22338)
chr16 17090102 17090259 Ypel1 (+20392), Ppil2 (+21144)
chr16 17090584 17090999 Ppil2 (+20533), Ypel1 (+21003)
chr16 19925935 19926054 A930003A15Rik (-42005), Klhl6 (+57115)
chr16 20129532 20130245 Yeats2 (-11247), Klhl24 (+32262)
chr16 22672855 22673155 Dgkg (-15759), Crygs (+138478)
chr16 31162663 31162843 Xxylt1 (-81235), Acap2 (+38324)
chr16 34671860 34672520 Ccdc14 (-18512), Ropn1 (+20916)
chr16 36991075 36991339 Fbxo40 (-654)
chr16 42569884 42570037 Zbtb20 (-677436), Gap43 (-229197)
chr16 56096558 56096901 Impg2 (-107721), Senp7 (+21208)
chr16 57391146 57391885 Filip1l (+38310), Cmss1 (+215426)
chr16 61238108 61238289 Epha6 (-633125)
chr16 67714057 67714263 Cadm2 (-93092)
chr16 68274642 68274795 Cadm2 (-653651)
chr16 70076415 70076548 Gbe1 (-237712), Speer2 (-212493)
chr16 72258386 72258542 Robo1 (-404930)
chr16 75294903 75295094 Robo2 (-883765), Lipi (+291302)
chr16 80759616 80759772 Ncam2 (-441248)
chr16 84647990 84648749 Mrpl39 (+87617)
chr16 84975160 84975506 Atp5j (-139463), App (+198615)
chr16 94057510 94057989 Cldn14 (-48668), Sim2 (-28311)
chr16 95979203 95979519 Ets2 (+55679), Psmg1 (+233206)
chr16 95995796 95996097 Ets2 (+72265), Psmg1 (+216620)
chr15 5099576 5099919 Ttc33 (-35812), Prkaa1 (+5887)
chr15 7527614 7527751 Gdnf (-233328), Egflam (-179332)
chr15 11259966 11260124 Tars (+69368), Adamts12 (+265500)
chr15 25143986 25144140 9230109A22Rik (-65149), Basp1 (+199456)
chr15 26188739 26188813 March11 (-50043), Zfp622 (+274655)
chr15 30510534 30510630 Dap (-643558), Ctnnd2 (+408234)
chr15 36131941 36132320 Spag1 (+23008), Rnf19a (+80771)
chr15 38212163 38212414 Klf10 (+18173), Odf1 (+63331)
chr15 44622528 44622623 Sybu (-2967)
chr15 76128460 76128765 Smpd5 (+3749), Oplah (+8918)
chr15 76128804 76129053 Smpd5 (+4065), Oplah (+8602)
chr15 79376866 79377092 Ddx17 (+192)
chr15 79560750 79561176 Sun2 (+12003), Gtpbp1 (+39643)
chr15 79561216 79561436 Sun2 (+11640), Gtpbp1 (+40006)
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chr15 82725119 82725439 Cyp2d26 (-100604), Tcf20 (+17285)
chr15 86025175 86025777 Tbc1d22a (-19401), Cerk (-8905)
chr15 87797353 87797527 Zdhhc25 (-633305), Fam19a5 (+422536)
chr15 88568772 88569185 Brd1 (-4316)
chr15 92626642 92626733 Pdzrn4 (+399342), Gxylt1 (+478904)
chr15 92628957 92629048 Pdzrn4 (+401657), Gxylt1 (+476589)
chr15 98364436 98364632 Kansl2 (+118)
chr15 101724635 101724846 Krt76 (-1390)
chr14 4814465 4814595 Gm9602 (-64846), Gm3159 (+313946)
chr14 11353424 11353519 Fhit (+641077)
chr14 12935863 12935995 3830406C13Rik (-180794), Ptprg (+549883)
chr14 14855953 14856561 Atxn7 (+11252), Psmd6 (+97241)
chr14 37719530 37719737 Ccser2 (+62316), 4930474N05Rik (+811489)
chr14 46052730 46052914 Gnpnat1 (-44345), Fermt2 (+96971)
chr14 48705251 48705540 Peli2 (-35148), Ktn1 (+421965)
chr14 48705553 48705674 Peli2 (-34930), Ktn1 (+422183)
chr14 49739614 49739845 Exoc5 (-53402), Naa30 (-52543)
chr14 54880915 54881135 Abhd4 (+2118), Olfr49 (+21575)
chr14 57315836 57316043 Mphosph8 (+28855), Pspc1 (+81213)
chr14 57430145 57430484 Zmym5 (+238)
chr14 57505231 57505594 Zmym2 (-1218)
chr14 57505618 57505797 Zmym2 (-923)
chr14 58458772 58459036 Mrp63 (+13828), Zdhhc20 (+50113)
chr14 59029643 59029822 Rpl13-ps3 (-482610), Fgf9 (+338210)
chr14 60064554 60064873 Setdb2 (-4993), Cab39l (+4896)
chr14 61964386 61964739 Ebpl (+14719), Arl11 (+35973)
chr14 63379777 63380091 Ints6 (+15)
chr14 69799171 69799572 Nkx3-1 (-9323), Nkx2-6 (+9739)
chr14 104736093 104736324 Ednrb (-492819), Pou4f1 (+130999)
chr14 105115012 105115391 Rnf219 (-193319), Rbm26 (+461338)
chr14 118206572 118206838 Dct (+244763), Gpc6 (+881952)
chr14 120737186 120737476 Rap2a (-140335), Mbnl2 (+62402)
chr14 121483899 121484504 Farp1 (+49416), Stk24 (+294354)
chr19 3767959 3768195 Suv420h1 (+656)
chr19 4078363 4078607 BC021614 (-19190), Cabp2 (-5034)
chr19 5803685 5803874 Scyl1 (-32379), Frmd8 (+71494)
chr19 6005129 6005459 Slc22a20 (-19151), Capn1 (+10531)
chr19 6363806 6363988 Sf1 (+207)
chr19 6996550 6997247 Esrra (-601)
chr19 7015773 7016395 Bad (-267), Gpr137 (-115)
chr19 9441752 9441926 Pcna-ps2 (+83970), Stxbp3b (+191899)
chr19 9633435 9633601 Stxbp3b (+220)
chr19 10379302 10379563 Dagla (-66)
chr19 21581779 21582122 Gm3443 (-48213), Gda (-34789)
chr19 29703448 29703901 Ermp1 (+19230), C030046E11Rik (+106903)
chr19 34812509 34812659 Slc16a12 (+9195), Ifit1 (+97223)
chr19 44076755 44076987 Cpn1 (-15825), Cyp2c44 (+26866)
chr19 46654640 46655055 Wbp1l (-18756), Sfxn2 (+6993)
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chr19 55776609 55776938 Tcf7l2 (-39600), Vti1a (+385934)
chr19 57565272 57565511 Atrnl1 (-120132), Trub1 (+37996)
chr19 58592967 58593225 Pnlip (-151759), Ccdc172 (+6604)
chr18 3004771 3005630 Vmn1r238 (+118264)
chr18 6543924 6544060 4921524L21Rik (-59639), Epc1 (-53138)
chr18 6544599 6544711 4921524L21Rik (-58976), Epc1 (-53801)
chr18 10151061 10151227 Usp14 (-121005), Rock1 (+30646)
chr18 10547960 10549005 Esco1 (+61867), Greb1l (+223306)
chr18 10569683 10569963 Esco1 (+40527), Greb1l (+244646)
chr18 12990093 12990353 Cabyr (+90390), Osbpl1a (+110127)
chr18 13201410 13201953 Hrh4 (+36183), Zfp521 (+929560)
chr18 14806362 14806473 Ss18 (+35005), Gm5160 (+224259)
chr18 15592764 15593169 Aqp4 (-31466), Chst9 (+283588)
chr18 18051314 18051426 NONE
chr18 24306003 24306426 Galnt1 (-57630), Ino80c (-25761)
chr18 24826363 24826870 Mocos (+14425), Gm9955 (+41232)
chr18 34602257 34602558 Pkd2l2 (+33331), Fam13b (+64069)
chr18 35803792 35803919 Slc23a1 (-16958), Mzb1 (+5165)
chr18 35815163 35815453 Prob1 (-467)
chr18 35815494 35815670 Prob1 (-741)
chr18 49829559 49829753 Dtwd2 (+85599)
chr18 51835086 51835240 Gm4950 (+190372), Prr16 (+557771)
chr18 57845035 57845163 Slc12a2 (-193233), 1700011I03Rik (+151665)
chr18 61541009 61541432 Ppargc1b (+18833), Pde6a (+161085)
chr18 66145885 66146203 Cplx4 (-16212), Lman1 (+16247)
chr18 75040100 75040260 Lipg (+80737), Acaa2 (+101329)
chr18 75040666 75040986 Lipg (+80091), Acaa2 (+101975)
chr18 76613456 76613637 Skor2 (-481597), Smad2 (+212313)
chr18 81797204 81797484 Sall3 (-614027), Galr1 (+778825)
chr18 83740362 83740551 Tshz1 (+515339), Zfp516 (+660186)
chr18 84588162 84588554 Zfp407 (+170538), Zadh2 (+330808)
chr18 87314713 87314808 Gm5096 (-610986), Cbln2 (+434259)
chrX 3302194 3302325 Gm14345 (-108408)
chrX 3376735 3376894 Gm14345 (-33853)
chrX 3512215 3512374 Gm14351 (-48975), Gm3701 (+155142)
chrX 3873121 3873280 Gm3701 (-205764), Gm14347 (-33810)
chrX 4041451 4041610 Gm3763 (-556635), Gm10922 (-45958)
chrX 25615314 25615470 Gm5168 (-137225), Gm2012 (+43089)
chrX 30762714 30762936 Gm21637 (-60425), Gm2799 (+164429)
chrX 31786255 31786414 Gm2927 (-45925), Gm2913 (-33869)
chrX 58586282 58586381 Ldoc1 (-376457), Cdr1 (-147599)
chrX 59903462 59903624 4931400O07Rik (+182377)
chrX 105879298 105879495 Gm732 (-735622), Brwd3 (+150290)
chrX 113580034 113580205 H2afb2-ps (-214667), Cpxcr1 (+17567)
chrX 115952722 115952852 Tgif2lx1 (-358441)
chrX 120113639 120114527 Nap1l3 (-603089), 3110007F17Rik (-103085)
chrX 120405249 120406500 Srsx (-69785), Vmn2r121 (+843644)
chrX 120634626 120635877 Srsx (-299162), Vmn2r121 (+614267)
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chrX 120970533 120970966 Srsx (-634660), Vmn2r121 (+278769)
chrX 121577239 121578865 Vmn2r121 (-328533)
chrX 121706644 121708339 Vmn2r121 (-457973)
chrX 122458051 122459744 4932411N23Rik (+891718)
chrX 130684776 130684881 Nox1 (-38436), Xkrx (+11638)
chrX 136596335 136596619 E230019M04Rik (-941), Nup62cl (+630)
chrX 137431184 137431272 Tex13 (-83256), Vsig1 (-10919)
chrX 150514181 150514469 Gm15140 (+40903), Spin2 (+247489)
chrX 150565454 150565742 Gm15140 (-10370), 4930524N10Rik (+212337)
chrX 150587185 150587473 Gm15140 (-32101), 4930524N10Rik (+190606)
chrX 157555276 157555507 Cdkl5 (-122758), Scml2 (-45600)
chrX 159793558 159793691 S100g (-391094), Grpr (+193984)
chrX 166438853 166447041 4933400A11Rik (-225380)
216
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2.5 Testes Peaks GO Term Associations 
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chr start stop p-value matched_sequence
chr19 34812509 34812659 1.02E-07 AGAAACAAAGAA
chr9 59505862 59506188 1.02E-07 AGAAACAAAGAA
chr13 12366712 12366965 1.85E-07 AGAAACAAAGGA
chr4 101763903 101764474 4.10E-07 AGAAACAAAGTA
chr12 5503370 5503761 4.10E-07 AGAAACAAAGTA
chr2 121962909 121963298 6.97E-07 TGAAACAAAGAA
chrX 122458051 122459744 7.80E-07 AGAAACAAAGAC
chrX 121706644 121708339 7.80E-07 AGAAACAAAGAC
chrX 121577239 121578865 7.80E-07 AGAAACAAAGAC
chr12 113338413 113338652 1.16E-06 GGAAACAAAGGA
chr10 61591506 61591858 1.66E-06 GGAAACAAAGTA
chr17 13911136 13911387 1.66E-06 GGAAACAAAGTA
chr4 125568410 125568787 1.97E-06 tgaaacaaagta
chr4 3429671 3429955 2.35E-06 AGAAACAAAGTC
chr9 120058537 120058711 4.99E-06 TGAAACAAAGAG
chr1 192053952 192054194 6.99E-06 CCAAACAAAGGA
chr9 120058537 120058711 7.60E-06 GAAAACAAAGGC
chr3 93518698 93518941 7.85E-06 AGAAACAAAGTT
chr16 95979203 95979519 8.33E-06 TAAAACAAAGAG
chr17 13911136 13911387 9.64E-06 TCAAACAAAGAC
chr11 76148608 76148883 9.64E-06 GGAAACAAAGAT
chr1 136920453 136920843 1.31E-05 aataacaaagaa
chr9 41056175 41056341 1.34E-05 AGTAACAAAGTA
chr3 144408324 144408651 1.34E-05 AGTAACAAAGTA
chr3 144467409 144467757 1.34E-05 AGTAACAAAGTA
chr3 144408324 144408651 1.34E-05 AGTAACAAAGTA
chr3 144467409 144467757 1.34E-05 AGTAACAAAGTA
chr3 144408324 144408651 1.34E-05 AGTAACAAAGTA
chr3 144408324 144408651 1.34E-05 AGTAACAAAGTA
chr3 144408324 144408651 1.34E-05 AGTAACAAAGTA
chr3 144467409 144467757 1.34E-05 AGTAACAAAGTA
chr3 144408324 144408651 1.34E-05 AGTAACAAAGTA
chr3 144467409 144467757 1.34E-05 AGTAACAAAGTA
chr3 144408324 144408651 1.34E-05 AGTAACAAAGTA
chr3 144408324 144408651 1.34E-05 AGTAACAAAGTA
chr3 144467409 144467757 1.34E-05 AGTAACAAAGTA
chr11 121518509 121519059 1.49E-05 AGAAACAAAAAA
chr19 34812509 34812659 1.49E-05 AGAAACAAAAAA
chr10 89139305 89139721 1.49E-05 AGAAACAAAAAA
chr6 83530301 83530768 1.49E-05 AGAAACAAAAAA
chr12 5503370 5503761 1.70E-05 AGGAACAAAGAA
chr11 11397628 11398506 1.87E-05 GGTAACAAAGGA
chr11 87275408 87276317 1.91E-05 AGAAACAAACAA
chr11 87239984 87240835 1.94E-05 AAAAACAAAAAA
chr5 14918464 14922081 1.94E-05 AAAAACAAAAAA
chrX 122458051 122459744 1.94E-05 aaaaacaaaaaa
chrX 121706644 121708339 1.94E-05 aaaaacaaaaaa
chr16 95979203 95979519 2.02E-05 AGAAACAAAATA
chr4 125568410 125568787 2.02E-05 agaaacaaaata
chr14 120737186 120737476 2.07E-05 TCAAACAAAGCC
chr18 35803792 35803919 2.17E-05 AGAAAGAAAGAA
chr18 35803792 35803919 2.17E-05 AGAAAGAAAGAA
3 SOX Motif Regions 
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chr18 35803792 35803919 2.17E-05 AGAAAGAAAGAA
chr18 35803792 35803919 2.17E-05 AGAAAGAAAGAA
chr18 35803792 35803919 2.17E-05 AGAAAGAAAGAA
chr18 35803792 35803919 2.17E-05 AGAAAGAAAGAA
chr18 35803792 35803919 2.17E-05 AGAAAGAAAGAA
chr18 35803792 35803919 2.17E-05 AGAAAGAAAGAA
chr2 34611014 34611361 2.20E-05 TGTAACAAAGTA
chrX 166438853 166447041 2.32E-05 CCAAACAAAGCC
chrX 166438853 166447041 2.32E-05 CCAAACAAAGCC
chrX 166438853 166447041 2.32E-05 CCAAACAAAGCC
chrX 166438853 166447041 2.32E-05 CCAAACAAAGCC
chr11 121518509 121519059 2.45E-05 AGAAACAAAAAC
chr1 173012987 173014985 2.47E-05 AAAAACAAACAA
chr9 110428485 110429550 2.47E-05 aaaaacaaacaa
chr9 110428485 110429550 2.47E-05 AAAAACAAACAA
chrX 122458051 122459744 2.47E-05 aaaaacaaacaa
chrX 121706644 121708339 2.47E-05 aaaaacaaacaa
chr12 20828925 20829099 2.51E-05 ACAAACAAAAAA
chrY 2869581 2872285 2.51E-05 acaaacaaaaaa
chr2 146335546 146336272 2.51E-05 GGTAACAAAGAC
chr9 110428485 110429550 2.51E-05 acaaacaaaaAA
chr9 110428485 110429550 2.51E-05 ACAAACAAAAAA
chr11 87275408 87276317 2.51E-05 ACAAACAAAAAA
chrX 122458051 122459744 2.51E-05 acaaacaaaaaa
chrX 121706644 121708339 2.51E-05 acaaacaaaaaa
chr17 15950608 15950912 2.57E-05 TGCAACAAAGAA
chr15 25143986 25144140 2.60E-05 gctaacaaagaa
chr9 65049332 65049789 2.61E-05 AAAAACAAAATA
chr11 70729707 70729900 2.71E-05 AAGAACAAAGGA
chr12 112341390 112341756 2.71E-05 AAGAACAAAGGA
chr12 112341390 112341756 2.75E-05 TGGAACAAAGAA
chr11 69571960 69572257 2.77E-05 GGAAACAAAAGA
chr9 25059849 25060024 2.83E-05 aaaaagaaagaa
chr17 39979856 39985845 2.83E-05 aaaaagaaagaa
chr13 12366712 12366965 2.86E-05 AGAAACAATGTA
chr3 96290119 96291035 2.86E-05 AGAAACAATGTA
chr3 96292179 96293188 2.86E-05 AGAAACAATGTA
chr12 20828925 20829099 2.94E-05 GGAAACAAACAA
chr1 133716876 133717034 2.96E-05 AGAAACAAAAAG
chr17 15344966 15345538 2.96E-05 AGAAACAAAAAG
chr7 118226353 118226835 3.00E-05 gaaaacaaaaaa
chr11 11397628 11398506 3.00E-05 GGCAACAAAGGA
chr5 54893762 54893923 3.20E-05 agaaacatagaa
chr14 54880915 54881135 3.26E-05 AGCAACAAAGAG
chr4 154231384 154231576 3.26E-05 AGCAACAAAGAG
chrX 120405249 120406500 3.35E-05 AAAAACAAAAAC
chrX 120634626 120635877 3.35E-05 AAAAACAAAAAC
chr1 180252156 180252389 3.35E-05 AAAAACAAAAAC
chrX 122458051 122459744 3.35E-05 aaaaacaaaaac
chrX 121706644 121708339 3.35E-05 aaaaacaaaaac
chr12 20828925 20829099 3.39E-05 ACAAACAAACAA
chrY 2869581 2872285 3.39E-05 acaaacaaacaa
chrY 2869581 2872285 3.39E-05 acaaacaaacaa
chrY 2869581 2872285 3.39E-05 acaaacaaacaa
chrY 2869581 2872285 3.39E-05 acaaacaaacaa
chr15 5099576 5099919 3.39E-05 ACAAACAAACAA
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chr15 5099576 5099919 3.39E-05 ACAAACAAACAA
chr15 5099576 5099919 3.39E-05 ACAAACAAACAA
chr1 173012987 173014985 3.39E-05 ACAAACAAACAA
chr1 173012987 173014985 3.39E-05 ACAAACAAACAA
chr1 173012987 173014985 3.39E-05 ACAAACAAACAA
chr11 11397628 11398506 3.39E-05 acaaacaaacaa
chr11 11397628 11398506 3.39E-05 acaaacaaacaa
chr11 11397628 11398506 3.39E-05 acaaacaaacaa
chr11 101466103 101466410 3.48E-05 TGAGACAAAGAA
chr11 87239984 87240835 3.48E-05 TGAGACAAAGAA
chr7 108458149 108458626 3.53E-05 AGACACAAAGTA
chr7 108458149 108458626 3.53E-05 AGACACAAAGTA
chr7 108458149 108458626 3.53E-05 AGACACAAAGTA
chr7 108458149 108458626 3.53E-05 AGACACAAAGTA
chr7 108458149 108458626 3.53E-05 AGACACAAAGTA
chr7 108458149 108458626 3.53E-05 AGACACAAAGTA
chr13 21809473 21809969 3.53E-05 AAAAACACAGAA
chr9 25059849 25060024 3.56E-05 agaaaaaaagaa
chrX 30762714 30762936 3.56E-05 agaaaaaaagaa
chr15 38212163 38212414 3.56E-05 AGAAAAAAAGAA
chr17 80606473 80606939 3.56E-05 AGAAAAAAAGAA
chr17 15950608 15950912 3.59E-05 TGAAACAATGAA
chr5 113763814 113764285 3.62E-05 AGGAACAAAGGC
chrX 122458051 122459744 3.62E-05 AAAAAGAAAGGA
chrX 121706644 121708339 3.62E-05 AAAAAGAAAGGA
chrX 121577239 121578865 3.62E-05 AAAAAGAAAGGA
chr13 12366712 12366965 3.68E-05 AGGAACAAAGCA
chr15 101724635 101724846 3.70E-05 TGCAACAAAGTA
chr4 123369561 123369835 3.70E-05 TGCAACAAAGTA
chr17 75509211 75509527 3.70E-05 TGCAACAAAGTA
chr18 3004771 3005630 3.86E-05 AGAAAGAAAGAC
chr12 93036365 93036569 3.86E-05 TAGAACAAAGAA
chr13 52846109 52846573 3.94E-05 AGTAACAAAGGT
chr19 44076755 44076987 3.97E-05 aaagacaaagta
chr19 44076755 44076987 3.97E-05 AAAGACAAAGTA
chr1 192053952 192054194 4.03E-05 AGAAACAGAGAA
chr5 11220304 11220562 4.08E-05 ggaaacaaaaac
chr5 11881170 11881428 4.08E-05 ggaaacaaaaac
chr8 85884272 85884590 4.15E-05 AAAAAGAAAGTA
chr8 127528426 127529090 4.18E-05 GGAGACAAAGGA
chr8 127528426 127529090 4.18E-05 GGAGACAAAGGA
chr11 86887233 86887808 4.24E-05 AGCAACAAAGGG
chr17 15098409 15099907 4.24E-05 AAAAACAAAAAG
chr17 15161360 15162859 4.24E-05 AAAAACAAAAAG
chr17 15129992 15131491 4.24E-05 AAAAACAAAAAG
chr18 84588162 84588554 4.40E-05 AAAAACAAAACA
chr16 84647990 84648749 4.40E-05 AAAAACAAAACA
chr1 180252156 180252389 4.40E-05 AAAAACAAAACA
chr17 15344966 15345538 4.40E-05 AAAAACAAAACA
chr5 123453058 123453399 4.47E-05 CAGAACAAAGAA
chr17 87452962 87453212 4.49E-05 AGAAATAAAGAA
chr7 5543821 5543962 4.49E-05 AGAAATAAAGAA
chrX 120634626 120635877 4.49E-05 AGAAATAAAGAA
chrX 120405249 120406500 4.49E-05 AGAAATAAAGAA
chr4 17379647 17379762 4.57E-05 AGAAAAAAAGGA
chr4 125568410 125568787 4.63E-05 aaaaacatagaa
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chr9 41056175 41056341 4.65E-05 AGAGACAAAGAG
chr16 84647990 84648749 4.69E-05 ataaacaaaCAA
chr14 69799171 69799572 4.74E-05 GCCAACAAAGAA
chr16 84647990 84648749 4.83E-05 acaaaCAAAAAC
chr11 87239984 87240835 4.86E-05 ACACACAAAGAA
chr18 35803792 35803919 4.90E-05 AGAAAGAAAGAG
chr16 84647990 84648749 4.96E-05 CAAAACAAAAGA
chr9 120058537 120058711 4.96E-05 GGGAACAAAGAC
chr15 88568772 88569185 4.96E-05 CAAAACAAAAGA
chr14 120737186 120737476 4.96E-05 tttaacaAAGGA
chr13 66394389 66396325 5.03E-05 tagaacaaagga
chr7 108458149 108458626 5.11E-05 ACAAACAATGGA
chr13 66394389 66396325 5.15E-05 ataaacaaaata
chr9 25059849 25060024 5.20E-05 aaaaaaaaagaa
chr13 9833500 9833762 5.20E-05 AAAAAAAAAGAA
chr7 16994559 16994776 5.20E-05 AAAAAAAAAGAA
chrX 30762714 30762936 5.20E-05 aaaaaaaaagaa
chrY 2869581 2872285 5.20E-05 aaaaaaaaagaa
chr17 39979856 39985845 5.20E-05 aaaaaaaaagaa
chr17 39979856 39985845 5.20E-05 aaaaaaaaagaa
chr11 101466103 101466410 5.25E-05 ACAAAGAAAGGA
chr16 34671860 34672520 5.25E-05 AGAAACAAAAAT
chr9 75471052 75471301 5.27E-05 AAGAACAAAGGC
chr9 110989678 110990024 5.27E-05 AAGAACAAAGGC
chr12 5503370 5503761 5.32E-05 AGAAACAGAGGA
chr13 21842001 21842479 5.39E-05 AAAGACAAAGAC
chr3 96290119 96291035 5.39E-05 CAAAACAAACAA
chr2 98506338 98507542 5.39E-05 TAAAAGAAAGAA
chr12 5503370 5503761 5.39E-05 AAGAACAAAGCA
chr13 65967440 65968021 5.39E-05 TAAAAGAAAGAA
chr17 15344966 15345538 5.39E-05 CAAAACAAACAA
chr13 65552554 65553189 5.39E-05 taaaagaaagaa
chr3 96292179 96293188 5.39E-05 CAAAACAAACAA
chr17 14847569 14847759 5.47E-05 TGAAACAATGTA
chr12 55835205 55835592 5.47E-05 ACCAACAAAGAc
chr12 55814849 55815664 5.47E-05 ACCAACAAAGAC
chr3 58469472 58469815 5.51E-05 AAAAACAATGAC
chr7 5543821 5543962 5.66E-05 ATAAAGAAAGAA
chr11 121518509 121519059 5.66E-05 ATAAAGAAAGAA
chr11 32076000 32076214 5.66E-05 aaaaacaaaagg
chr9 120058537 120058711 5.73E-05 TGAAACAAAAAG
chr7 39352222 39353766 5.85E-05 AGCAACAAAGAT
chr7 39231479 39233273 5.85E-05 AGCAACAAAGAT
chr9 118647931 118648304 5.88E-05 TGTAACAAAGAT
chr8 83262886 83263555 6.01E-05 GGCAACAAAGGC
chr12 5503370 5503761 6.07E-05 ACAAAGAAAGTA
chrY 2869581 2872285 6.21E-05 ACAAACAAAAAG
chr3 58469948 58470228 6.29E-05 GGAAACAAAATC
chr16 34671860 34672520 6.29E-05 GCCAACAAAGGA
chr4 132994761 132995022 6.69E-05 AAAAATAAAGAA
chr4 149612437 149612864 6.69E-05 TAAGACAAAGGA
chr17 87452962 87453212 6.73E-05 AATAACAAAGTT
chr15 5099576 5099919 6.96E-05 ACAAACAAACAC
chr7 31306647 31307327 7.04E-05 ACCAACAAAGAG
chr11 32076000 32076214 7.12E-05 tctaacaaagag
chr9 59505862 59506188 7.12E-05 AAAGACAAAGGC
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chr1 173012987 173014985 7.16E-05 ACAAACAAATAA
chr3 68096244 68096863 7.47E-05 AAAAGCAAAGAA
chr13 51941709 51941925 7.50E-05 AAAAAGAAAGGC
chr1 194061545 194061791 7.50E-05 AAAAAGAAAGGC
chr3 23209200 23209294 7.65E-05 tgaaacaaaagg
chr13 51941709 51941925 7.65E-05 ACAAAAAAAGAA
chr11 87239984 87240835 7.65E-05 ACAAAAAAAGAA
chr2 98505008 98505437 7.70E-05 gaaaagaaagta
chr2 121962909 121963298 7.81E-05 TTTAACAAAGAC
chr11 11397628 11398506 7.92E-05 GGCAACAAAGGG
chr11 11397628 11398506 7.92E-05 ccaaacaaacaa
chr13 51941709 51941925 8.00E-05 AAAAAAAAAGTA
chr9 82869297 82869515 8.00E-05 GGAAACAAATGA
chr7 108458149 108458626 8.00E-05 TCCAACAAAGTA
chr5 14918464 14922081 8.14E-05 cgaaacaaaatc
chr1 169328474 169328599 8.49E-05 TAAAACAAAAAG
chr4 123369561 123369835 8.49E-05 GGGAACAAAGGG
chr15 88568772 88569185 8.49E-05 GGAAAAAAAGGA
chr3 96290119 96291035 8.89E-05 AGAAACTAAGAA
chr11 32076000 32076214 8.89E-05 aaaaataaagga
chr3 96292179 96293188 8.89E-05 AGAAACTAAGAA
chr5 14918464 14922081 8.95E-05 AAACACAAAGAG
chr16 36991075 36991339 9.08E-05 TGTAACAAagtt
chr7 120444291 120444522 9.17E-05 TGAAAAAAAGGA
chr7 120444291 120444522 9.17E-05 TGAAAAAAAGGA
chr7 120444291 120444522 9.17E-05 TGAAAAAAAGGA
chr7 120444291 120444522 9.17E-05 TGAAAAAAAGGA
chr7 120444291 120444522 9.17E-05 TGAAAAAAAGGA
chr12 19226266 19226526 9.30E-05 ATAAACAAAACA
chr13 56199754 56200260 9.41E-05 AAAAACAATGGG
chr13 56199754 56200260 9.41E-05 AAAAACAATGGG
chr13 56199754 56200260 9.41E-05 AAAAACAATGGG
chrY 2869581 2872285 9.41E-05 GCAAACACAGAA
chr16 34671860 34672520 9.49E-05 AGAAAAAAAGAG
chr3 52059270 52059807 9.49E-05 ttaaacaaacaa
chr17 39979856 39985845 9.58E-05 gaaaaaaaagaa
chr18 3004771 3005630 9.69E-05 AAAAAGAAAGGG
chr17 14847569 14847759 9.93E-05 TGAAACAATGCA
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3.2 drAAACAATGka
chr start stop p-value matched_sequence
chr13 12366712 12366965 1.02E-07 AGAAACAATGTA
chr3 96292179 96293188 1.02E-07 AGAAACAATGTA
chr3 96290119 96291035 1.02E-07 AGAAACAATGTA
chr17 14847569 14847759 4.38E-07 TGAAACAATGTA
chr17 15950608 15950912 1.76E-06 TGAAACAATGAA
chr7 108458149 108458626 3.04E-06 ACAAACAATGGA
chr17 14847569 14847759 3.79E-06 TGAAACAATGCA
chr13 56199754 56200260 4.84E-06 AAAAACAATGGG
chr13 56199754 56200260 4.84E-06 AAAAACAATGGG
chr16 84975160 84975506 4.84E-06 AAAAACAATGTT
chr13 56199754 56200260 4.84E-06 AAAAACAATGGG
chr12 112341390 112341756 5.62E-06 GAAAACAATGTT
chr3 144408324 144408651 7.22E-06 AGTAACAATGTA
chr3 58469472 58469815 9.19E-06 AAAAACAATGAC
chr3 69490627 69490976 9.19E-06 CCAAACAATGGA
chr11 22170490 22170823 1.03E-05 agcaacaatgta
chr11 22170490 22170823 1.03E-05 agcaacaatgta
chr11 22170490 22170823 1.03E-05 agcaacaatgta
chr19 57565272 57565511 1.03E-05 AGCAACAATGTA
chr11 22170490 22170823 1.03E-05 agcaacaatgta
chr11 22170490 22170823 1.03E-05 agcaacaatgta
chr11 22170490 22170823 1.03E-05 agcaacaatgta
chr11 22170490 22170823 1.03E-05 agcaacaatgta
chr11 22170490 22170823 1.03E-05 agcaacaatgta
chr11 22170490 22170823 1.03E-05 agcaACAATGTA
chr15 87797353 87797527 1.05E-05 GAAAACAATGAC
chr14 121483899 121484504 1.09E-05 GCAAACAATGGC
chr14 121483899 121484504 1.09E-05 GCAAACAATGGC
chr14 121483899 121484504 1.09E-05 GCAAACAATGGC
chr14 121483899 121484504 1.09E-05 GCAAACAATGGC
chr14 121483899 121484504 1.09E-05 GCAAACAATGGC
chr14 121483899 121484504 1.09E-05 GCAAACAATGGC
chr14 121483899 121484504 1.09E-05 GCAAACAATGGC
chr14 121483899 121484504 1.09E-05 GCAAACAATGGC
chr14 121483899 121484504 1.09E-05 GCAAACAATGGC
chr3 152996314 152997030 1.18E-05 AGATACAATGTA
chr3 152996314 152997030 1.18E-05 AGATACAATGTA
chr19 44076755 44076987 1.18E-05 AGATACAATGTA
chr3 152996314 152997030 1.18E-05 AGATACAATGTA
chr19 44076755 44076987 1.18E-05 AGATACAATGTA
chr3 152996314 152997030 1.18E-05 AGATACAATGTA
chr3 152996314 152997030 1.18E-05 AGATACAATGTA
chr3 152996314 152997030 1.18E-05 AGATACAATGTA
chr3 152996314 152997030 1.18E-05 AGATACAATGTA
chr3 152996314 152997030 1.18E-05 AGATACAATGTA
chr4 125568410 125568787 1.25E-05 CAAAACAATGTT
chr7 91561750 91562035 1.31E-05 AGATACAATGGA
chr7 91561750 91562035 1.31E-05 AGATACAATGGA
chr7 91561750 91562035 1.31E-05 AGATACAATGGA
chr7 91561750 91562035 1.31E-05 AGATACAATGGA
chr7 91561750 91562035 1.31E-05 AGATACAATGGA
chr9 49183419 49183597 1.33E-05 GGATACAATGTA
3 SOX Motif Regions 
231
chr4 101763903 101764474 1.33E-05 AGAAACAGTGTA
chr4 101763903 101764474 1.33E-05 AGAAACAGTGTA
chr4 101763903 101764474 1.33E-05 AGAAACAGTGTA
chr4 101763903 101764474 1.33E-05 AGAAACAGTGTA
chr4 101763903 101764474 1.33E-05 AGAAACAGTGTA
chr4 101763903 101764474 1.33E-05 AGAAACAGTGTA
chr4 101763903 101764474 1.33E-05 AGAAACAGTGTA
chr16 95979203 95979519 1.37E-05 TGCAACAATGTA
chr16 95979203 95979519 1.49E-05 TGCAACAATGGA
chr8 119567477 119567793 1.52E-05 TGATACAATGTA
chr3 68096244 68096863 1.52E-05 TGATACAATGTA
chr8 31438279 31438743 1.75E-05 AACAACAATGGA
chr2 57246848 57247325 1.94E-05 AGTAACAATGGC
chr2 57246848 57247325 1.94E-05 AGTAACAATGGC
chr2 57246848 57247325 1.94E-05 AGTAACAATGGC
chr2 57246848 57247325 1.94E-05 AGTAACAATGGC
chr4 8154834 8155634 1.97E-05 gacaacaatgga
chr8 31438279 31438743 2.00E-05 AGTAACAATGGG
chr11 108872866 108873417 2.05E-05 TGGAACAATGTA
chr7 108458149 108458626 2.11E-05 AGACACAATGTA
chr13 52846109 52846573 2.21E-05 GGTAACAATGGC
chr8 127528426 127529090 2.27E-05 TGGAACAATGGA
chr10 89139305 89139721 2.27E-05 TGGAACAATGGA
chr8 127528426 127529090 2.27E-05 TGGAACAATGGA
chr10 9467362 9467556 2.36E-05 CAAAACAATGAT
chrY 2869581 2872285 2.40E-05 GGACACAATGTA
chr19 57565272 57565511 2.45E-05 CCAAACAATGGT
chr9 110989678 110990024 2.47E-05 GGATACAATGAA
chr17 15950608 15950912 2.51E-05 AGAAACAGTGAA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
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chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr6 116201111 116202043 2.52E-05 GAAAACAGTGGA
chr16 84975160 84975506 2.63E-05 AGCAACAATGTT
chr16 84975160 84975506 2.63E-05 AGCAACAATGTT
chr4 123369561 123369835 2.68E-05 agatacaatgtg
chr18 81797204 81797484 2.69E-05 AGAAACACTGTA
chr18 81797204 81797484 2.69E-05 AGAAACACTGTA
chr18 81797204 81797484 2.69E-05 AGAAACACTGTA
chr16 95979203 95979519 2.72E-05 TGTAACAATGCA
chr15 87797353 87797527 2.89E-05 GGCAACAATGTT
chr17 33811718 33812117 2.89E-05 GGCAACAATGTT
chr7 91561750 91562035 2.89E-05 AGATACAATGTT
chr4 3429671 3429955 2.97E-05 GAGAACAATGGA
chr6 83530301 83530768 3.17E-05 AAACACAATGTA
chr16 36991075 36991339 3.22E-05 GGATACAATGTT
chr19 21581779 21582122 3.36E-05 TGCAACAATGTT
chr15 82725119 82725439 3.40E-05 GATAACAATGTT
chr3 146005710 146006075 3.40E-05 TGATACAATGTG
chr9 19029130 19029345 3.74E-05 GTAAACAATGAT
chr1 192053952 192054194 3.79E-05 TGGAACAATGAA
chr1 88617661 88617989 3.85E-05 TATAACAATGGC
chr1 88617661 88617989 3.85E-05 TATAACAATGGC
chr1 88617661 88617989 3.85E-05 TATAACAATGGC
chr1 88617661 88617989 3.85E-05 TATAACAATGGC
chr17 15950608 15950912 3.85E-05 TACAACAATGAA
chr1 88617661 88617989 3.85E-05 TATAACAATGGC
chr1 88617661 88617989 3.85E-05 TATAACAATGGC
chr1 88617661 88617989 3.85E-05 TATAACAATGGC
chr17 84581105 84581330 3.98E-05 AGGAACAATGGG
chr15 88568772 88569185 3.98E-05 TTAAACAATGAG
chr5 28661168 28661314 4.04E-05 AACAACAATGTT
chr5 28661168 28661314 4.04E-05 AACAACAATGTT
chr5 28661168 28661314 4.04E-05 AACAACAATGTT
chr5 28661168 28661314 4.04E-05 AACAACAATGTT
chr11 87261721 87262640 4.04E-05 AACAACAATGTT
chr1 88422999 88423418 4.17E-05 AGGAACAATGCA
chr8 31438279 31438743 4.18E-05 AACAACAATGCA
chr12 19226266 19226526 4.29E-05 TGAAACAGTGTT
chr4 114943768 114943896 4.37E-05 ggacacaatgaa
chr4 114986056 114986184 4.37E-05 GGACACAATGAA
chr1 72290738 72291074 4.41E-05 GGGAACAATGTT
chr16 84975160 84975506 4.43E-05 AACAACAATGGT
chr5 72438606 72438857 4.49E-05 GAATACAATGTG
chr16 84975160 84975506 4.55E-05 AAGAACAATGAA
chr16 22672855 22673155 4.57E-05 GGAAAAAATGGA
chr3 124418625 124418909 4.82E-05 AGCAACAATGAT
chr3 124418625 124418909 4.82E-05 AGCAACAATGAT
chr3 124418625 124418909 4.82E-05 AGCAACAATGAT
chr3 124418625 124418909 4.82E-05 AGCAACAATGAT
chr3 124418625 124418909 4.82E-05 AGCAACAATGAT
chr18 76613456 76613637 4.87E-05 AGATACAATGAG
chr5 14918464 14922081 4.91E-05 AGAAACACTGAA
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chr12 20828925 20829099 4.94E-05 GAAAACACTGGA
chr4 101763903 101764474 5.05E-05 AGAAACAAAGTA
chr12 5503370 5503761 5.05E-05 AGAAACAAAGTA
chr10 12273996 12274342 5.46E-05 ACACACAATGTA
chr15 11259966 11260124 5.53E-05 ATATACAATGTA
chr13 12366712 12366965 5.53E-05 AGAAACAAAGGA
chr10 61591506 61591858 5.59E-05 GGAAACAAAGTA
chr17 13911136 13911387 5.59E-05 GGAAACAAAGTA
chr8 25462270 25462920 5.59E-05 GAAAACAGTGTT
chr1 136920453 136920843 5.69E-05 CAGAACAATGGA
chr17 87452962 87453212 5.69E-05 CAGAACAATGGA
chr10 4930547 4930938 5.71E-05 GGACACAATGTT
chrY 2869581 2872285 5.71E-05 GGACACAATGGG
chr14 54880915 54881135 5.84E-05 AAGAACAATGGC
chr11 87236084 87236908 5.84E-05 AAGAACAATGGC
chr18 81797204 81797484 5.87E-05 AGAAACACTGTG
chr12 113338413 113338652 6.13E-05 GGAAACAAAGGA
chr11 121518509 121519059 6.32E-05 TTCAACAATGTA
chr4 125568410 125568787 6.39E-05 tgaaacaaagta
chr17 15950608 15950912 6.60E-05 TCCAACAATGAA
chr3 96163525 96164181 6.64E-05 TCTAACAATGTT
chr3 96177802 96178458 6.64E-05 TCTAACAATGTT
chr3 146005710 146006075 6.70E-05 GCACACAATGGA
chr3 93518698 93518941 6.86E-05 ggaaacaatata
chr13 70231949 70232253 7.21E-05 TGAAACATTGTA
chr2 22443076 22443924 7.35E-05 TGAAACACTGTC
chr1 24618332 24623038 7.35E-05 TGAAACACTGTC
chr9 41056175 41056341 7.40E-05 CGGAACAATGTG
chr9 41056175 41056341 7.75E-05 GTTAACAATGAA
chr5 11829495 11829872 7.75E-05 TTATACAATGGA
chr5 11400416 11400736 7.75E-05 TTATACAATGGA
chr2 162688176 162688554 7.79E-05 agctacaatgta
chr2 131233744 131234170 7.84E-05 AGAAACAATTTA
chr9 110989678 110990024 8.77E-05 TTTAACAATGAA
chr1 141954325 141954737 8.90E-05 AATTACAATGTA
chr19 34812509 34812659 8.95E-05 AGAAACAAAGAA
chr9 59505862 59506188 8.95E-05 AGAAACAAAGAA
chr6 83417694 83418110 9.02E-05 GCATACAATGGT
chr13 52846109 52846573 9.21E-05 GAAAACATTGTA
chr14 118206572 118206838 9.26E-05 AGAAACAAGGGA
chr3 68096244 68096863 9.42E-05 AAAATCAATGGA
chr5 143579353 143579517 9.68E-05 GGGAACAATGCG
chr18 84588162 84588554 9.73E-05 TGCTACAATGTA
chr5 16974433 16975269 9.73E-05 TGCTACAATGTA
chr5 14918464 14922081 9.73E-05 tgctacaatgta
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3.3 awACAAAGwa
chr start stop p-value matched_sequence
chr19 44076755 44076987 2.69E-06 agacaaagta
chr19 44076755 44076987 2.69E-06 AGACAAAGTA
chr7 108458149 108458626 2.69E-06 ACACAAAGTA
chr7 108458149 108458626 2.69E-06 ACACAAAGTA
chr7 108458149 108458626 2.69E-06 ACACAAAGTA
chr7 108458149 108458626 2.69E-06 ACACAAAGTA
chr7 108458149 108458626 2.69E-06 ACACAAAGTA
chr7 108458149 108458626 2.69E-06 ACACAAAGTA
chr4 101763903 101764474 4.34E-06 AAACAAAGTA
chr10 61591506 61591858 4.34E-06 AAACAAAGTA
chr12 5503370 5503761 4.34E-06 AAACAAAGTA
chr17 13911136 13911387 4.34E-06 AAACAAAGTA
chr4 125568410 125568787 4.34E-06 aaacaaagta
chr17 10380494 10380692 5.98E-06 ATACAAAGTA
chr10 80827990 80829989 8.19E-06 CCACAAAGTA
chr15 101724635 101724846 9.54E-06 CAACAAAGTA
chr4 123369561 123369835 9.54E-06 CAACAAAGTA
chr7 108458149 108458626 9.54E-06 CAACAAAGTA
chr17 75509211 75509527 9.54E-06 CAACAAAGTA
chr18 84588162 84588554 1.09E-05 CTACAAAGTA
chr14 121483899 121484504 1.09E-05 CTACAAAGTA
chr14 121483899 121484504 1.09E-05 CTACAAAGTA
chr14 121483899 121484504 1.09E-05 CTACAAAGTA
chr14 121483899 121484504 1.09E-05 CTACAAAGTA
chr14 121483899 121484504 1.09E-05 CTACAAAGTA
chr14 121483899 121484504 1.09E-05 CTACAAAGTA
chr11 101466103 101466410 1.36E-05 AGACAAAGAA
chr4 8154834 8155634 1.36E-05 agacaaagaa
chrX 113580034 113580205 1.36E-05 ACACAAAGAA
chr4 8154834 8155634 1.36E-05 agacaaagaa
chr4 8154834 8155634 1.36E-05 agacaaagaa
chr4 8154834 8155634 1.36E-05 agacaaagaa
chr4 8154834 8155634 1.36E-05 agacaaagaa
chr11 87239984 87240835 1.36E-05 AGACAAAGAA
chr4 8154834 8155634 1.36E-05 agacaaagaa
chr4 8154834 8155634 1.36E-05 agacaaagaa
chr4 8154834 8155634 1.36E-05 agacaaagaa
chr4 8154834 8155634 1.36E-05 agacaaagaa
chr11 87239984 87240835 1.36E-05 ACACAAAGAA
chr11 87275408 87276317 1.36E-05 ACACAAAGAA
chr19 34812509 34812659 1.52E-05 AAACAAAGAA
chr9 59505862 59506188 1.52E-05 AAACAAAGAA
chr2 121962909 121963298 1.52E-05 AAACAAAGAA
chrX 30762714 30762936 1.69E-05 atacaaagaa
chr19 57565272 57565511 1.69E-05 ATACAAAGAA
chr6 145881183 145881640 1.91E-05 GGACAAAGTA
chr8 127528426 127529090 2.40E-05 AGACAAAGGA
chr8 127528426 127529090 2.40E-05 AGACAAAGGA
chr4 149612437 149612864 2.40E-05 AGACAAAGGA
chr1 136457440 136457676 2.40E-05 ACACAAAGGA
chr1 192053952 192054194 2.53E-05 AAACAAAGGA
chr12 113338413 113338652 2.53E-05 AAACAAAGGA
3 SOX Motif Regions 
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chr13 12366712 12366965 2.53E-05 AAACAAAGGA
chr15 5099576 5099919 2.89E-05 CCACAAAGAA
chrX 120634626 120635877 2.89E-05 CCACAAAGAA
chrX 120405249 120406500 2.89E-05 CCACAAAGAA
chr14 69799171 69799572 3.02E-05 CAACAAAGAA
chr17 15950608 15950912 3.02E-05 CAACAAAGAA
chr9 75471052 75471301 3.16E-05 CTACAAAGAA
chr3 52059270 52059807 3.43E-05 TCACAAAGTA
chr15 101724635 101724846 3.43E-05 tcacaaagta
chr6 83417694 83418110 3.43E-05 TGACAAAGTA
chrX 120405249 120406500 3.43E-05 TCACAAAGTA
chrX 120634626 120635877 3.43E-05 TCACAAAGTA
chr13 66394389 66396325 3.43E-05 TCACAAAGTA
chr3 144408324 144408651 3.59E-05 TAACAAAGTA
chr3 144467409 144467757 3.59E-05 TAACAAAGTA
chr3 144408324 144408651 3.59E-05 TAACAAAGTA
chr3 144467409 144467757 3.59E-05 TAACAAAGTA
chr2 34611014 34611361 3.59E-05 TAACAAAGTA
chr9 41056175 41056341 3.59E-05 TAACAAAGTA
chr3 144408324 144408651 3.59E-05 TAACAAAGTA
chr3 144408324 144408651 3.59E-05 TAACAAAGTA
chr3 144408324 144408651 3.59E-05 TAACAAAGTA
chr3 144467409 144467757 3.59E-05 TAACAAAGTA
chr3 144408324 144408651 3.59E-05 TAACAAAGTA
chr3 144467409 144467757 3.59E-05 TAACAAAGTA
chr3 144408324 144408651 3.59E-05 TAACAAAGTA
chr3 144408324 144408651 3.59E-05 TAACAAAGTA
chr3 144467409 144467757 3.59E-05 TAACAAAGTA
chr11 105301298 105301520 3.76E-05 TTACAAAGTA
chr9 59505862 59506188 3.76E-05 TTACAAAGTA
chr16 84647990 84648749 3.76E-05 TTACAAAGTA
chr4 101763903 101764474 3.98E-05 GGACAAAGAA
chr11 11397628 11398506 3.98E-05 GGACAAAGAA
chr7 108789576 108789755 3.98E-05 GGACAAAGAA
chr16 84647990 84648749 3.98E-05 GCACAAAGAA
chr5 14918464 14922081 3.98E-05 gcacaaagaa
chr17 80606473 80606939 3.98E-05 GCACAAAGAA
chr6 83417694 83418110 3.98E-05 GGACAAAGAA
chr11 76191172 76191993 3.98E-05 GCACAAAGAA
chr5 123453058 123453399 4.11E-05 GAACAAAGAA
chr12 93036365 93036569 4.11E-05 GAACAAAGAA
chr12 112341390 112341756 4.11E-05 GAACAAAGAA
chr12 5503370 5503761 4.11E-05 GAACAAAGAA
chr11 76148608 76148883 4.43E-05 ccacaaagga
chr11 76191172 76191993 4.43E-05 ccacaaagga
chr11 76148608 76148883 4.43E-05 CCACAAAGGA
chr14 57315836 57316043 4.43E-05 CCACAAAGGA
chr11 11397628 11398506 4.54E-05 CAACAAAGGA
chr16 34671860 34672520 4.54E-05 CAACAAAGGA
chr4 153394885 153395163 4.65E-05 CTACAAAGGA
chr2 80302072 80302264 4.65E-05 CTACAAAGGA
chr5 66330250 66330572 4.83E-05 GGACAAAGGA
chr5 108295958 108296386 4.83E-05 ggacaaagga
chr11 76191172 76191993 4.83E-05 gcacaaagga
chr11 76191172 76191993 4.83E-05 GCACAAAGGA
chr11 70729707 70729900 4.94E-05 GAACAAAGGA
236
chr12 112341390 112341756 4.94E-05 GAACAAAGGA
chr13 66394389 66396325 4.94E-05 gaacaaagga
chr16 72258386 72258542 5.05E-05 GTACAAAGGA
chr12 112341390 112341756 5.05E-05 GTACAAAGGA
chr11 76191172 76191993 5.05E-05 GTACAAAGGA
chrX 113580034 113580205 5.32E-05 TGACAAAGAA
chrX 122458051 122459744 5.32E-05 TGACAAAGAA
chrX 121706644 121708339 5.32E-05 TGACAAAGAA
chrX 121577239 121578865 5.32E-05 TGACAAAGAA
chr14 54880915 54881135 5.32E-05 TGACAAAGAA
chr11 108872866 108873417 5.32E-05 tcacaaagaa
chr1 136920453 136920843 5.49E-05 taacaaagaa
chr15 25143986 25144140 5.49E-05 taacaaagaa
chr2 3356844 3357148 5.87E-05 ACACAAAGTC
chr2 3356844 3357148 5.87E-05 ACACAAAGTC
chr2 3356844 3357148 5.87E-05 ACACAAAGTC
chr2 3356844 3357148 5.87E-05 ACACAAAGTC
chr2 3356844 3357148 5.87E-05 ACACAAAGTC
chr2 3356844 3357148 5.87E-05 ACACAAAGTC
chr4 3429671 3429955 6.01E-05 AAACAAAGTC
chr13 24025614 24026204 6.36E-05 TCACAAAGGA
chr14 120737186 120737476 6.50E-05 taacaAAGGA
chr11 11397628 11398506 6.50E-05 TAACAAAGGA
chr17 71834308 71834443 6.85E-05 acacaaagtg
chr15 38212163 38212414 6.85E-05 AGACAAAGTG
chr9 75471052 75471301 6.85E-05 AGACAAAGTG
chr12 55838910 55839950 7.30E-05 CCACAAAGTC
chr19 29703448 29703901 7.30E-05 CCACAAAGTC
chr19 29703448 29703901 7.30E-05 CCACAAAGTC
chr12 55810882 55811993 7.30E-05 CCACAAAGTC
chr13 21842001 21842479 7.75E-05 AGACAAAGAC
chr18 35815494 35815670 7.75E-05 AGACAAAGAC
chr6 68200903 68201280 7.75E-05 agacaaagac
chr4 46596519 46596890 7.75E-05 agacaaagac
chrX 122458051 122459744 7.88E-05 AAACAAAGAC
chrX 121706644 121708339 7.88E-05 AAACAAAGAC
chrX 121577239 121578865 7.88E-05 AAACAAAGAC
chr17 13911136 13911387 7.88E-05 AAACAAAGAC
chr9 115695410 115695590 8.02E-05 ATACAAAGAC
chr12 55819723 55820200 8.64E-05 AGACAAAGCA
chr2 146335546 146336272 8.64E-05 ACACAAAGCA
chr12 55830120 55831178 8.64E-05 AGACAAAGCA
chr9 59505862 59506188 9.09E-05 AGACAAAGGC
chr9 120058537 120058711 9.38E-05 AAACAAAGGC
chr7 39231479 39233273 9.61E-05 CAACAAAGTG
chr3 103897340 103897866 9.72E-05 ctacaaagtg
chr15 82725119 82725439 9.72E-05 ctacaaagtg
chr17 13911136 13911387 9.72E-05 CTACAAAGTG
chr18 3004771 3005630 9.72E-05 CTACAAAGTG
chr18 81797204 81797484 9.94E-05 AGACAAAGAG
chr9 120058537 120058711 9.94E-05 AGACAAAGAG
chr9 41056175 41056341 9.94E-05 AGACAAAGAG
chr4 154231384 154231576 9.94E-05 AGACAAAGAG
chr11 87239984 87240835 9.94E-05 ACACAAAGAG
chr5 14918464 14922081 9.94E-05 ACACAAAGAG
237
chr start stop nearest gene (distance to TSS)
chr19 34812509 34812659 Slc16a12 (+9195), Ifit1 (+97223)
chr9 59505862 59506188 Gramd2 (-49419), Pkm (+1642)
chr13 12366712 12366965 Mtr (-16572), Actn2 (+66188)
chr4 101763903 101764474 Pde4b (-163419), Gm12789 (+104958)
chr12 5503370 5503761 2810032G03Rik (+85119)
chr2 121962909 121963298 Spg11 (-18982), B2m (-10318)
chrX 122458051 122459744 4932411N23Rik (+891718)
chrX 121706644 121708339 Vmn2r121 (-457973)
chrX 121577239 121578865 Vmn2r121 (-328533)
chr12 113338413 113338652 BC048943 (-119571), Aspg (-6361)
chr10 61591506 61591858 Neurog3 (-4156)
chr17 13911136 13911387 Gm7168 (-174118), Mllt4 (+13707)
chr4 125568410 125568787 Csf3r (-133195), Grik3 (+400655)
chr4 3429671 3429955 Vmn1r3 (-317308), Tmem68 (+72187)
chr9 120058537 120058711 Mobp (-236)
chr1 192053952 192054194 Prox1 (-59514), Rps6kc1 (+681576)
chr3 93518698 93518941 Tdpoz4 (-81500), S100a10 (+159818)
chr16 95979203 95979519 Ets2 (+55679), Psmg1 (+233206)
chr11 76148608 76148883 Glod4 (-91519), Nxn (+63896)
chr1 136920453 136920843 Ube2t (+61506), Lgr6 (+81205)
chr9 41056175 41056341 Ubash3b (-90113), Sorl1 (+876122)
chr3 144408324 144408651 Sh3glb1 (-25201), Clca1 (+15317)
chr3 144467409 144467757 Clca1 (-43778), Clca2 (+14875)
chr11 121518509 121519059 Zfp750 (-138137), B3gntl1 (+15683)
chr10 89139305 89139721 Slc17a8 (-55515), Scyl2 (+9517)
chr6 83530301 83530768 Stambp (-8037), Clec4f (+75646)
chr11 11397628 11398506 4930415F15Rik (+8798), 4930512M02Rik (+129760)
chr11 87275408 87276317 Gm11492 (-104292), Tex14 (+57296)
chr11 87239984 87240835 Gm11492 (-139745), Tex14 (+21843)
chr5 14918464 14922081 Gm9758 (-5374), Speer4e (+18156)
chr14 120737186 120737476 Rap2a (-140335), Mbnl2 (+62402)
chr18 35803792 35803919 Slc23a1 (-16958), Mzb1 (+5165)
chr2 34611014 34611361 Gapvd1 (-25021), Hspa5 (-16424)
chrX 166438853 166447041 4933400A11Rik (-225380)
chr1 173012987 173014985 1700009P17Rik (-37806), Fcgr3 (-24452)
chr9 110428485 110429550 Setd2 (-6083), Kif9 (+49520)
chr12 20828925 20829099 1700030C10Rik (-7424), Zfp125 (+77716)
chrY 2869581 2872285 Gm10352 (+480543)
chr2 146335546 146336272 Ralgapa2 (+1831), Insm1 (+288252)
chr17 15950608 15950912 Rgmb (+12790), Chd1 (+108829)
chr15 25143986 25144140 9230109A22Rik (-65149), Basp1 (+199456)
chr9 65049332 65049789 Parp16 (-13393), Igdcc3 (+60600)
chr11 70729707 70729900 Nup88 (+53660), Rabep1 (+71524)
chr12 112341390 112341756 Traf3 (-63101), Rcor1 (+63748)
chr11 69571960 69572257 Polr2a (+30)
chr9 25059849 25060024 Sept7 (-232)
chr17 39979856 39985845 Gm7148 (-269450)
chr3 96290119 96291035 Hfe2 (-38531), BC107364 (-34348)
chr3 96292179 96293188 BC107364 (-36455), Hfe2 (-36424)
chr1 133716876 133717034 Slc41a1 (-7599), Pm20d1 (+22997)
chr17 15344966 15345538 2210404J11Rik (+166647), Dll1 (+167688)
chr7 118226353 118226835 Eif4g2 (-50)
chr5 54893762 54893923 Stim2 (+504187)
chr14 54880915 54881135 Abhd4 (+2118), Olfr49 (+21575)
4 Regions containing 1 or more SOX Motif
238
chr4 154231384 154231576 Mmel1 (-14258), Ttc34 (+1171)
chrX 120405249 120406500 Srsx (-69785), Vmn2r121 (+843644)
chrX 120634626 120635877 Srsx (-299162), Vmn2r121 (+614267)
chr1 180252156 180252389 Cox20 (+3012), Hnrnpu (+15655)
chr15 5099576 5099919 Ttc33 (-35812), Prkaa1 (+5887)
chr11 101466103 101466410 Rdm1 (-22999), Tmem106a (+22701)
chr7 108458149 108458626 Atg16l2 (-7786), Stard10 (-7212)
chr13 21809473 21809969 Hist1h2bm (-4192), Hist1h3h (+224)
chrX 30762714 30762936 Gm21637 (-60425), Gm2799 (+164429)
chr15 38212163 38212414 Klf10 (+18173), Odf1 (+63331)
chr17 80606473 80606939 Srsf7 (-686), Ttc39d (-94)
chr5 113763814 113764285 Sgsm1 (-24244), Aym1 (-22264)
chr15 101724635 101724846 Krt76 (-1390)
chr4 123369561 123369835 Macf1 (-8095), Ndufs5 (+25747)
chr17 75509211 75509527 Rasgrp3 (-355509), Ltbp1 (+104461)
chr18 3004771 3005630 Vmn1r238 (+118264)
chr12 93036365 93036569 Ston2 (-11591), Sel1l (+51130)
chr13 52846109 52846573 Syk (+167799), Auh (+178689)
chr19 44076755 44076987 Cpn1 (-15825), Cyp2c44 (+26866)
chr5 11220304 11220562 4933402N22Rik (-374523), Gm5861 (+37361)
chr5 11881170 11881428 Sema3d (-501867), 4933402N22Rik (+286343)
chr8 85884272 85884590 Clgn (-29346), 4933434I20Rik (+12061)
chr8 127528426 127529090 Egln1 (-55604), Tsnax (-8139)
chr11 86887233 86887808 Gdpd1 (+43)
chr17 15098409 15099907 Phf10 (-921)
chr17 15161360 15162859 9030025P20Rik (+14910), Tcte3 (+16413)
chr17 15129992 15131491 Gm3435 (+14913), Gm3417 (+16406)
chr18 84588162 84588554 Zfp407 (+170538), Zadh2 (+330808)
chr16 84647990 84648749 Mrpl39 (+87617)
chr5 123453058 123453399 Kdm2b (-14121), Orai1 (-11854)
chr17 87452962 87453212 Gm5499 (-24524), Cript (+28197)
chr7 5543821 5543962 Vmn1r62 (-82337), Vmn1r60 (-47161)
chr4 17379647 17379762 Mmp16 (-400900)
chr14 69799171 69799572 Nkx3-1 (-9323), Nkx2-6 (+9739)
chr15 88568772 88569185 Brd1 (-4316)
chr13 66394389 66396325 Vmn2r-ps104 (+60964), 2610044O15Rik8 (+256118)
chr13 9833500 9833762 Zmynd11 (-69225), Chrm3 (+44698)
chr7 16994559 16994776 Tmem160 (-43460), Zc3h4 (+8438)
chr16 34671860 34672520 Ccdc14 (-18512), Ropn1 (+20916)
chr9 75471052 75471301 Lysmd2 (-2362)
chr9 110989678 110990024 Lrrfip2 (-30764), Ccrl2 (-30077)
chr13 21842001 21842479 Hist1h4k (+134)
chr2 98506338 98507542 Gm10800 (+518)
chr13 65967440 65968021 Gm10772 (-39856), Gm10139 (+354117)
chr13 65552554 65553189 Gm10139 (-60742), Zfp369 (+172750)
chr17 14847569 14847759 Thbs2 (-16395), Wdr27 (+223994)
chr12 55835205 55835592 Eapp (-38531), Snx6 (+61291)
chr12 55814849 55815664 Eapp (-18389), Snx6 (+81433)
chr3 58469472 58469815 Fam194a (-28515), Siah2 (+26678)
chr11 32076000 32076214 Il9r (+24129), Nsg2 (+175644)
chr7 39352222 39353766 Gm5591 (-39782)
chr7 39231479 39233273 Pop4 (-176009), Gm5591 (+80836)
chr9 118647931 118648304 Ctdspl (-187453), Itga9 (+132310)
chr8 83262886 83263555 Smarca5 (+175)
chr3 58469948 58470228 Fam194a (-28959), Siah2 (+26234)
chr4 132994761 132995022 Fam46b (-41155), Slc9a1 (+69271)
239




31307327 Arhgap33 (+13092), Prodh2 (+28346) 
68096863 Il12a (-398012), Schip1 (+227690) 
51941925 Gadd45g (-230)
chr1 194061545 194061791 Kcnh1 (+47002), Hhat (+535739)
chr3 23209200 23209294 NONE
chr2 98505008 98505437 Gm10800 (+2235), Gm10801 (+2829)
chr9 82869297 82869515 Phip (-310)
chr1 169328474 169328599 Mgst3 (-4565)
chr16 36991075 36991339 Fbxo40 (-654)
chr7 120444291 120444522 Btbd10 (+68446), Arntl (+93428)
chr12 19226266 19226526 Gm5784 (-167269), 5730507C01Rik (+704852)
chr13 56199754 56200260 Pitx1 (-267221), H2afy (+36985)
chr3 52059270 52059807 Maml3 (-150726), Foxo1 (-12720)
chr16 84975160 84975506 Atp5j (-139463), App (+198615)
chr3 69490627 69490976 B3galnt1 (-88019), Nmd3 (-35105)
chr11 22170490 22170823 Otx1 (-269039), Ehbp1 (+15184)
chr19 57565272 57565511 Atrnl1 (-120132), Trub1 (+37996)
chr15 87797353 87797527 Zdhhc25 (-633305), Fam19a5 (+422536)
chr14 121483899 121484504 Farp1 (+49416), Stk24 (+294354)
chr3 152996314 152997030 St6galnac5 (-351462), St6galnac3 (+391354)
chr7 91561750 91562035 Arnt2 (-3424)
chr9 49183419 49183597 Drd2 (+34776), Ankk1 (+51618)
chr8 119567477 119567793 Gcsh (-50198), Pkd1l2 (+38714)
chr8 31438279 31438743 Dusp26 (-761432)
chr2 57246848 57247325 Galnt5 (-603208), Gpd2 (+156379)
chr4 8154834 8155634 Car8 (+10954)
chr11 108872866 108873417 Axin2 (+91479), E030025P04Rik (+132541)
chr10 9467362 9467556 Samd5 (-72453), Stxbp5 (+153418)
chr6 116201111 116202043 Zfand4 (-12663), Fam21 (+43526)
chr18 81797204 81797484 Sall3 (-614027), Galr1 (+778825)
chr17 33811718 33812117 Hnrnpm (+11887), Pram1 (+36917)
chr19 21581779 21582122 Gm3443 (-48213), Gda (-34789)
chr15 82725119 82725439 Cyp2d26 (-100604), Tcf20 (+17285)
chr3 146005710 146006075 Ssx2ip (-61713), Lpar3 (+121968)
chr9 19029130 19029345 Olfr843 (+24669), Olfr836 (+103837)
chr1 88617661 88617989 Dis3l2 (+17446), Alppl2 (+368678)
chr17 84581105 84581330 Haao (-335088), Zfp36l2 (+6069)
chr5 28661168 28661314 Evc2 (-9068497), Rbm33 (+17512), Shh (+132400)
chr11 87261721 87262640 Gm11492 (-117974), Tex14 (+43614)
chr1 88422999 88423418 Ptma (-102)
chr4 114943768 114943896 Cyp4x1 (-137250), Cyp4a12a (-27819)
chr4 114986056 114986184 Cyp4a12b (-98109), Cyp4a12a (+14469)
chr1 72290738 72291074 Mreg (-32025), Pecr (+39982)
chr5 72438606 72438857 Commd8 (+120690), Gabrb1 (+347561)
chr16 22672855 22673155 Dgkg (-15759), Crygs (+138478)
chr3 124418625 124418909 Ndst4 (-688242), 1700003H04Rik (-134758)
chr18 76613456 76613637 Skor2 (-481597), Smad2 (+212313)
chr10 12273996 12274342 Utrn (+307364), Gm9797 (+945148)
chr15 11259966 11260124 Tars (+69368), Adamts12 (+265500)
chr8 25462270 25462920 1810011O10Rik (+86823), A730045E13Rik (+178219)
chr10 4930547 4930938 Syne1 (+126216), Esr1 (+803777)
chr11 87236084 87236908 Gm11492 (-143659), Tex14 (+17929)
chr3 96163525 96164181 Fcgr1 (-65961), BC107364 (+92376)
chr3 96177802 96178458 Fcgr1 (-80238), BC107364 (+78099)
chr13 70231949 70232253 Med10 (+283341), BC018507 (+544411)
240
chr2 22443076 22443924 Gad2 (-34225), Myo3a (+294370)
chr1 24618332 24623038 Gm10222 (-1146)
chr5 11829495 11829872 Sema3d (-553482), 4933402N22Rik (+234728)
chr5 11400416 11400736 4933402N22Rik (-194380), Gm5861 (+217504)
chr2 162688176 162688554 Ptprt (-201482), Srsf6 (-68899)
chr2 131233744 131234170 Smox (-83722), Rnf24 (-55340)
chr1 141954325 141954737 Gm4788 (-276715), Cfh (+125457)
chr6 83417694 83418110 Tet3 (-26233), Dguok (+39061)
chr14 118206572 118206838 Dct (+244763), Gpc6 (+881952)
chr5 143579353 143579517 Tnrc18 (-369)
chr5 16974433 16975269 Speer4f (-7065), Gm3495 (+95825)
chr17 10380494 10380692 Pabpc6 (-518024), Qk (+131633)









113580205 H2afb2-ps (-214667), Cpxcr1 (+17567) 
145881640 Sspn (-1230)
136457676 Kdm5b (+810)
105301520 March10 (+16640), Mrc2 (+147449) 
108789755 Art2b (-59991), Clpb (-22481)
76191993 Glod4 (-134356), Nxn (+21059) 
57316043 Mphosph8 (+28855), Pspc1 (+81213) 
153395163 Smim1 (+5237), Lrrc47 (+9184)
chr2 80302072 80302264 Frzb (-14386), Nckap1 (+119369)
chr5 66330250 66330572 Chrna9 (-27952), Rhoh (+75603)
chr5 108295958 108296386 Evi5 (+7954), Ube2d2b (+36900)
chr16 72258386 72258542 Robo1 (-404930)
chr2 3356844 3357148 Dclre1c (+15574), Suv39h2 (+35307)
chr13 24025614 24026204 Hist1h2aa (-422), Hist1h2ba (+116)
chr17 71834308 71834443 Smchd1 (-9693), Ndc80 (+41821)
chr12 55838910 55839950 Eapp (-42562), Snx6 (+57260)
chr19 29703448 29703901 Ermp1 (+19230), C030046E11Rik (+106903)
chr12 55810882 55811993 Eapp (-14570), Snx6 (+85252)
chr18 35815494 35815670 Prob1 (-741)
chr6 68200903 68201280 Tacstd2 (-715276), Igkv4-71 (+992347)
chr4 46596519 46596890 Trim14 (-47692), Coro2a (+18369)
chr9 115695410 115695590 Stt3b (-475961), Gadl1 (-122182)
chr12 55819723 55820200 Eapp (-23094), Snx6 (+76728)
chr12 55830120 55831178 Eapp (-33781), Snx6 (+66041)
chr3 103897340 103897866 Phtf1 (+125570), Magi3 (+126423)
241
chr start stop nearest gene (distance to TSS)
chr1 12634809 12634963 Sulf1 (-73,740)
chr1 24618373 24623025 Gm10222 (-1,160)
chr1 36425881 36426233 Kansl3 (-1,198)
chr1 39576302 39576463 Tbc1d8 (-40,791), Cnot11 (-15,454)
chr1 46910029 46910937 Slc39a10 (+408)
chr1 72283446 72283800 Mreg (-24,742), Pecr (+47,265)
chr1 72290752 72291047 Mreg (-32,019), Pecr (+39,988)
chr1 72301572 72301858 Mreg (-42,834), Pecr (+29,173)
chr1 120355509 120355898 2900060B14Rik (-380)
chr1 172958057 172958254 Fcgr4 (+9,105), Fcgr3 (+31,378)
chr1 173432897 173433394 Alyref2 (-463)
chr1 180250830 180251028 Cox20 (+1,668), Hnrnpu (+16,999)
chr1 180251135 180251576 Cox20 (+2,095), Hnrnpu (+16,572)
chr10 12273996 12274252 Utrn (+307,409), Gm9797 (+945,103)
chr10 39978217 39978605 Gtf3c6 (-940)
chr10 81167521 81167907 Zfp873 (-353,448), Ankrd24 (+76,334)
chr10 81326630 81327016 Zfp873 (-194,339), Ankrd24 (+235,443)
chr10 81459738 81460166 Zfp873 (-61,210), Ankrd24 (+368,572)
chr11 22170496 22170759 Otx1 (-269,010), Ehbp1 (+15,213)
chr11 52099833 52100032 Tcf7 (-3,860)
chr11 76191172 76191993 Glod4 (-134,356), Nxn (+21,059)
chr11 83084989 83085258 Pex12 (+27,355), Slfn3 (+80,292)
chr11 86887233 86887609 Gdpd1 (+143)
chr11 87236084 87236908 Gm11492 (-143,659), Tex14 (+17,929)
chr11 87239984 87240724 Gm11492 (-139,801), Tex14 (+21,787)
chr11 87256379 87257209 Gm11492 (-123,361), Tex14 (+38,227)
chr11 87261777 87262640 Gm11492 (-117,946), Tex14 (+43,642)
chr11 87275408 87276302 Gm11492 (-104,300), Tex14 (+57,288)
chr11 87284520 87285299 Gm11492 (-95,245), Tex14 (+66,343)
chr11 95893927 95894077 Snf8 (-2,197)
chr11 101466103 101466410 Rdm1 (-22,999), Tmem106a (+22,701)
chr11 101488657 101488966 Rdm1 (-444)
chr11 101502809 101503485 Arl4d (-23,708), Rdm1 (+13,891)
chr11 101506785 101507524 Arl4d (-19,700), Rdm1 (+17,899)
chr11 101519481 101519810 Arl4d (-7,209), Rdm1 (+30,390)
chr11 106586499 106586648 Tex2 (-112,330), Pecam1 (+25,368)
chr12 55797359 55798055 Eapp (-839)
chr12 55810882 55811864 Eapp (-14,505), Snx6 (+85,317)
chr12 55814849 55815664 Eapp (-18,389), Snx6 (+81,433)
chr12 55819723 55820200 Eapp (-23,094), Snx6 (+76,728)
chr12 55820236 55820781 Eapp (-23,641), Snx6 (+76,181)
chr12 55830120 55831178 Eapp (-33,781), Snx6 (+66,041)
chr12 55835205 55835589 Eapp (-38,529), Snx6 (+61,293)
chr12 55835629 55836060 Eapp (-38,977), Snx6 (+60,845)
chr12 55839039 55839950 Eapp (-42,627), Snx6 (+57,195)
chr12 98299628 98300037 NONE
chr12 111934191 111934354 Hsp90aa1 (+332)
chr13 21813490 21813709 Hist1h2bm (-313)
chr13 21826870 21827022 Hist1h4j (+43)
chr13 21827037 21827336 Hist1h4j (+284)
chr13 21842001 21842463 Hist1h4k (+142)
chr13 21901526 21901858 Hist1h4m (-1,923), Hist1h2bq (+361)
chr13 21923627 21924238 Hist1h2br (-1,694), Hist1h4n (+132)
chr13 21925185 21925768 Hist1h4n (-1,412), Hist1h2br (-150)
5 Overlapping Peak Regions of NPC and Testes ChIP Datasets
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chr13 21925821 21926153 Hist1h4n (-1,922), Hist1h2br (+360)
chr13 22132895 22133107 Hist1h2bj (-2,082), Hist1h4i (+220)
chr13 22135090 22135471 Hist1h4i (-2,060), Hist1h2ag (-463), Hist1h2bj (+198)
chr13 23623016 23623365 Hist1h3g (-4,100), Hist1h2af (-2,584), Hist1h4h (+272)
chr13 23643141 23643381 Hist1h1d (-3,640), Hist1h4f (+256)
chr13 23789960 23790459 Hist1h4c (+113)
chr13 23830593 23831031 Hist1h1c (+136)
chr13 23848946 23849239 Hist1h4b (+287)
chr13 23852658 23852981 Hist1h1a (-2,717), Hist1h4a (+279)
chr13 51297963 51298394 Hist1h2al (+255)
chr14 121483899 121484504 Farp1 (+49,416), Stk24 (+294,354)
chr15 88568772 88569183 Brd1 (-4,315)
chr16 11143902 11144450 Txndc11 (-9,433), Zc3h7a (+32,310)
chr16 20129532 20130245 Yeats2 (-11,247), Klhl24 (+32,262)
chr16 57391146 57391854 Filip1l (+38,294), Cmss1 (+215,442)
chr17 4626224 4626585 Nox3 (-930,144), Arid1b (-368,669)
chr17 15098574 15099277 Phf10 (-689)
chr17 15099292 15099907 Phf10 (-1,363)
chr17 15115491 15116168 Gm3448 (-209), Gm3435 (+1)
chr17 15130157 15131491 Gm3435 (+14,995), Gm3417 (+16,324)
chr17 15146863 15147540 Gm3417 (-54), 9030025P20Rik (+2)
chr17 15161525 15162859 9030025P20Rik (+14,992), Tcte3 (+16,331)
chr17 15344966 15345538 2210404J11Rik (+166,647), Dll1 (+167,688)
chr17 39979865 39985845 Gm7148 (-269,446)
chr17 80606527 80606939 Srsf7 (-713), Ttc39d (-67)
chr18 10151061 10151227 Usp14 (-121,005), Rock1 (+30,646)
chr19 4078426 4078532 BC021614 (-19,184), Cabp2 (-5,040)
chr19 6996550 6996897 Esrra (-426)
chr19 7015795 7016395 Bad (-256), Gpr137 (-126)
chr19 10379354 10379563 Dagla (-92)
chr19 21581807 21582122 Gm3443 (-48,199), Gda (-34,803)
chr2 25035827 25036514 Nrarp (-107)
chr3 5860327 5860828 Pex2 (-284,339), 1700008P02Rik (+759,865)
chr3 96042667 96043048 Hist2h3c2 (+192)
chr3 96043599 96043917 Hist2h3c2 (-708), Hist2h2aa2 (+458)
chr3 96043950 96044507 Hist2h3c2 (-1,179), Hist2h2aa2 (-13)
chr3 96049212 96049726 Hist2h3c1 (-1,205), Hist2h2aa1 (+8)
chr3 96049759 96050060 Hist2h3c1 (-764), Hist2h2aa1 (+449)
chr3 96050624 96051005 Hist2h3c1 (+141)
chr3 96072452 96072813 Hist2h2bb (-1,042), Hist2h3b (+56)
chr3 96132007 96132599 Fcgr1 (-34,411), BC107364 (+123,926)
chr3 96163525 96164181 Fcgr1 (-65,961), BC107364 (+92,376)
chr3 96177802 96178458 Fcgr1 (-80,238), BC107364 (+78,099)
chr3 96226594 96226840 Fcgr1 (-128,825), BC107364 (+29,512)
chr3 96254032 96254704 Fcgr1 (-156,476), BC107364 (+1,861)
chr3 96263776 96264448 Hfe2 (-64,996), BC107364 (-7,883)
chr3 96290119 96291009 Hfe2 (-38,544), BC107364 (-34,335)
chr3 96292179 96293188 BC107364 (-36,455), Hfe2 (-36,424)
chr3 144408348 144408645 Sh3glb1 (-25,210), Clca1 (+15,308)
chr3 152165632 152166311 Zzz3 (+107,005), Ak5 (+165,132)
chr3 154136647 154137000 Tyw3 (+123,235), Slc44a5 (+500,424)
chr4 51825350 51825556 Smc2 (-626,662), Cylc2 (+595,903)
chr4 108952605 108952944 Eps15 (-98)
chr4 116862488 116862794 Kif2c (-7,397), Gm1661 (+61,881)
chr4 124617836 124618210 Cdca8 (-3,906)
chr4 131825783 131826441 Taf12 (-4,178)
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chr4 134024169 134024324 Stmn1 (+12)
chr5 115939403 115939805 Sirt4 (-4,870)
chr5 149864485 149864708 Hmgb1 (+19)
chr6 3150763 3151774 Samd9l (+198,302)
chr6 50146939 50147260 Dfna5 (+66,761), Mpp6 (+86,860)
chr6 51419690 51420373 Hnrnpa2b1 (-2,604), Cbx3 (-327)
chr6 132413723 132413820 Prh1 (-106,055), Gm8882 (-99,620)
chr6 146525985 146526146 Fgfr1op2 (-315), Asun (+291)
chr8 73222346 73222949 Jund (+1,010), Gm11175 (+1,331)
chr8 83262886 83263555 Smarca5 (+175)
chr9 65044185 65044584 Parp16 (-18,569), Igdcc3 (+55,424)
chr9 65049402 65049749 Parp16 (-13,378), Igdcc3 (+60,615)
chr9 110989678 110990024 Lrrfip2 (-30,764), Ccrl2 (-30,077)
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chr start stop nearest gene (distance to TSS)
chr1 6638065 6638194 St18 (-82002), Fam150a (+288593)
chr1 8400880 8401020 Sntg1 (+59651)
chr1 16647040 16647245 Tceb1 (-197)
chr1 23067721 23067887 Rims1 (-464382), 4933415F23Rik (+41288)
chr1 30819114 30819315 Gm9898 (-42409), Phf3 (+100886)
chr1 33951484 33951619 Zfp451 (-80112), Bend6 (+13109)
chr1 33951622 33951859 Zfp451 (-80301), Bend6 (+12920)
chr1 38461097 38461289 Rev1 (-274686), Aff3 (+135494)
chr1 48519013 48519161 C230029F24Rik (-782373)
chr1 49014660 49014787 C230029F24Rik (-286736)
chr1 57513605 57513800 Spats2l (-318002), Tyw5 (-49758)
chr1 66863661 66863845 Kansl1l (+367)
chr1 69851276 69851438 Ikzf2 (-118823), Spag16 (-22205)
chr1 83996431 83996610 Sphkap (-591746), Pid1 (+284699)
chr1 84836064 84836238 Trip12 (-272), Fbxo36 (-265)
chr1 88383859 88384257 Ptma (-39253), 1700019O17Rik (+61112)
chr1 88422999 88423418 Ptma (-102)
chr1 88617661 88617989 Dis3l2 (+17446), Alppl2 (+368678)
chr1 91355897 91356040 D130058E05Rik (-470840), Agap1 (+4583)
chr1 95841863 95842057 Gm6086 (-45126), Gm9994 (+17596)
chr1 99816002 99816317 Ppip5k2 (-149172), Pam (+176038)
chr1 105755854 105756011 Cdh20 (-909173)
chr1 115518268 115518479 NONE
chr1 130932071 130932291 Cxcr4 (-443314), Thsd7b (-237740)
chr1 133716876 133717034 Slc41a1 (-7599), Pm20d1 (+22997)
chr1 134318052 134318382 Rbbp5 (-55727), Dstyk (+4187)
chr1 136457209 136457415 Kdm5b (+564)
chr1 136457440 136457676 Kdm5b (+810)
chr1 136457717 136457907 Syt2 (-148065), Kdm5b (+1064)
chr1 136920453 136920843 Ube2t (+61506), Lgr6 (+81205)
chr1 138233122 138233315 Gpr25 (-75769), Camsap2 (+9462)
chr1 138235598 138235739 Gpr25 (-78219), Camsap2 (+7012)
chr1 141954325 141954737 Gm4788 (-276715), Cfh (+125457)
chr1 142869679 142869779 Kcnt2 (+726934)
chr1 159482429 159482704 Sec16b (+45708), Fam5b (+803824)
chr1 159661262 159661466 Sec16b (+224505), Fam5b (+625027)
chr1 162275331 162275404 Cacybp (-132460), Rabgap1l (+447701)
chr1 163027312 163027488 Cenpl (+26502), Klhl20 (+34242)
chr1 169270302 169270622 Aldh9a1 (-9660), Tmco1 (+31661)
chr1 169328474 169328599 Mgst3 (-4565)
chr1 169600816 169601057 Lmx1a (-18752), Rxrg (+72422)
chr1 172572750 172572955 Olfml2b (-1810)
chr1 173001780 173005313 1700009P17Rik (-48245), Fcgr3 (-14013)
chr1 173012987 173014985 1700009P17Rik (-37806), Fcgr3 (-24452)
chr1 173808683 173808857 Gm10521 (-17025), Cd84 (+38942)
chr1 174196993 174197081 Atp1a4 (-8492), Atp1a2 (+31158)
6 Peaks only present with Testes ChIP (Testes Specific)  
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chr1 178744251 178744519 Sdccag8 (-406)
chr1 180251592 180252051 Cox20 (+2561), Hnrnpu (+16106)
chr1 180252156 180252389 Cox20 (+3012), Hnrnpu (+15655)
chr1 180252951 180253209 Cox20 (+3819), Hnrnpu (+14848)
chr1 180266685 180267253 Hnrnpu (+959)
chr1 183634010 183634190 Ccdc121 (-192518), Dnahc14 (-37067)
chr1 186854896 186855388 Rab3gap2 (-172905), Mark1 (-31714)
chr1 192053952 192054194 Prox1 (-59514), Rps6kc1 (+681576)
chr1 194061545 194061791 Kcnh1 (+47002), Hhat (+535739)
chr1 197190299 197190481 Cr2 (-187481)
chr10 3831543 3831933 Rgs17 (-592417), Gm10945 (+246958)
chr10 4930547 4930938 Syne1 (+126216), Esr1 (+803777)
chr10 9467362 9467556 Samd5 (-72453), Stxbp5 (+153418)
chr10 11710100 11710246 Gm9797 (+381152), Utrn (+871360)
chr10 17037210 17037294 Cited2 (-405782)
chr10 17044382 17044530 Cited2 (-398578)
chr10 21000123 21000287 Myb (-119415), Hbs1l (-15580)
chr10 26647120 26647204 Arhgap18 (+154879), Lama2 (+689586)
chr10 26655097 26655181 Arhgap18 (+162856), Lama2 (+681609)
chr10 35943971 35944136 Amd2 (-512357), Hs3st5 (-282566)
chr10 37782321 37782472 Lama4 (-902924), 5930403N24Rik (+923033)
chr10 39691073 39691718 G630090E17Rik (-11437), BC021785 (+15049)
chr10 49977195 49977294 Grik2 (-468673), Ascc3 (-335230)
chr10 59378436 59378712 Ddit4 (+35944), Dnajb12 (+36251)
chr10 61591506 61591858 Neurog3 (-4156)
chr10 76766491 76766846 Pofut2 (+44624), Adarb1 (+114346)
chr10 77152943 77153141 Gm10272 (-16347), Ube2g2 (+67961)
chr10 80827990 80829989 4930404N11Rik (-429)
chr10 89139305 89139721 Slc17a8 (-55515), Scyl2 (+9517)
chr10 110654809 110655409 Bbs10 (-80626), Osbpl8 (+53251)
chr10 115632868 115633040 Ptprb (-105476), 4933416C03Rik (-81981)
chr11 3724658 3725260 Osbp2 (+38947), Morc2a (+175462)
chr11 3971581 3971778 Sec14l3 (+6836), Mtfp1 (+23768)
chr11 11397628 11398506 4930415F15Rik (+8798), 4930512M02Rik (+129760)
chr11 14977824 14977948 NONE
chr11 23624548 23624891 Pex13 (-58761), Rel (+46250)
chr11 25000048 25000203 5730522E02Rik (+670444)
chr11 32076000 32076214 Il9r (+24129), Nsg2 (+175644)
chr11 40613689 40613785 Ccng1 (-44924)
chr11 50191163 50191410 Hnrnph1 (+16)
chr11 58775172 58775820 Trim17 (-1808)
chr11 60187409 60187676 Lrrc48 (+20712), Atpaf2 (+43010)
chr11 62364915 62365180 Ubb (+375)
chr11 62365648 62366351 Trpv2 (-22040), Ubb (+1327)
chr11 69571960 69572257 Polr2a (+30)
chr11 70729707 70729900 Nup88 (+53660), Rabep1 (+71524)
chr11 73312282 73312397 Olfr381 (-7361), Olfr382 (+18359)
chr11 76148608 76148883 Glod4 (-91519), Nxn (+63896)
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chr11 76191995 76192164 Glod4 (-134853), Nxn (+20562)
chr11 79398713 79398991 Evi2a (-54762), Rab11fip4 (-5862)
chr11 79687340 79687428 Utp6 (+88508), Rab11fip4 (+282670)
chr11 82841057 82841310 Slfn2 (-37430), Slfn8 (-6872)
chr11 95737123 95737400 Abi3 (-33539), B4galnt2 (+38943)
chr11 98724900 98725256 Wipf2 (+126)
chr11 103268409 103268520 Arhgap27 (-46251), Plekhm1 (+5513)
chr11 105301298 105301520 March10 (+16640), Mrc2 (+147449)
chr11 108872866 108873417 Axin2 (+91479), E030025P04Rik (+132541)
chr11 115885512 115885926 Galk1 (-11686), H3f3b (+3557)
chr11 116928412 116928569 Sec14l1 (-47995), Mgat5b (+148314)
chr11 119320596 119321173 Endov (-31776), Rnf213 (+66471)
chr11 119720614 119720939 Chmp6 (-54347), Rptor (+256314)
chr11 120092832 120092980 Bahcc1 (-1355)
chr11 121518509 121519059 Zfp750 (-138137), B3gntl1 (+15683)
chr12 3036912 3037000 Rab10 (+273013)
chr12 4786211 4786418 0610009D07Rik (-38099), Pfn4 (+10214)
chr12 5503370 5503761 2810032G03Rik (+85119)
chr12 9432167 9432451 Osr1 (-148939), Ttc32 (+395506)
chr12 12018484 12018858 Fam49a (-250274), Rad51ap2 (+555786)
chr12 12018866 12019112 Fam49a (-249956), Rad51ap2 (+556104)
chr12 13143011 13143206 Mycn (-194389), Ddx1 (+112910)
chr12 17539673 17540043 Odc1 (-11821), Nol10 (+184573)
chr12 19226266 19226526 Gm5784 (-167269), 5730507C01Rik (+704852)
chr12 20828925 20829099 1700030C10Rik (-7424), Zfp125 (+77716)
chr12 22990713 22991030 NONE
chr12 35958601 35958755 Snx13 (+226817), Ahr (+261032)
chr12 37392265 37392572 Meox2 (-442708), D630036H23Rik (-283651)
chr12 38091134 38091230 Dgkb (-516110), Agmo (+122954)
chr12 50712141 50712236 Gm9804 (+209925)
chr12 59261099 59261197 Foxa1 (-614040), Sstr1 (-51611)
chr12 62477546 62477700 Lrfn5 (-147312)
chr12 71978715 71978914 Actr10 (-60029), Frmd6 (+52314)
chr12 79949073 79949263 Atp6v1d (+13457), Mpp5 (+99234)
chr12 92828267 92828427 Gtf2a1 (+102)
chr12 93036365 93036569 Ston2 (-11591), Sel1l (+51130)
chr12 103079306 103079937 Fbln5 (-22357), Trip11 (+71855)
chr12 112341390 112341756 Traf3 (-63101), Rcor1 (+63748)
chr12 112579306 112579480 Cdc42bpb (+36536), Amn (+70071)
chr12 113088150 113088677 Ppp1r13b (+22412), Zfyve21 (+36033)
chr12 113338413 113338652 BC048943 (-119571), Aspg (-6361)
chr13 3026151 3026232 Gdi2 (-511129)
chr13 3179280 3179495 Gdi2 (-357933)
chr13 6134585 6134854 Pitrm1 (-412683), Klf6 (+273985)
chr13 9833500 9833762 Zmynd11 (-69225), Chrm3 (+44698)
chr13 12366712 12366965 Mtr (-16572), Actn2 (+66188)
chr13 16464769 16464850 Inhba (+361126)
chr13 20876498 20876763 Aoah (-9357), Elmo1 (+694143)
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chr13 21809473 21809969 Hist1h2bm (-4192), Hist1h3h (+224)
chr13 21846168 21846343 Hist1h4k (-3882), Hist1h2ak (-480)
chr13 21874791 21875299 Hist1h2bp (-4285), Hist1h1b (-2551), Hist1h3i (+221)
chr13 21879560 21879759 Hist1h3i (-4394), Hist1h2an (-573), Hist1h2bp (+330)
chr13 21901911 21902528 Hist1h4m (-1395), Hist1h2bq (-167)
chr13 23646975 23647201 Hist1h4f (-3571), Hist1h1d (+187)
chr13 23667674 23668022 Hist1h2ae (-4759), Hist1h2bf (-1783), Hist1h3d (+216)
chr13 23714034 23714302 Hist1h2be (-1175), Hist1h1e (+203)
chr13 23776051 23776229 Hist1h2ac (-323), Hist1h2bc (+72)
chr13 23838768 23839012 Hist1h2ab (-4067), Hist1h3c (-1419), Hist1h2bb (+287)
chr13 23844179 23844628 Hist1h4b (-4402), Hist1h3b (+268)
chr13 23853920 23854301 Hist1h1a (-1426), Hist1h4a (-1012), Hist1h3a (+144)
chr13 24025614 24026204 Hist1h2aa (-422), Hist1h2ba (+116)
chr13 24633416 24633684 Fam65b (-96967), Cmah (+214261)
chr13 42190662 42190816 Edn1 (-205900), Hivep1 (+43349)
chr13 44964885 44965059 Dtnbp1 (+132537), Jarid2 (+138780)
chr13 47046203 47046525 Kif13a (-21277), Nhlrc1 (+63855)
chr13 49494901 49495368 Ippk (-21545), Bicd2 (+58217)
chr13 51941709 51941925 Gadd45g (-230)
chr13 51941968 51942164 Gadd45g (+19)
chr13 52846109 52846573 Syk (+167799), Auh (+178689)
chr13 56199754 56200260 Pitx1 (-267221), H2afy (+36985)
chr13 58502820 58503374 Rmi1 (-861)
chr13 58503773 58503940 Rmi1 (-101), Hnrnpk (+847)
chr13 61052440 61052524 Tpbpa (-9186), Ctsj (+54795)
chr13 62460597 62460717 Gm10260 (-141328), Gm5141 (+12639)
chr13 65552554 65553189 Gm10139 (-60742), Zfp369 (+172750)
chr13 65967440 65968021 Gm10772 (-39856), Gm10139 (+354117)
chr13 66394389 66396325 Vmn2r-ps104 (+60964), 2610044O15Rik8 (+256118)
chr13 67299065 67299259 Zfp455 (+3720), Zfp458 (+70842)
chr13 67474005 67474254 Zfp953 (-12589), Zfp456 (+2616)
chr13 67497929 67498144 Zfp456 (-21291), Zfp429 (+2666)
chr13 68096842 68096930 BC048507 (+132612), Mtrr (+624112)
chr13 69733647 69733870 Papd7 (-61042), Srd5a1 (+16561)
chr13 70231949 70232253 Med10 (+283341), BC018507 (+544411)
chr13 91778066 91778279 Acot12 (-102944), Ssbp2 (+177518)
chr13 91778284 91778432 Acot12 (-102759), Ssbp2 (+177703)
chr13 92094003 92094177 Ckmt2 (-77600), Rasgrf2 (+807359)
chr13 97342467 97342837 Col4a3bp (+29962), Hmgcr (+98239)
chr13 101432401 101432811 Ccdc125 (-6830), Taf9 (+11308)
chr14 4814465 4814595 Gm9602 (-64846), Gm3159 (+313946)
chr14 11353424 11353519 Fhit (+641077)
chr14 12935863 12935995 3830406C13Rik (-180794), Ptprg (+549883)
chr14 14855953 14856561 Atxn7 (+11252), Psmd6 (+97241)
chr14 37719530 37719737 Ccser2 (+62316), 4930474N05Rik (+811489)
chr14 46052730 46052914 Gnpnat1 (-44345), Fermt2 (+96971)
chr14 48705251 48705540 Peli2 (-35148), Ktn1 (+421965)
chr14 48705553 48705674 Peli2 (-34930), Ktn1 (+422183)
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chr14 49739614 49739845 Exoc5 (-53402), Naa30 (-52543)
chr14 54880915 54881135 Abhd4 (+2118), Olfr49 (+21575)
chr14 57315836 57316043 Mphosph8 (+28855), Pspc1 (+81213)
chr14 57430145 57430484 Zmym5 (+238)
chr14 57505231 57505594 Zmym2 (-1218)
chr14 57505618 57505797 Zmym2 (-923)
chr14 58458772 58459036 Mrp63 (+13828), Zdhhc20 (+50113)
chr14 59029643 59029822 Rpl13-ps3 (-482610), Fgf9 (+338210)
chr14 60064554 60064873 Setdb2 (-4993), Cab39l (+4896)
chr14 61964386 61964739 Ebpl (+14719), Arl11 (+35973)
chr14 63379777 63380091 Ints6 (+15)
chr14 69799171 69799572 Nkx3-1 (-9323), Nkx2-6 (+9739)
chr14 104736093 104736324 Ednrb (-492819), Pou4f1 (+130999)
chr14 105115012 105115391 Rnf219 (-193319), Rbm26 (+461338)
chr14 118206572 118206838 Dct (+244763), Gpc6 (+881952)
chr14 120737186 120737476 Rap2a (-140335), Mbnl2 (+62402)
chr15 5099576 5099919 Ttc33 (-35812), Prkaa1 (+5887)
chr15 7527614 7527751 Gdnf (-233328), Egflam (-179332)
chr15 11259966 11260124 Tars (+69368), Adamts12 (+265500)
chr15 25143986 25144140 9230109A22Rik (-65149), Basp1 (+199456)
chr15 26188739 26188813 March11 (-50043), Zfp622 (+274655)
chr15 30510534 30510630 Dap (-643558), Ctnnd2 (+408234)
chr15 36131941 36132320 Spag1 (+23008), Rnf19a (+80771)
chr15 38212163 38212414 Klf10 (+18173), Odf1 (+63331)
chr15 44622528 44622623 Sybu (-2967)
chr15 76128460 76128765 Smpd5 (+3749), Oplah (+8918)
chr15 76128804 76129053 Smpd5 (+4065), Oplah (+8602)
chr15 79376866 79377092 Ddx17 (+192)
chr15 79560750 79561176 Sun2 (+12003), Gtpbp1 (+39643)
chr15 79561216 79561436 Sun2 (+11640), Gtpbp1 (+40006)
chr15 82725119 82725439 Cyp2d26 (-100604), Tcf20 (+17285)
chr15 86025175 86025777 Tbc1d22a (-19401), Cerk (-8905)
chr15 87797353 87797527 Zdhhc25 (-633305), Fam19a5 (+422536)
chr15 92626642 92626733 Pdzrn4 (+399342), Gxylt1 (+478904)
chr15 92628957 92629048 Pdzrn4 (+401657), Gxylt1 (+476589)
chr15 98364436 98364632 Kansl2 (+118)
chr15 101724635 101724846 Krt76 (-1390)
chr16 3174030 3174196 Olfr161 (-418285)
chr16 4301021 4301518 Crebbp (-87866), Adcy9 (+118538)
chr16 9241776 9241912 1810013L24Rik (+411651), Grin2a (+753170)
chr16 11015717 11015936 Snn (-50564), Litaf (-22613)
chr16 17088054 17088368 Ypel1 (+18422), Ppil2 (+23114)
chr16 17088394 17089580 Ypel1 (+19198), Ppil2 (+22338)
chr16 17090102 17090259 Ypel1 (+20392), Ppil2 (+21144)
chr16 17090584 17090999 Ppil2 (+20533), Ypel1 (+21003)
chr16 19925935 19926054 A930003A15Rik (-42005), Klhl6 (+57115)
chr16 22672855 22673155 Dgkg (-15759), Crygs (+138478)
chr16 31162663 31162843 Xxylt1 (-81235), Acap2 (+38324)
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chr16 34671860 34672520 Ccdc14 (-18512), Ropn1 (+20916)
chr16 36991075 36991339 Fbxo40 (-654)
chr16 42569884 42570037 Zbtb20 (-677436), Gap43 (-229197)
chr16 56096558 56096901 Impg2 (-107721), Senp7 (+21208)
chr16 61238108 61238289 Epha6 (-633125)
chr16 67714057 67714263 Cadm2 (-93092)
chr16 68274642 68274795 Cadm2 (-653651)
chr16 70076415 70076548 Gbe1 (-237712), Speer2 (-212493)
chr16 72258386 72258542 Robo1 (-404930)
chr16 75294903 75295094 Robo2 (-883765), Lipi (+291302)
chr16 80759616 80759772 Ncam2 (-441248)
chr16 84647990 84648749 Mrpl39 (+87617)
chr16 84975160 84975506 Atp5j (-139463), App (+198615)
chr16 94057510 94057989 Cldn14 (-48668), Sim2 (-28311)
chr16 95979203 95979519 Ets2 (+55679), Psmg1 (+233206)
chr16 95995796 95996097 Ets2 (+72265), Psmg1 (+216620)
chr17 5011512 5011895 Arid1b (+16630), Tmem242 (+428556)
chr17 10380494 10380692 Pabpc6 (-518024), Qk (+131633)
chr17 13743457 13746115 Mllt4 (-152769), Smok4a (+30464)
chr17 13911136 13911387 Gm7168 (-174118), Mllt4 (+13707)
chr17 14847569 14847759 Thbs2 (-16395), Wdr27 (+223994)
chr17 15178018 15178623 2210404J11Rik (-284), Tcte3 (+202)
chr17 15950608 15950912 Rgmb (+12790), Chd1 (+108829)
chr17 25896831 25897067 Narfl (-13772), Msln (-5677)
chr17 27298995 27299442 Mnf1 (-28358), Ip6k3 (+5490)
chr17 33811718 33812117 Hnrnpm (+11887), Pram1 (+36917)
chr17 34256094 34256550 Brd2 (+2370), H2-Oa (+27037)
chr17 35618079 35618232 Pou5f1 (-24826), H2-Q10 (+11122)
chr17 43892632 43892898 Rcan2 (-46035), Cyp39a1 (+88391)
chr17 56339395 56339517 D17Wsu104e (-16113), Dpp9 (+18856)
chr17 60653649 60653794 NONE
chr17 65987738 65987998 Vapa (-24973), Txndc2 (+3676)
chr17 66713720 66713971 Soga2 (+85244), Ddx11 (+240986)
chr17 69054628 69055037 Epb4.1l3 (-451317), L3mbtl4 (+431696)
chr17 69816419 69816669 Dlgap1 (-957590), A330050F15Rik (+27878)
chr17 71834308 71834443 Smchd1 (-9693), Ndc80 (+41821)
chr17 71834471 71834609 Smchd1 (-9857), Ndc80 (+41657)
chr17 75509211 75509527 Rasgrp3 (-355509), Ltbp1 (+104461)
chr17 80606236 80606439 Ttc39d (-462), Srsf7 (-318)
chr17 84581105 84581330 Haao (-335088), Zfp36l2 (+6069)
chr17 86824334 86824518 Gm10309 (+80146), Prkce (+257301)
chr17 87452962 87453212 Gm5499 (-24524), Cript (+28197)
chr17 87608182 87608477 Mcfd2 (+56945), Socs5 (+101311)
chr17 89174552 89174875 Lhcgr (+16602), Gtf2a1l (+106714)
chr18 3004771 3005630 Vmn1r238 (+118264)
chr18 6543924 6544060 4921524L21Rik (-59639), Epc1 (-53138)
chr18 6544599 6544711 4921524L21Rik (-58976), Epc1 (-53801)
chr18 10547960 10549005 Esco1 (+61867), Greb1l (+223306)
250
chr18 10569683 10569963 Esco1 (+40527), Greb1l (+244646)
chr18 12990093 12990353 Cabyr (+90390), Osbpl1a (+110127)
chr18 13201410 13201953 Hrh4 (+36183), Zfp521 (+929560)
chr18 14806362 14806473 Ss18 (+35005), Gm5160 (+224259)
chr18 15592764 15593169 Aqp4 (-31466), Chst9 (+283588)
chr18 18051314 18051426 NONE
chr18 24306003 24306426 Galnt1 (-57630), Ino80c (-25761)
chr18 24826363 24826870 Mocos (+14425), Gm9955 (+41232)
chr18 34602257 34602558 Pkd2l2 (+33331), Fam13b (+64069)
chr18 35803792 35803919 Slc23a1 (-16958), Mzb1 (+5165)
chr18 35815163 35815453 Prob1 (-467)
chr18 35815494 35815670 Prob1 (-741)
chr18 49829559 49829753 Dtwd2 (+85599)
chr18 51835086 51835240 Gm4950 (+190372), Prr16 (+557771)
chr18 57845035 57845163 Slc12a2 (-193233), 1700011I03Rik (+151665)
chr18 61541009 61541432 Ppargc1b (+18833), Pde6a (+161085)
chr18 66145885 66146203 Cplx4 (-16212), Lman1 (+16247)
chr18 75040100 75040260 Lipg (+80737), Acaa2 (+101329)
chr18 75040666 75040986 Lipg (+80091), Acaa2 (+101975)
chr18 76613456 76613637 Skor2 (-481597), Smad2 (+212313)
chr18 81797204 81797484 Sall3 (-614027), Galr1 (+778825)
chr18 83740362 83740551 Tshz1 (+515339), Zfp516 (+660186)
chr18 84588162 84588554 Zfp407 (+170538), Zadh2 (+330808)
chr18 87314713 87314808 Gm5096 (-610986), Cbln2 (+434259)
chr19 3767959 3768195 Suv420h1 (+656)
chr19 5803685 5803874 Scyl1 (-32379), Frmd8 (+71494)
chr19 6005129 6005459 Slc22a20 (-19151), Capn1 (+10531)
chr19 6363806 6363988 Sf1 (+207)
chr19 9441752 9441926 Pcna-ps2 (+83970), Stxbp3b (+191899)
chr19 9633435 9633601 Stxbp3b (+220)
chr19 29703448 29703901 Ermp1 (+19230), C030046E11Rik (+106903)
chr19 34812509 34812659 Slc16a12 (+9195), Ifit1 (+97223)
chr19 44076755 44076987 Cpn1 (-15825), Cyp2c44 (+26866)
chr19 46654640 46655055 Wbp1l (-18756), Sfxn2 (+6993)
chr19 55776609 55776938 Tcf7l2 (-39600), Vti1a (+385934)
chr19 57565272 57565511 Atrnl1 (-120132), Trub1 (+37996)
chr19 58592967 58593225 Pnlip (-151759), Ccdc172 (+6604)
chr2 3356844 3357148 Dclre1c (+15574), Suv39h2 (+35307)
chr2 16187859 16187954 Plxdc2 (-90024), Gm13318 (+224154)
chr2 18461040 18461299 Dnajc1 (-146713), Commd3 (-132880)
chr2 20196979 20197177 Etl4 (-244340), Otud1 (+617389)
chr2 20821416 20821899 Arhgap21 (+67689), Etl4 (+380240)
chr2 22443076 22443924 Gad2 (-34225), Myo3a (+294370)
chr2 28980310 28981010 Setx (+148)
chr2 34611014 34611361 Gapvd1 (-25021), Hspa5 (-16424)
chr2 51198320 51198829 Tas2r134 (-284456), Rnd3 (-193944)
chr2 57246848 57247325 Galnt5 (-603208), Gpd2 (+156379)
chr2 57481881 57482153 Galnt5 (-368278), Gpd2 (+391309)
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chr2 80302072 80302264 Frzb (-14386), Nckap1 (+119369)
chr2 83373876 83374011 Zc3h15 (-110648), Fsip2 (+590153)
chr2 98502287 98503234 Gm10801 (+367)
chr2 98503710 98504293 Gm10801 (+1608), Gm10800 (+3456)
chr2 98505008 98505437 Gm10800 (+2235), Gm10801 (+2829)
chr2 98506338 98507542 Gm10800 (+518)
chr2 99785651 99785785 NONE
chr2 105308425 105308582 Pax6 (-200549), Rcn1 (-69028)
chr2 111925966 111926040 Olfr1313 (-13263), Olfr1314 (+6853)
chr2 117059330 117059501 Fam98b (-16059), Spred1 (+112306)
chr2 121962909 121963298 Spg11 (-18982), B2m (-10318)
chr2 124986392 124986659 Dut (-86400), Slc12a1 (+8285)
chr2 125443221 125443497 Fbn1 (-111238), Cep152 (+7490)
chr2 131233744 131234170 Smox (-83722), Rnf24 (-55340)
chr2 142290456 142290537 Kif16b (+436770)
chr2 146335546 146336272 Ralgapa2 (+1831), Insm1 (+288252)
chr2 162688176 162688554 Ptprt (-201482), Srsf6 (-68899)
chr2 166065850 166066134 Sulf2 (-84829), Prex1 (+473340)
chr2 167702233 167702451 Ptpn1 (-55485), Cebpb (+187927)
chr2 167702530 167702802 Ptpn1 (-55161), Cebpb (+188251)
chr2 170945712 170946046 Dok5 (+388572), Cbln4 (+923087)
chr3 22026150 22026308 Tbl1xr1 (+50655)
chr3 23209200 23209294 NONE
chr3 31260640 31260800 Kcnmb2 (-540709), Slc7a14 (-51420)
chr3 52059270 52059807 Maml3 (-150726), Foxo1 (-12720)
chr3 58469472 58469815 Fam194a (-28515), Siah2 (+26678)
chr3 58469948 58470228 Fam194a (-28959), Siah2 (+26234)
chr3 61949655 61949811 B430305J03Rik (-779860), Arhgef26 (-192533)
chr3 64230774 64230952 Vmn2r4 (-11645), Vmn2r5 (+82794)
chr3 68096244 68096863 Il12a (-398012), Schip1 (+227690)
chr3 69490627 69490976 B3galnt1 (-88019), Nmd3 (-35105)
chr3 77059606 77059705 NONE
chr3 93518698 93518941 Tdpoz4 (-81500), S100a10 (+159818)
chr3 95276043 95276623 Ctsk (-26875), Arnt (+38023)
chr3 96024557 96024756 Hist2h2be (-387), Hist2h2ac (+146), Hist2h2ab (+869)
chr3 103897340 103897866 Phtf1 (+125570), Magi3 (+126423)
chr3 106243488 106243658 BC051070 (-34473), 2010016I18Rik (+42782)
chr3 109061732 109061903 Vav3 (-81753), Slc25a24 (+135751)
chr3 115609465 115610475 Dph5 (+18869), Slc30a7 (+100354)
chr3 124418625 124418909 Ndst4 (-688242), 1700003H04Rik (-134758)
chr3 142973853 142974253 Pkn2 (-429085), Lmo4 (+891228)
chr3 144467409 144467757 Clca1 (-43778), Clca2 (+14875)
chr3 146005710 146006075 Ssx2ip (-61713), Lpar3 (+121968)
chr3 152996314 152997030 St6galnac5 (-351462), St6galnac3 (+391354)
chr3 154085430 154086146 Tyw3 (+174271), Slc44a5 (+449388)
chr3 159218929 159219028 Rpe65 (-43218), Depdc1a (+60582)
chr4 3429671 3429955 Vmn1r3 (-317308), Tmem68 (+72187)
chr4 3540699 3541766 Lyn (-64029), Tgs1 (+39211)
252
chr4 8154834 8155634 Car8 (+10954)
chr4 8619372 8619621 Clvs1 (-576967), Chd7 (+1429)
chr4 9133821 9134179 Clvs1 (-62464), Chd7 (+515932)
chr4 11324250 11324666 1110037F02Rik (-88647), Esrp1 (-10528)
chr4 17379647 17379762 Mmp16 (-400900)
chr4 37908025 37908169 NONE
chr4 41811878 41812712 Ccl27a (-91280), Gm20938 (-24489)
chr4 41925351 41926345 Gm2564 (+17616), Gm20938 (+89064)
chr4 41963771 41963931 Gm13304 (-21689), Gm2564 (-20387)
chr4 42023793 42024677 Gm13306 (-528)
chr4 42269110 42269783 Gm13305 (-230121), Il11ra2 (-69813)
chr4 42353908 42354512 Il11ra2 (+14950), Gm13298 (+187497)
chr4 42414654 42414814 Il11ra2 (+75474), Gm13298 (+126973)
chr4 42452240 42453234 Gm13298 (+88970), Il11ra2 (+113477)
chr4 42565486 42566480 4930578G10Rik (-183094), Gm13298 (-24276)
chr4 42603910 42604070 4930578G10Rik (-145087), Gm13298 (-62283)
chr4 42663761 42664645 Gm13298 (-122496), 4930578G10Rik (-84874)
chr4 42748677 42749163 4930578G10Rik (-157)
chr4 46596519 46596890 Trim14 (-47692), Coro2a (+18369)
chr4 50709855 50710061 Grin3a (-851537), Cylc2 (-519592)
chr4 80355629 80355771 Tyrp1 (-124434)
chr4 81597155 81597635 Mpdz (-508684), Nfib (+553817)
chr4 83269166 83269399 Ccdc171 (+97834)
chr4 101763903 101764474 Pde4b (-163419), Gm12789 (+104958)
chr4 107831578 107831728 Scp2 (-40516), Echdc2 (-6389)
chr4 114943768 114943896 Cyp4x1 (-137250), Cyp4a12a (-27819)
chr4 114986056 114986184 Cyp4a12b (-98109), Cyp4a12a (+14469)
chr4 115718594 115718991 Faah (-28262), Nsun4 (+7192)
chr4 115893683 115893927 Pik3r3 (-461)
chr4 116862455 116862794 Kif2c (-7381), Gm1661 (+61897)
chr4 116875066 116875292 Kif2c (-19935), Gm1661 (+49343)
chr4 116883412 116883551 Kif2c (-28238), Gm1661 (+41040)
chr4 117559595 117559777 B4galt2 (-3594), Atp6v0b (+248)
chr4 118110022 118110315 Cdc20 (-212)
chr4 118219655 118221372 Tmem125 (-4181)
chr4 120709969 120710060 Col9a2 (-1975)
chr4 123369561 123369835 Macf1 (-8095), Ndufs5 (+25747)
chr4 125568410 125568787 Csf3r (-133195), Grik3 (+400655)
chr4 131301601 131301835 Ptpru (+92428), Matn1 (+801418)
chr4 131673819 131674044 Epb4.1 (-42725), Oprd1 (+26469)
chr4 132894275 132894409 Wdtc1 (+897)
chr4 132994761 132995022 Fam46b (-41155), Slc9a1 (+69271)
chr4 141102627 141102930 Spen (-8267), Fblim1 (+53060)
chr4 146316224 146316405 Gm13150 (-29770), Zfp600 (+191224)
chr4 149185046 149185351 Slc25a33 (-36813), Spsb1 (+143953)
chr4 149612437 149612864 Rere (-43104), Eno1 (+1590)
chr4 153394885 153395163 Smim1 (+5237), Lrrc47 (+9184)
chr4 153527347 153527613 Tprgl (+7295), Wrap73 (+10999)
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chr4 154231384 154231576 Mmel1 (-14258), Ttc34 (+1171)
chr4 154306287 154306408 Tnfrsf14 (-4162)
chr5 11220304 11220562 4933402N22Rik (-374523), Gm5861 (+37361)
chr5 11220573 11220751 4933402N22Rik (-374294), Gm5861 (+37590)
chr5 11400416 11400736 4933402N22Rik (-194380), Gm5861 (+217504)
chr5 11829495 11829872 Sema3d (-553482), 4933402N22Rik (+234728)
chr5 11881170 11881428 Sema3d (-501867), 4933402N22Rik (+286343)
chr5 14918464 14922081 Gm9758 (-5374), Speer4e (+18156)
chr5 16889535 16889710 Speer4f (-92293), Gm3495 (+10597)
chr5 16974433 16975269 Speer4f (-7065), Gm3495 (+95825)
chr5 28661168 28661314 Evc2 (-9068497), Rbm33 (+17512), Shh (+132400)
chr5 54893762 54893923 Stim2 (+504187)
chr5 66330250 66330572 Chrna9 (-27952), Rhoh (+75603)
chr5 66375177 66375388 Chrna9 (+16920), 9130230L23Rik (+20241)
chr5 72438606 72438857 Commd8 (+120690), Gabrb1 (+347561)
chr5 76651154 76651299 Tmem165 (+38322), Clock (+82590)
chr5 76657257 76657453 Tmem165 (+44450), Clock (+76462)
chr5 78845888 78845995 NONE
chr5 102235572 102235858 Cds1 (+41566), Wdfy3 (+263225)
chr5 105855709 105855904 Lrrc8c (-92600), Lrrc8b (+11013)
chr5 108295958 108296386 Evi5 (+7954), Ube2d2b (+36900)
chr5 109111463 109111867 Fgfrl1 (-11583), Slc26a1 (-7077)
chr5 109176965 109177370 Rnf212 (+1299), Fgfrl1 (+53920)
chr5 109231240 109231381 Tmed11 (-6929), Vmn2r8 (+6462)
chr5 109722239 109722366 Vmn2r14 (-68662), Vmn2r15 (+4272)
chr5 113763814 113764285 Sgsm1 (-24244), Aym1 (-22264)
chr5 115940244 115940408 Pxn (-16491), Sirt4 (-5592)
chr5 123453058 123453399 Kdm2b (-14121), Orai1 (-11854)
chr5 123960959 123961289 B3gnt4 (+655)
chr5 123961314 123961799 B3gnt4 (+1088), Diablo (+12628)
chr5 129661847 129662082 Sfswap (-345141), Gpr133 (+59340)
chr5 129760523 129760777 Sfswap (-246456), Gpr133 (+158025)
chr5 135003226 135003818 Gtf2ird1 (-70941), Clip2 (+24782)
chr5 137540337 137540712 Ap1s1 (-18520), Serpine1 (+7617)
chr5 140277688 140278199 Mafk (+10477), Tmem184a (+12293)
chr5 143455156 143455542 Tnrc18 (+123717), Slc29a4 (+277294)
chr5 143579353 143579517 Tnrc18 (-369)
chr5 143579622 143579759 Tnrc18 (-625)
chr5 148910391 148910631 Mtus2 (+141615), Slc7a1 (+300969)
chr6 8115351 8115691 Col28a1 (+10873), C1galt1 (+320679)
chr6 12106365 12106464 Gm6578 (-46832), Thsd7a (+592838)
chr6 17741408 17741763 St7 (+97554), Wnt2 (+238999)
chr6 17741787 17742080 St7 (+97902), Wnt2 (+238651)
chr6 22299685 22299898 Fam3c (+6374), Wnt16 (+61562)
chr6 30677243 30677546 Cep41 (-33646), Mest (-10668)
chr6 42445265 42445364 Olfr456 (-8102), Fam115e (+102056)
chr6 44742921 44743299 Cntnap2 (-266950)
chr6 47091238 47091832 Cul1 (-312784)
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chr6 47110170 47110764 Cul1 (-293852)
chr6 51419242 51419535 Hnrnpa2b1 (-1961), Cbx3 (-970)
chr6 51936401 51936542 Skap2 (+26076), Snx10 (+462572)
chr6 54927446 54927856 Nod1 (-5045), Ggct (+15293)
chr6 54927977 54928346 Nod1 (-5556), Ggct (+14782)
chr6 58767579 58767663 Herc3 (-16073), Abcg2 (+220956)
chr6 58775563 58775687 Herc3 (-8069), Abcg2 (+228960)
chr6 66579484 66579697 Vmn1r33 (-13535), Vmn1r34 (+8155)
chr6 68200903 68201280 Tacstd2 (-715276), Igkv4-71 (+992347)
chr6 79075351 79075546 Lrrtm4 (-893422), Reg3g (-656583)
chr6 83417694 83418110 Tet3 (-26233), Dguok (+39061)
chr6 83530301 83530768 Stambp (-8037), Clec4f (+75646)
chr6 87931409 87931718 Gm5577 (-113), H1fx (-88)
chr6 88444425 88445476 Sec61a1 (+23948), Ruvbl1 (+29548)
chr6 89950379 89950539 Vmn1r47 (-21423), Vmn1r46 (+24294)
chr6 92356089 92356462 Trh (-161632), Prickle2 (+161084)
chr6 103599005 103599368 Cntn6 (-843729), Chl1 (+138317)
chr6 116201111 116202043 Zfand4 (-12663), Fam21 (+43526)
chr6 121600081 121600259 Mug1 (-188389), A2m (+13979)
chr6 126489214 126489669 Kcna5 (-3869)
chr6 143101173 143101323 C2cd5 (-52621), Etnk1 (-14502)
chr6 145881183 145881640 Sspn (-1230)
chr6 147501623 147501803 Far2 (-494225), Ccdc91 (+77320)
chr7 3000020 3000235 Gm7353 (+111822)
chr7 4999282 4999547 Zfp580 (-3719)
chr7 4999598 4999859 Zfp580 (-3405)
chr7 5543821 5543962 Vmn1r62 (-82337), Vmn1r60 (-47161)
chr7 6147041 6147413 Galp (-1465)
chr7 11787109 11787324 Zscan4d (-35720), Zscan4e (+108814)
chr7 16994559 16994776 Tmem160 (-43460), Zc3h4 (+8438)
chr7 27031275 27031464 Vmn1r184 (-20480), Cyp2b9 (+72940)
chr7 29827407 29827755 Map4k1 (+59708), Ryr1 (+82589)
chr7 29958939 29959245 Ggn (+3853), Psmd8 (+6600)
chr7 31306647 31307327 Arhgap33 (+13092), Prodh2 (+28346)
chr7 31307390 31308185 Arhgap33 (+12291), Prodh2 (+29147)
chr7 39231479 39233273 Pop4 (-176009), Gm5591 (+80836)
chr7 39352222 39353766 Gm5591 (-39782)
chr7 50122401 50122572 Gm2381 (+117)
chr7 50509190 50509325 EU599041 (+30313), Zfp715 (+57598)
chr7 52964901 52965056 Rpl18 (-5848), Dbp (+4521)
chr7 52965206 52965362 Rpl18 (-5543), Dbp (+4826)
chr7 52965417 52966222 Rpl18 (-5007), Dbp (+5362)
chr7 72747499 72747658 Tjp1 (-231454), Tarsl2 (-42205)
chr7 72750212 72750303 Tjp1 (-234133), Tarsl2 (-39526)
chr7 87853701 87853957 Crtc3 (-20066), Iqgap1 (+94388)
chr7 88903178 88903348 Fam103a1 (-4548)
chr7 90974226 90974809 1700026D08Rik (-31128), Mesdc1 (+58333)
chr7 91561750 91562035 Arnt2 (-3424)
255
chr7 95678989 95679332 Rab38 (+100378), Tmem135 (+808136)
chr7 96802485 96802569 A230065N10Rik (-20893), Ccdc81 (+249601)
chr7 107520727 107520893 Ppme1 (-404), C2cd3 (+67)
chr7 108458149 108458626 Atg16l2 (-7786), Stard10 (-7212)
chr7 108789576 108789755 Art2b (-59991), Clpb (-22481)
chr7 115820499 115820711 Olfr512 (-36229), Olfr510 (+9673)
chr7 117817849 117818128 Ampd3 (-93731), Adm (+46814)
chr7 118226353 118226835 Eif4g2 (-50)
chr7 120444291 120444522 Btbd10 (+68446), Arntl (+93428)
chr7 121290447 121290617 Rras2 (-29237), Copb1 (+107662)
chr7 122814005 122814257 Gm6816 (-742891), Sox6 (+324469)
chr7 124444366 124444948 Xylt1 (-79836), Nucb2 (+796769)
chr7 130559517 130559817 Aqp8 (-46141), Lcmt1 (+38171)
chr7 133056871 133057003 Gsg1l (+168988), D430042O09Rik (+205508)
chr7 134171142 134171368 Maz (-1262)
chr7 138559852 138560095 Hmx3 (-126407), Acadsb (+5859)
chr7 141150079 141150413 Fank1 (+181702), Adam12 (+266534)
chr7 148151421 148151685 Ifitm1 (-2386)
chr8 4944835 4945023 Shcbp1 (-165395), Slc10a2 (+160303)
chr8 10676257 10676741 3930402G23Rik (+251958), Myo16 (+403927)
chr8 12651761 12651915 Tubgcp3 (+20410), Spaca7 (+78789)
chr8 15519762 15520194 Myom2 (+462325)
chr8 25462270 25462920 1810011O10Rik (+86823), A730045E13Rik (+178219)
chr8 31438279 31438743 Dusp26 (-761432)
chr8 48678169 48678670 Rwdd4a (+59402), Ing2 (+82092)
chr8 48799209 48799365 Cdkn2aip (-2)
chr8 53422254 53422419 NONE
chr8 62368986 62369151 Gm10283 (+612926), BC030500 (+978517)
chr8 68498956 68499055 March1 (+357082), Tma16 (+511412)
chr8 82479259 82479547 Hhip (+102502), Anapc10 (+243684)
chr8 85884272 85884590 Clgn (-29346), 4933434I20Rik (+12061)
chr8 89571694 89572030 N4bp1 (-162705), Cbln1 (+424646)
chr8 93860665 93860961 Fto (+23382), Irx3 (+464740)
chr8 97794284 97794571 Kifc3 (-127988), Cngb1 (+13653)
chr8 107828141 107828923 Elmo3 (-969)
chr8 110220901 110221068 Psmd7 (-108603)
chr8 112302324 112302543 Ap1g1 (-20)
chr8 119567477 119567793 Gcsh (-50198), Pkd1l2 (+38714)
chr8 122124325 122124484 Taf1c (+4717), Dnaaf1 (+25270)
chr8 122125009 122125167 Taf1c (+4034), Dnaaf1 (+25953)
chr8 122126044 122126895 Taf1c (+2652), Dnaaf1 (+27335)
chr8 124494912 124495249 Gm22 (-298388), Banp (+20637)
chr8 125801296 125801869 Vps9d1 (-23335), Fanca (+40893)
chr8 127528426 127529090 Egln1 (-55604), Tsnax (-8139)
chr9 2999998 3002205 Gm10722 (+180)
chr9 3002257 3003490 Gm10720 (-12780), Gm10722 (+1952)
chr9 3003894 3004721 Gm10720 (-11346), Gm10722 (+3386)
chr9 3008887 3009792 Gm10720 (-6314), Gm10722 (+8418)
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chr9 3011305 3013245 Gm10720 (-3379)
chr9 3013318 3014219 Gm10720 (-1885)
chr9 3015054 3015859 Gm10720 (-197)
chr9 3016808 3017613 Gm10718 (-6336), Gm10720 (+1557)
chr9 3017722 3018549 Gm10718 (-5411), Gm10720 (+2482)
chr9 3023697 3024501 Gm10718 (+552)
chr9 3024619 3028825 Gm10718 (+3175), 4930433N12Rik (+173060)
chr9 3029353 3030835 Gm10718 (+6547), 4930433N12Rik (+169688)
chr9 3030999 3033810 Gm10718 (+8858), 4930433N12Rik (+167377)
chr9 3035278 3036770 Gm10718 (+12477), 4930433N12Rik (+163758)
chr9 3036840 3037472 Gm10718 (+13609), 4930433N12Rik (+162626)
chr9 3037542 3038423 Gm10718 (+14436), 4930433N12Rik (+161799)
chr9 9927813 9927959 Arhgap42 (-688873), Cntn5 (+976889)
chr9 10564871 10565170 Cntn5 (+339754)
chr9 13338640 13339469 Maml2 (-85379), Phxr4 (+104474)
chr9 19029130 19029345 Olfr843 (+24669), Olfr836 (+103837)
chr9 25059849 25060024 Sept7 (-232)
chr9 28182826 28182970 Opcml (+584366)
chr9 35112756 35113275 Cdon (-116166), Rpusd4 (+37566)
chr9 37980371 37980508 Olfr891 (+7966), Olfr890 (+29718)
chr9 41056175 41056341 Ubash3b (-90113), Sorl1 (+876122)
chr9 41780734 41780824 Ubash3b (-814634), Sorl1 (+151601)
chr9 44142700 44142969 H2afx (+37)
chr9 44689301 44689523 Mll1 (-33)
chr9 45064717 45064951 Tmprss4 (-52659), Il10ra (+12398)
chr9 45443886 45444033 Cep164 (+192814), Dscaml1 (+205584)
chr9 49183419 49183597 Drd2 (+34776), Ankk1 (+51618)
chr9 56071355 56071791 Tspan3 (-62977), C230081A13Rik (+194284)
chr9 58538904 58539073 2410076I21Rik (+50377), Nptn (+108890)
chr9 58743557 58744359 Hcn4 (+72639), Neo1 (+140290)
chr9 59505862 59506188 Gramd2 (-49419), Pkm (+1642)
chr9 67419497 67419783 C2cd4b (-187604), Tln2 (-12130)
chr9 70942604 70942770 Lipc (-160072), Aqp9 (+68409)
chr9 71908716 71909086 Cgnl1 (-289492), Tcf12 (+50725)
chr9 75471052 75471301 Lysmd2 (-2362)
chr9 82868925 82869191 Phip (+38)
chr9 82869297 82869515 Phip (-310)
chr9 96435662 96435871 Rnf7 (-56673), Rasa2 (+96269)
chr9 99341156 99341459 Mras (-4171)
chr9 100119352 100119755 Sox14 (-342891), Il20rb (+267653)
chr9 100119779 100119975 Sox14 (-343214), Il20rb (+267330)
chr9 108465913 108466233 Impdh2 (+3299), Ndufaf3 (+3600)
chr9 108466612 108467145 Ndufaf3 (+2794), Impdh2 (+4105)
chr9 110154884 110154975 Elp6 (-52766), Cspg5 (+8643)
chr9 110428162 110428353 Setd2 (-6843), Kif9 (+48760)
chr9 110428485 110429550 Setd2 (-6083), Kif9 (+49520)
chr9 112911176 112911399 Arpp21 (-776283), Pdcd6ip (+706074)
chr9 115695410 115695590 Stt3b (-475961), Gadl1 (-122182)
257
chr9 115695612 115695770 Stt3b (-476152), Gadl1 (-121991)
chr9 118647931 118648304 Ctdspl (-187453), Itga9 (+132310)
chr9 120058537 120058711 Mobp (-236)
chr9 123370836 123371309 Limd1 (-16746), Lars2 (+95015)
chrX 3302194 3302325 Gm14345 (-108408)
chrX 3376735 3376894 Gm14345 (-33853)
chrX 3512215 3512374 Gm14351 (-48975), Gm3701 (+155142)
chrX 3873121 3873280 Gm3701 (-205764), Gm14347 (-33810)
chrX 4041451 4041610 Gm3763 (-556635), Gm10922 (-45958)
chrX 25615314 25615470 Gm5168 (-137225), Gm2012 (+43089)
chrX 30762714 30762936 Gm21637 (-60425), Gm2799 (+164429)
chrX 31786255 31786414 Gm2927 (-45925), Gm2913 (-33869)
chrX 58586282 58586381 Ldoc1 (-376457), Cdr1 (-147599)
chrX 59903462 59903624 4931400O07Rik (+182377)
chrX 105879298 105879495 Gm732 (-735622), Brwd3 (+150290)
chrX 113580034 113580205 H2afb2-ps (-214667), Cpxcr1 (+17567)
chrX 115952722 115952852 Tgif2lx1 (-358441)
chrX 120113639 120114527 Nap1l3 (-603089), 3110007F17Rik (-103085)
chrX 120405249 120406500 Srsx (-69785), Vmn2r121 (+843644)
chrX 120634626 120635877 Srsx (-299162), Vmn2r121 (+614267)
chrX 120970533 120970966 Srsx (-634660), Vmn2r121 (+278769)
chrX 121577239 121578865 Vmn2r121 (-328533)
chrX 121706644 121708339 Vmn2r121 (-457973)
chrX 122458051 122459744 4932411N23Rik (+891718)
chrX 130684776 130684881 Nox1 (-38436), Xkrx (+11638)
chrX 136596335 136596619 E230019M04Rik (-941), Nup62cl (+630)
chrX 137431184 137431272 Tex13 (-83256), Vsig1 (-10919)
chrX 150514181 150514469 Gm15140 (+40903), Spin2 (+247489)
chrX 150565454 150565742 Gm15140 (-10370), 4930524N10Rik (+212337)
chrX 150587185 150587473 Gm15140 (-32101), 4930524N10Rik (+190606)
chrX 157555276 157555507 Cdkl5 (-122758), Scml2 (-45600)
chrX 159793558 159793691 S100g (-391094), Grpr (+193984)
chrX 166438853 166447041 4933400A11Rik (-225380)
chrY 2869581 2872285 Gm10352 (+480543)
258










































7 .1 Testes Only GO Term Associations 
Nucleosome Organisation
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7.2 Testes Peaks GO Term Associations 
Nucleosome Assembly
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7.3 Testes Peaks GO Term Associations 
Chromatin Assembly or Disassembly
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